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Abstract 
     The development of new chemical entities is expensive and time consuming. Therefore, 
the path taken by research into the last century was directed to find new methods to exploit 
the already existing pharmaceutical tools. “There’s plenty of room at the bottom” was the 
title of a lecture delivered in 1959 by Richard Feynman, who introduced the concept of 
nanotechnology as an important field for future research. This novel science covers areas 
of biomedical disciplines and engineering involved in the development of materials and 
devices in the nanometer scale. These systems is nowadays drawing major attention in the 
medical field for the delivery of therapeutics, especially in the treatment of complex 
diseases such as cancer. in fact, this malignancy possesses unique features that perfectly 
suits the concepts underlying nano delivery. Amongst all, the enhanced and permeability 
retention efffect (EPR) certainly is widely recognized as the rational basis for using 
nanotherapeutics in the treatment of cancer. EPR is phenomenon by which 
macromolecules preferentially accumulate in tumor tissues due to immature, tortuous, and 
multi-fenestrated cancer vessels. Moreover, the opportunity to improve drug 
pharmacokinetics without affecting the chemical features of the carried molecules, 
provides not only the ability to overcome several  biological  obstacles  that  normally  
reduce  the accumulation of therapeutics into the target area but also to increase their 
therapeutic impact.  
The general aim of this thesis was to develop different strategies for the delivery of 
conventional chemotherapeutics in the field of cancer therapies.  
Infact, different nanocarriers for cancer treatment have been developed so far basically 
differing for composition, size and shape, as well as stiffness. Particularly promising are 
those based on amphiphilic block polyester copolymers (NPs). Polymeric NPs of poly(ε-
caprolactone) (PCL) covered with a hydrophilic poly(ethylene glycol) (PEG) can be 
employed as passive delivery system and possibly decorated with targeting ligands such 
as folate to accumulate in cancerous tissue. However, the density and conformation of PEG 
on the surface affect the exposition of small targeting ligands and the receptor mediated 
cell uptake. In this context Chapter 3 – Shedding light on surface exposition of 
poly(ethylene glycol) and folate targeting units on nanoparticles of poly(ε-caprolactone) 
diblock copolymers: beyond a paradigm – is dedicated to PEG-PCL NPs targeted to folate 
receptor.  The impact of preparation method on PEGylation extent and folate surface 
exposition is fully addressed in the attempt to relate quality attributes of NPs to biological 
behavior.  
 
 
Although the EPR effect has been postulated to carry NPs and spread inside the cancer 
tissue, only a small percentage (0.7% median) of the total administered nanoparticle dose 
is usually able to reach a solid tumor. New strategies based on the microscale and 
combining different disciplines together such as biology, chemistry, physics and 
engineering has been proposed to address this issue. The multistage vector (MSV) is an 
platform that combine nano and microcarriers conceived to overcome the biological 
obstacles in a sequentially manner. This platform consists of three components. The first 
stage is a discoidal porous silicon microparticles designed to navigate into the circulatory 
stream and preferentially adhere to the tumor abnormal endothelial wall. Depending on the 
application, different types of NPs can be loaded into the pores of the microparticle as 
second stage. In contrast to the discoidal microparticle, the second stage enter into the cells 
by exploiting the fenestrature of vascular endothelium and finally releases the third stage, 
i.e. the therapeutic agent that can be freely selected depending on the application. In 
addition to this general concept, a new generation of MSV that display additional 
properties was developed in the attempt to improve the therapeutic performance of the 
platform. As an example MSV that possesses a biomimetic coating, novel approaches to 
load multiple types of nanotherapeutics inside the microdiscoidal carrier and more recently 
the application of this platform to cancer immunotherapy have been proposed. Despite all 
these applications, this versatile vector has not yet been used to treat brain disease. This is 
because brain represent a major challange in drug delivery due to the presence of the Blood 
Brain Barrier (BBB). Within this framework the aim of the project described in Chapter 4 
– Strategies to overcome the Blood Brain Barrier (BBB) – is the development of novel 
approaches based on the combination of micro- and nano-delivery systems to treat brain 
metastases arisen from primary tumors as melanoma and breast cancer. The idea is to 
functionalize the micro-vector surface to promote preferential accumulation at the brain 
microvasculature and after obtaining the intended accumulation, near the endothelial wall, 
the capacity of transporting simultaneously more than one active component in the porous 
micro particle. The concept is validated by the development of in vitro and in vivo models.  
Despite the considerable progress made with NPs, only a limited number of NPs have been 
approved for clinical use. As an example, Doxil® the first FDA approved formulation for 
the delivery of Doxorubicin (Dox) is able to reduced systemic side effects compared to the 
free drugs but not to significantly improve the antitumor effects into the metastatic 
diseases. This clinical evidence suggests that further delivery approaches needs to be 
developed and that there is a need for an in depth study of the anatomical knowledge of 
the EPR. In this context, the aim of the work described in Chapter 2 – Synthesis and 
characterization of rationally-designed Dextran-Doxorubicin conjugate: a novel strategy 
to improve the antitumor efficacy of doxorubicin in multiple breast cancer liver metastases 
– is to develop a rationally-designed Dox-dextran conjugate with appropriate molecular 
weight (MW) based on estimated EPR effect in established liver metastases to overcome 
the limited clinical efficacy of PEGylated liposomes and Dox. 
In the two annexes the development of a novel antibacterial polymeric film of poly(lactic-
co-glycolic acid) (PLGA) for the release of nitric oxide (NO) under visible light is reported 
(Annex I) and a study of the growth of the drug delivery literature published during 1974-
2015 was discussed (Annex II). 
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1. Disadvantages of standard chemotherapy 
     Cancer can be defined as a heterogeneous disease and one of the leading cause of death 
worldwide.1 Cancer can generate from different tissues but the common features is the loss of 
cell-proliferation control with an abnormal growth of the diseased tissue. Furthermore the 
formation of metastasis, a secondary cancer that spreads in the body and leads to multiple organ 
failure and death, is a recurring event.2 The origin and type of cancer are important elements 
for the choice of the best treatment for a cancer patient. Currently the treatment of cancer is 
based on a combination of drugs therapy (chemoterapy), surgery, radiotherapy and 
immunotherapy. However, these approaches present some drawbacks such as the high cost of 
the therapy for the radio or the limitation of the surgery to treat only well localized tumor mass. 
The chemotherapy provides an opportunity to decrease the costs of treatment and to reach also 
metastasis but is associated to many side effects due to the inability of the drugs to kill only the 
cancerous cells or to accumulate only at the target site. Other limitations come from the route 
of administration. Usually chemotherapeutic agents are administered by intravenous route but 
most of them are poorly water-soluble and need toxic vehicles for administration 
(Chremophor®, ethanol, surfactants). The effectiveness of a chemotherapy is also limited by 
intrinsic or acquired drug resistence. The most common forms of chemoresistance are drug 
inactivation, drug target alteration, drug efflux, DNA damage repair and cell death inhibition.3 
Different strategies have been tried in order to improve the quality and reduce the side effects 
of the systemic administration of the chemotherapeutic agents such as the chemical 
modification of the drug itself but the most promising seems to be the application of 
nanotechnology.  
 
 
 
 
 
                                                          
1 Fitzmaurice, C., Dicker, D., Pain, A., Hamavid, H., Moradi-Lakeh, M., MacIntyre, M. F., et al. (2015). The 
Global Burden of Cancer 2013. JAMA Oncol, 1(4), 505-527. 
2 Mehlen, P., & Puisieux, A. (2006). Metastasis: a question of life or death. Nat Rev Cancer, 6(6), 449-458. 
3 Wilson, T. R., Longley, D. B., & Johnston, P. G. (2006). Chemoresistance in solid tumours. Ann Oncol, 17 
Suppl 10, x315-324. 
 6 
 
2. Fundamentals of Nanotechnology 
     Nanotechnology is referred to materials and healthcare products engineered at the molecular 
scale approximately in the size range from 1 nm to 100 nm (Figure 1).4  
 
 
 
Figure 1. Comparison of various biological assemblies and nanodevices. 
The application of nanotechnology into the medical field is called nanomedicine. The European 
Medicines Agency (EMA) had outlined a working definition of nanomedicine based on three 
point: i) systems designed for clinical applications, ii) at least one component at nano-scale and 
iii) resulting in specific properties and characteristics [related to the specific nanotechnology 
application and characteristics for the intended use (route of admin and dose) or associated with 
the expected clinical advantages of nano- (e.g. preferential organ/tissue distribution)]. As well 
the Food and Drug Administrtion (FDA) in the United States (US) defined as products that 
contain or are manufactured using materials in the nano-scale range or products that contain or 
are manufactured using certain materials that exhibit related dimension-dependent properties 
or phenomena. The word “products” (or “FDA-regulated products”) is referred to materials or 
other substances regulated by FDA, including drugs, biological products, medical devices, food 
substances (including food for animals) and cosmetic products.5 This technology arise to aid 
                                                          
4 De Jong, W. H., & Borm, P. J. (2008). Drug delivery and nanoparticles:applications and hazards. Int J 
Nanomedicine, 3(2), 133-149. 
5 US FDA. Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology. 
http://www.fda.gov/RegulatoryInformation/Guidances/ucm257698.htm. 
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molecules that cannot be used due to own toxicity by increasing their therapeutic efficacy. 
However, these products are not regualted by a specific legislation in the European Union (EU) 
and in the US since they are included in the regulatory system of medical products as is stands. 
The high standards of the medical product are difficult to achieve by this new nano sized carriers 
due to size related physicochemical properties and unexpected biological effects. For this 
reason they require additional quality control compared to standard products. Accurate 
parameters such as stability, size, physical morphology, solubility, exc have to be identified and 
translated into standardised and regulatory accepted development methods. In order to ensure 
the safety of nanodevices the National Cancer Institute (NCI) togheter with the National 
Institute of Standards and Technology (NIST) and the FDA established the Nanotechnology 
Characterization Laboratory (NCI-NCL) to perform preclinical efficacy and toxicity testing. 
Recently, also the EU founded the European Nanotechnology Characterisation Laboratory (EU-
NCL) that work in close partnership with the NCI. The NCLs accelerates the transition of basic 
nanoscale particles and devices into clinical applications. Therefore, the application of these 
nanotherapeutics is retarded by the lack of a specific regulatory system but despite this the great 
potential to improve medical treatments of disease such as cancer resulted in the last few 
decades in a tremendous impact on the field of research. 
2.1 Nanotechnology and cancer 
     Nanocarriers are expected (i) to protect drug cargo and to improve its pharmacokinetics; (ii) 
to provide the drugs with the ability to overcome several biological obstacles that normally 
reduce the accumulation of therapeutics into the target area; (iii) to provide  multifunctionality 
by loading various compounds such as two different drugs or a drug with an imaging agent; (iv) 
to increase the therapeutic impact by interacting with specific tissues and cells through surface 
functionalization; (v) to impact clinical application of several drugs or potential drugs. Several 
types of nanovectors such as liposomes6, polymeric nanoparticles7,8, micelles9, and inorganic 
nanoparticles10,11 have been exploited, being the intravenous injection the preferred route of 
                                                          
6 Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., et al. (2013). 
Liposome: classification, preparation, and applications. Nanoscale Res Lett, 8(1), 102. 
7 Banik, B. L., Fattahi, P., & Brown, J. L. (2016). Polymeric nanoparticles: the future of nanomedicine. Wiley 
Interdiscip Rev Nanomed Nanobiotechnol, 8(2), 271-299. 
8 Grottkau, B. E., Cai, X., Wang, J., Yang, X., & Lin, Y. (2013). Polymeric nanoparticles for a drug delivery 
system. Curr Drug Metab, 14(8), 840-846. 
9 Croy, S. R., & Kwon, G. S. (2006). Polymeric micelles for drug delivery. Curr Pharm Des, 12(36), 4669-4684. 
10Ali, A., Zafar, H., Zia, M., Ul Haq, I., Phull, A. R., Ali, J. S., et al. (2016). Synthesis, characterization, 
applications, and challenges of iron oxide nanoparticles. Nanotechnol Sci Appl, 9, 49-67. 
11 Arvizo, R., Bhattacharya, R., & Mukherjee, P. (2010). Gold nanoparticles: opportunities and challenges in 
nanomedicine. Expert Opin Drug Deliv, 7(6), 753-763. 
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entry in the body. Since a solid tumor has an abnormal vasculature conformation, its hypoxic 
environment stimulates pathways resulting in the release of growth factors such as the vascular 
endothelial growth factor (VEGF) which leads to immature, tortuous, and multi-fenestrated 
vessels.12 This unique architecture was observed from Maeda and his colleagues that found that 
molecules with molecular weight larger than 40-50 kDa showed selective accumulation in 
tumor tissues and they retained in tumor tissues for long periods.13 This concept is know as 
enhanced permeability and retention (EPR) effect and lays the basis for the mechanism of 
passive accumulation of drugs into the tumor exploited also by nanotherapeutics. It should also 
be considered that the tumor interstitium has an impaired lymphatic drainage that decreases the 
clearance of macromolecules. This is due to mechanical forces generated by the growing tumor 
that deforms the normal tissue and indirectly by warps capillaries and lymphatic vessels.14  
However, progress in developing effective drugs using this approach has been hampered by 
heterogeneity of EPR effect in different tumor animal models as an example very aggressive 
tumors that are highly vascularized such as carcinomas showed more blood vessels and the 
leakage of the particles is higher, while other tumors are characterized by a slower growth 
resulting in an uneffective accumulation of particles.15,16  
This evidence pave the way to a novel reductionist approach in drug development to the 
nanometric level. Reductionism study a phenomenon separating it in its elementary parts in that 
a complex system is nothing if not the sum of its parts. In the case of drug delivery the simplicist 
view of a system that accumulate in tumors only exploiting the anatomical architecture of 
cancer vessels is not satisfactory because the route of access of nanoparticles is dynamically 
remodelled.  Tumour is a complex entity and all the single variable must be considered such as 
rates of extravasation, binding or uptake by tumour cells, release from binding, rate of 
elimination from blood, as well as plasma volume, tumour interstitial volume, tumour cellular 
volume and tumour vascular and some of this cannot be studied in vivo.17   
                                                          
12 Lee, S. H., Jeong, D., Han, Y. S., & Baek, M. J. (2015). Pivotal role of vascular endothelial growth factor 
pathway in tumor angiogenesis. Ann Surg Treat Res, 89(1), 1-8. 
13 Matsumura, Y., & Maeda, H. (1986). A new concept for macromolecular therapeutics in cancer 
chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer 
Res, 46(12 Pt 1), 6387-6392. 
14 Jain, R. K., Martin, J. D., & Stylianopoulos, T. (2014). The role of mechanical forces in tumor growth and 
therapy. Annu Rev Biomed Eng, 16, 321-346. 
15 Hansen, A. E., Petersen, A. L., Henriksen, J. R., Boerresen, B., Rasmussen, P., Elema, D. R., et al. (2015). 
Positron Emission Tomography Based Elucidation of the Enhanced Permeability and Retention Effect in Dogs 
with Cancer Using Copper-64 Liposomes. ACS Nano, 9(7), 6985-6995. 
16 Wang, A. Z. (2015). EPR or no EPR? The billion-dollar question. [10.1126/scitranslmed.aac8108]. Science 
Translational Medicine, 7(294), 294ec112. 
17 Florence, A. T. (2012). Reductionism and complexity in nanoparticle-vectored drug targeting. J Control 
Release, 161(2), 399-402. 
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In any case, efforts in the field of research have been made to increase the accumulation of 
nanotherapeutics in cancer tissue by EPR.  
Nanoparticles may be recognized by the host immune system particularly the mononuclear 
phagocyte system (MPS) which rapidly clear-up nanoparticles from the circulation and 
accumulate them into liver, spleen and bone narrow. Hydrophobicity of the surface determine 
the quantity of blood components that bind the carrier. Therefore to minimize the opsonization 
and to evade the uptake from the MPS several strategies have been tried to make the particles 
“stealth”. Coating with hydrophilic polymers or surfactants can prevent complement activation 
and impart long-circulating properties. However, these coating polymers may also greatly 
decrease the cellular uptake efficiency of nanoparticles. For this reason, novel approaches were 
developed by taking advantage of the opportunity of modifying the surface and the physico-
chemical properties of the nanovectors, such as the active targeting approach and the stimuli-
responsive particles. The active strategies requires on the surface of the nanoparticles the 
conjugation of several moieties that are able to bind receptors mainly expressed on cancer cells 
like the G protein coupled receptors (GPCRs), integrins, folate receptors (FRs) and transferrin 
receptors (TfRs).18  In addition to the cellular target another promising approach is the vascular 
target. Integrins are a family of heterodimeric transmembrane glycoproteins involved in a wide 
range of cell-to-extracellular matrix (ECM) and cell-to-cell interactions. As cell surface 
receptors, integrins readily interact with extracellular ligands and play a vital role in 
angiogenesis, leukocytes function and tumor development, which sets up integrins as an 
excellent target for chemotherapy treatment. The peptide ligands containing the arginine-
glycine-aspartic acid (RGD), which displays a strong binding affinity and selectivity to 
integrins, particularly to integrin αvβ3, have been developed to conjugate with various 
conventional chemotherapeutic agents, such as small molecules, peptides and proteins, and 
nanoparticle-carried drugs for integtrin targeted therapeutic studies. The RGD-decorated nano 
delivery systems have been extensively investigated in that after bearing multiple RGD-
peptides, can be more readily internalized via receptor-mediated endocytosis. Instead the 
stimuli-responsive nanoparticles can release their cargo in two different ways or exploiting the 
physical features of the tumor enviroment such as the low pH or through external stimuli such 
                                                          
18 Akhtar, M. J., Ahamed, M., Alhadlaq, H. A., Alrokayan, S. A., & Kumar, S. (2014). Targeted anticancer 
therapy: overexpressed receptors and nanotechnology. Clin Chim Acta, 436, 78-92. 
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as light and magnetic field and temperature.19,20 Actually, there are several nanotherapeutics 
that have been approved for clinical use by the FDA in the United States and by EMA in 
European countries (Table 1). The first FDA-approved nanoformulation was Doxil®.21 Doxil® 
is a PEGylated liposome encapsulating doxorubicin that minimizes side effects, such 
cardiotoxicity associated to the drug. All these system are liposome based formulation except 
for Abraxane® that consist of human serum albumin bound to paclitaxel and allows to deliver 
paclitaxel, that is the standard treatment for metastatic breast cancer, without using solvents as 
vehicles that cause severe toxicity.22 It is also noteworthy that most of this formulation are non-
PEGylated and all of them are supposed to accumulate through the passive meccanisms.  
 
Table 1 FDA and EMA-approved nanoformulations. 
Name Particle type/drug Approved application Approval (year) 
Doxil®/Caelyx® 
Liposomal doxorubicin 
(PEGylated) 
Ovarian cancer 
HIV-associated Kaposi’s sarcoma 
Multiple myeloma 
FDA (1995) 
EMA (1996) 
DaunoXome® 
Liposomal doxorubicin 
(non-PEGylated) 
HIV-associated Kaposi’s sarcoma FDA (1996) 
Myocet® 
Liposomal doxorubicin 
(non-PEGylated) 
Metastatic breast cancer EMA (2000) 
Abraxane® Albumin bound paclitaxel 
Advanced non-small cell lung 
cancer 
Metastatic breast cancer 
Metastatic pancreatic cancer 
FDA (2005) 
EMA (2008) 
Mepact® 
Liposomal mifamurtide 
(non-PEGylated) 
Osteosarcoma EMA (2009) 
Marqibo® 
Liposomal vincristine 
(non-PEGylated) 
Philadelphia chromosome-negative 
acute lymphoblastic leukemia 
FDA (2012) 
Onivyde® 
Liposomal irinotecan 
(PEGylated) 
Metastatic pancreatic cancer FDA (2015) 
 
                                                          
19 Shen, Y., Tang, H., Radosz, M., Van Kirk, E., & Murdoch, W. J. (2008). pH-responsive nanoparticles for 
cancer drug delivery. Methods Mol Biol, 437, 183-216. 
20 Torchilin, V. (2009). Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm 
Biopharm, 71(3), 431-444. 
21 Barenholz, Y. (2012). Doxil®--the first FDA-approved nano-drug: lessons learned. J Control Release, 160(2), 
117-134. 
22 Gradishar, W. J. (2006). Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother, 
7(8), 1041-1053. 
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2.2 Polymers in cancer 
     Chemotherapy is based on the use of anti-cancer drugs that inhibit the fast proliferation of 
cancer cells but at the same time acting on healthy cells causing several systemic adverse side 
effects. Furthermore, due to their chemical structure and size, drugs also show low half-life 
times in the circulation and a low bioavailability. In order to address that drawbacks the use of 
carriers for the conventional chemotherapeutics can offer significant benefits in the field of 
cancer therapy. The drugs carriers allow to delivery an active compound in a controlled way 
(time and release rate) improving the therapeutic window. Among the many approaches for 
drug delivery the use of polymers have been widely explored in the development of drug 
carriers due to their versatility. Natural polymers are highly biocompatible and biodegradable 
and present functional groups (e.g., -COOH, -NH2) that can be exploited for further 
modification. Secondly, synthetic polymers can be simply prepared in term of compositions 
and properties for a specific application. In particular, the production of biodegradable materials 
that can be metabolized in the biological environment marked a change in the field of drug 
delivery. The natural polymers mainly consist of proteins (i.e., albumin and gelatin) and 
polysaccharides (i.e., hyaluronic acid, chitosan and dextran). The bioabsorbable materials that 
are commonly used in cancer therapy are polyesters, polyanhydrides, polyphosphoesters. 
Poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), and poly(ɛ-caprolactone) (PCL) 
are the most widely syntethic polymers used for the delivery of anti-cancer drugs. PLGA is 
obtained through the copolymerization of lactic acid (LA) and glycolic acid, PCL is synthesized 
by the ROP of ɛ-caprolactone (ɛ-CL) and PLA can be obtained either from the polycondensation 
of LA or by the ring opening polymerization (ROP) of lactide. Poly(ethyleneglycol) (PEG) is 
the most commonly used nonionic polymer in the field of polymer-based drug delivery. Due to 
high aqueous solubility, PEG polymer is considered as a versatile candidate for the prodrug 
conjugation. The drugs can be chemically conjugated to the polymer or physically entrapped 
within the core of polymeric structure formed in acqueous media. 
2.3 Drug Conjugates 
     Low-molecular weight chemotherapeutics typically spread throughout the body, and this 
often leads to systemic side effects. In the 1975, Ringsdorf proposed a polymer–drug conjugate 
model that could enhance the delivery of an anti cancer drug to a tumor.23 The clinical purpose 
                                                          
23 Ringsdorf, H. (1975), Structure and properties of pharmacologically active polymers. J. polym. sci., C Polym. 
symp., 51: 135–153. doi:10.1002/polc.5070510111 
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of polymer–drug conjugate is to produce long-circulating conjugates to taking advantage of 
passive tumour targeting (EPR), improve drug accumulation to the tumour, reduce drug toxicity 
and to overcome the mechanisms of drug resistance. Nevertheless, conjugation to hydrophilic 
polymer can also improve the water solubility of hydrophobic drugs such as doxorubicin and 
paclitaxel. To develop an optimal polymer conjugate carrier is crucial consider the 
physiopathology of tumors (e.g., location and vascularization) and the properties of the drug 
that will be bound to the polymer. Other important aspect is the choice of the polymer–drug 
linkers. If is too stable could prevent drug release but instead if degrades quickly in aqueous 
media leads to premature drug release. The polymer must be non-toxic, non-immunogenic and 
must be able to carry an adequate drug payload. Indeed, many polymers have been used as drug 
carriers but due to these issues only few have been tested in clinical studies. As an example 
PEG has been used in the development of drug conjugates24 but it posses only two terminal 
groups exploitable for conjugation and this limits the drug-loading. N-(2-
hydroxypropyl)methacrylamide (HPMA) copolymers were active against numerous cancer 
models and are in clinical trials.25,26 A dextran–doxorubicin conjugate (AD-70) with a 
molecular weight (MW) of ~70,000 containing drug bound to oxidized dextran was used in a 
phase I trial and also another dextran-conjugate was clinically tested suggest that natural 
polymers are suitable for drug delivery.27,28  
2.3.1 Polymers based conjugate 
An ideal polymeric conjugate consists of i) a polymeric backbone, ii) one or more than one 
therapeutic component, iii) a spacer that ensures the release of the bioactive molecules and 
facilitates the conjugation and further iv) an imaging agent and v) a targeting moiety.  
                                                          
24 Greenwald, R. B., Choe, Y. H., McGuire, J., & Conover, C. D. (2003). Effective drug delivery by PEGylated 
drug conjugates. Adv Drug Deliv Rev, 55(2), 217-250. 
25 Bissett, D., Cassidy, J., de Bono, J. S., Muirhead, F., Main, M., Robson, L., et al. (2004). Phase I and 
pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). Br J 
Cancer, 91(1), 50-55. 
26 Vasey, P. A., Kaye, S. B., Morrison, R., Twelves, C., Wilson, P., Duncan, R., et al. (1999). Phase I clinical and 
pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a 
new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II 
Committee. Clin Cancer Res, 5(1), 83-94. 
27 Danhauser-Riedl, S., Hausmann, E., Schick, H. D., Bender, R., Dietzfelbinger, H., Rastetter, J., et al. (1993). 
Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest New 
Drugs, 11(2-3), 187-195. 
28 Kumazawa, E. and Ochi, Y. (2004), DE-310, a novel macromolecular carrier system for the camptothecin 
analog DX-8951f: Potent antitumor activities in various murine tumor models. Cancer Science, 95: 168–175. 
doi:10.1111/j.1349-7006.2004.tb03199.x 
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Figure 2. Schematic representation of an ideal polymeric conjugate. 
Many different drug conjugates have been synthesized utilizing water soluble polymers such as 
Polyvinylpyrrolidone (PVP) 29, poly(vinyl alcohol) 30, poly-L-glutamic acid 31, poly(ethylene 
glycol) (PEG) 32,33 and N-(2-hydroxypropyl)methacrylamide (HPMA) 34. In this systems the 
drugs have been fixed directly or through a spacer group onto the polymer backbone. An 
important aspect is that a proper selection of the spacer provides the possibility of controlling 
the site and rate of release of drug from conjugate by hydrolytic or enzymatic cleavage. The 
choice of linkers depends on the stability in the physiological pH and on the ability to release 
the therapeutic agent at an appropriate site of action. Successful conjugation is correleted to the 
chemical structure especially both chemicals need to posses a reactive or functional groups such 
as –COOH, –OH, –SH or –NH2, while also molecular weight and steric hindrance are important 
aspects. Often the conjugation leads to the formation of stable bonds such as ester, amide, and 
disulphide. Commonly, the conjugation is performed by coupling the drugs to the end chains 
                                                          
29 D'Souza, A. J., Schowen, R. L., & Topp, E. M. (2004). Polyvinylpyrrolidone-drug conjugate: synthesis and 
release mechanism. J Control Release, 94(1), 91-100. 
30 Kakinoki, A., Kaneo, Y., Ikeda, Y., Tanaka, T., & Fujita, K. (2008). Synthesis of poly(vinyl alcohol)-doxorubicin 
conjugates containing cis-aconityl acid-cleavable bond and its isomer dependent doxorubicin release. Biol 
Pharm Bull, 31(1), 103-110. 
31 Li, C. (2002). Poly(L-glutamic acid)--anticancer drug conjugates. Adv Drug Deliv Rev, 54(5), 695-713. 
32 Greenwald, R. B., Choe, Y. H., McGuire, J., & Conover, C. D. (2003). Effective drug delivery by PEGylated drug 
conjugates. Ibid., 55(2), 217-250. 
33 Banerjee, S. S., Aher, N., Patil, R., & Khandare, J. (2012). Poly(ethylene glycol)-Prodrug Conjugates: Concept, 
Design, and Applications. Journal of Drug Delivery, 2012, 17. 
34 Kopecek, J., Kopecková, P., Minko, T., & Lu, Z. (2000). HPMA copolymer-anticancer drug conjugates: design, 
activity, and mechanism of action. Eur J Pharm Biopharm, 50(1), 61-81. 
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of the polymers but another opportunity comes from “click” chemistry 35. A click reaction is a 
highly specific, posses an high yield of conjugation and the waste products are easily removed. 
Usually coupling agents such as dicyclohexyl carbodiimide (DCC) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide or use of N-hydroxysuccinimide esters are employed for 
the activation of chemical groups. Monomethoxy poly(ethyleneglycol) (mPEG–OH) is one of 
the most widely used polymer in delivering anticancer drugs but its use is strictly limited by 
conjugation capacity since only one terminal functional group exist at the end of the polymer 
chain, which can be functionalized and conjugated to the drugs. Synthetic poly(-amino acids) 
like poly(L-lysine), poly(L-glutamic acid), and poly((N-hydroxyalkyl) glutamines) have 
functionalities in their side groups (amine, hydroxyl, and carboxyl) that allow covalent coupling 
with drug molecules. HPMA is also a well studied polymer due to its versatility as a vehicle. 
Various functionalities may be incorporated into HPMA copolymers side chains and several 
have been used in clinical trials.  Dendritic polymers are emerging as potentially ideal drug 
delivery vehicles because they are easily manipulated and they provide a large density of 
functional groups. In contrast with the linear polymers, dendritic micelles are more stable to 
various environmental effects, such as dilution, shear force, and pH value due to structural 
advantages. Common drawback is that all polymers exhibit some degree of heterogeneity 
despite the well defined chemical structures of conventional small molecular therapeutics and 
also the macroscale architecture of polymers causes steric hindrance. Steric hindrance describes 
how molecular groups interfere with other groups in the structure or other molecules during 
chemical conjugation. This effect drives chemical conformations and may affect the chemical 
conjugation with molecules. 
2.3.2 Polysaccharides based conjugate 
Amongst the polysaccharides, dextrans, due to their excellent physico-chemical properties and 
physiological compliance, are one of the most promising carrier candidates for a wide variety 
of therapeutic agents.  Dextran possesses multiple primary and secondary hydroxyl groups and 
therefore can be easily conjugated either by direct conjugation or by incorporation of a spacer 
arm. 
 
                                                          
35 Thirumurugan, P., Matosiuk, D., & Jozwiak, K. (2013). Click Chemistry for Drug Development and Diverse 
Chemical–Biology Applications. Chemical Reviews, 113(7), 4905-4979. 
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Figure 3. General structure of dextrans. 
Dextrans might be linked irreversibly or reversibly to the therapeutic agents through direct 
linkage or by using a spacer arm. The widely used methods for the synthesis of dextran 
conjugates include direct esterification (ref), carbonate ester method in which an hydroxyl 
group belonging to the drugs is coupled to the polymer by forming a carbonate ester linkage, 
oxidation method that allows to obtain a dialdehyde dextran that can interact with amino 
compounds yielding Schiff bases, carbamate ester method and the cyanogen bromide activation 
of dextrans. Dextrans once internalized are exposed in the endosomal or lysosomal 
compartment to acid pH (~4.5-5.5). Using a pH-sensitive spacers like hydrazon spacer and N-
cis-aconityl spacer one can ensure a controlled intracellular drug release especially in the case 
tumor characterized by acid enviroment that could be exploited to increase the accumulation of 
the drugs only at the targeted site. Also one of the major problem in cancer drug delivery is the 
development of multidrug resistance which occurs mainly due to over-expression of the P-
glycoprotein (Pgp). This transmembrane glycoprotein reduces the intracellular accumulation of 
anticancer drugs because the free drugs enter the cell by diffusion through the plasma 
membrane. When the drugs are conjugated to macromolecular carriers, the drug-conjugate is 
taken up by endocytosis and subsequently efflux pumps are circumvented in turn reducing the 
multidrug resistance and increasing drug influx. However this drug delivery approach is limited 
by the amount of the conjugated therapeutics or by a premature release of it in the blood and 
this results in a low concentration into the cancerous cells not sufficient to be effective. 
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2.4 Physical entrapment: Polymeric nanoparticles (NPs) 
     Polymeric nanoparticles (NPs) are one of the most studied approaches in nanomedicine. The 
research of an ideal system for the delivery of therapeutics was the major challenge in 
nanomedicine and the evolution of the nano polymerics carriers brought to different generation 
of NPs.  The first attempts were focused on the biocompatibility and non toxicity of materials, 
after that more effort have been made to optimize particles surface to increase stability, to give 
to NPs stealth properties and also to improve cellular uptake of the NPs using targeting moieties, 
most recent in the last generation of NPs arise the idea of dynamic carriers that can exploit the 
cellular enviroment to improve the therapeutic efficiency, the stimuli-responsive NPs. One of 
the most important biomedical applications of biodegradable polymeric particles is the delivery 
of conventional chemotherapeutics to improve drug efficacy in cancerous cells. These 
polymeric NPs decrease the drug toxicity, increase aqueous solubility of anticancer agents, 
overcome multidrug resistance of tumors, provided a controlled release and enhanced the cell 
cytotoxicity.  Polymeric NPs also provide the opportunity to monitor tumor activity by tracking 
NP kinetics and can be used as theranostics agents for simultaneous cancer targeted imaging 
and therapy.  
There are some requirements to consider in order to achieve successfully the release of drug 
payloads to the target site. Particle size and size distribution are the most important 
characteristics of these carriers that determine the in vivo distribution and toxicity. 
Nanoparticles need to avoid renal excreation, which depends on molecular weight: broadly 
molecules with a diameter over 15 nm own prolonged half-life in the blood.36 The size affects 
also the degradation rate generally smaller particles degrade slower than the big ones37 and this 
influences the release rate of the cargo.  
A valuable drug delivery system (DDS) needs also a high-drug loading capacity that is the drug 
amount associated to the nanoparticle mass which is animportat aspect in the manufacturing 
process of nanotherapeutics. Association of a drug to a nanocarrior can be performed in two 
distinctive ways: the incorporation method in which the drug is integrated during the 
manufacturing process and the adsorption method in which the drug is incubated with the 
particles already assembled. Another interesting aspect of the DDS is the opportunity to obtain 
                                                          
36 Choi, H. S., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., et al. (2007). Renal clearance of 
quantum dots. Nat Biotechnol, 25(10), 1165-1170. 
37 Dunne, M., Corrigan, I., & Ramtoola, Z. (2000). Influence of particle size and dissolution conditions on the 
degradation properties of polylactide-co-glycolide particles. Biomaterials, 21(16), 1659-1668.  
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a prolonged release of their cargo potentially reducing the number of administration and 
increaseing patient compliance. The release depends on the solubility of the drug, or on the 
diffusion of the drug through the material forming the DDS or on the degradation of the DDS 
itself. DDS potentially are important tools in cancer therapy for optimizing the effect of drugs 
and reducing side effects for this reason nanotechnology has become one of the most growing 
research area. Most recently polymer-based nanoparticles drew attention due to the possibility 
of manipulate their properties thanks to the progress made by polymer chemistry.38  
Due to the wide variety of materials and drugs that can be used in the production of NPs the 
choice of a proper method for their fabrication is of crucial importance and depends on the 
chemical features of the polymer and the drug that must be loaded. Solvent evaporation, 
emulsification, nanoprecipitation and salting out are the widely used technique for the 
preparation of NPs. These method are based on the dispersion of preformed polymers involving 
an organic solution (e.g., dichloromethane, chloroform, ethyl acetate, acetone) containing the 
nanoparticle components and an aqueous solution containing stabilizers that will constitute the 
dispersion medium. The volatile organic solvent is removed by continuous stirring or by 
reducing the pressure. This leads to the formation of polymeric NPs with an efficient 
encapsulation of the lipophilic compound that finally are collected by ultra-centrifugation. 
Particullary, in the solvent diffusion method (nanoprecipitation) the polymer and the drug are 
solubilized into a water-miscibile organic solvent such as acetone. The organic phase is added 
dropwise to a stirred aqueous solution and the fast diffusion of the organic solvent into the 
aqueous medium causes the instantanious formation of NPs. This is due to the interaction of 
the polymer with the two different phases. The solvent is removed under reduced pressure. This 
method is limited to the water-miscibile solvents but ensures high reproducibility and high 
encapsulation efficacy. 
Once formulated particles are charachterized to ensure that the system is suitable to deliver the 
drug into the body. Dynamic light scattering (DLS) that utilizes the interaction of light with 
suspended particles under Brownian motion is the most used technique to obtain their 
hydrodynamic size. Particles are also imaged via Transmission Electron Microscopy (TEM) 
and Scanning Electron Microscopy (SEM). The two microscopes differ in which the SEM 
collects the secondary electrons that bounce back from the sample creating a well-rounded 
image while the TEM collects the electrons that pass through the sample generating just a 
                                                          
38 Binder, W. H. and Sachsenhofer, R. (2008), ‘Click’ Chemistry in Polymer and Material Science: An Update. 
Macromol. Rapid Commun., 29: 952–981. doi:10.1002/marc.200800089 
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shadow of the sample. Surface charge of the particles is another fundamental parameter that is 
related to suspension stability and particle surface morphology. The widespread technique to 
determine the surface charge is the measurement of the electric potential away from the particle 
surface in the diffuse layer. This location is known as slipping or shear plane and the potential 
measured at this plane is called zeta potential (ζ ).  
2.4.1 Stealth nanoparticles: poly(ethylene glycol) (PEG) 
     Materials employed for NPs production have the fundamental requirement to be 
biodegradable. A biodegradable material is cleaved in the human body by several mechanisms 
such as hydrolysis (reaction with water), oxidation (due to oxidants produced by tissues) and 
enzymatic degradation and then reabsorbed or excreted without any adverse effects. A material 
for systemic use should be also biocompatible. Biocompatibility is defined as the capacity of a 
material to be in contact with a living system without producing any adverse effect such as host 
immune system response. Different strategies have been adopted so far to fabricate “stealth” 
NPs. The most widely used is coating the surface with polyethylene glycol (PEG) that 
minimizes the absorption of plasma proteins by creating a hindrance layer on the surface of 
NPs. The PEG layer can assume two different shape depending on the surface density. When 
PEG density is low, a mushroom like structure is formed while as PEG density increases, the 
chains reach out to not overlap and a brush structure is established (Figure 2).  
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Figure 4. Representations of different PEG conformations top: the low density surface coverage of PEG chains 
leads to the “mushroom” configuration where most of the chains are located closer to the particles surface. Bottom: 
the high density surface coverage of the PEG chains leads to the “brush” configuration where most of the chains 
are extended away from the surface.  
Functionalization of teh particles surface can be done pre- or post-assembly. In pre-assembly 
approach, the ligand is incorporated with the NPs building blocks before NPs are formed. This 
is done by conjugating the ligand to the employed polymer, or by adding the ligand with NPs 
components in the solution. In post-assembly approach, the ligand is attached to pre-formed 
NPs by establishing a strong, covalent or non-covalent, interaction between the ligand and the 
NPs surface (Figure 3). PEG can be occasionally incorporated through both approaches, not 
only as stealth molecules, but also as a ‘spacer’ that separate ligands on NPs surface, therefore 
reducing the steric interference and allowing higher targeting efficiency.39 Polymeric NPs 
should be rationally designed to have optimum size, surface properties, drug loading and 
cellular interactions, and then appropriately characterized and tested in vitro and in vivo. 
                                                          
39 Abd Ellah, N. H., & Abouelmagd, S. A. (2017). Surface functionalization of polymeric nanoparticles for 
tumor drug delivery: approaches and challenges. Expert Opin Drug Deliv, 14(2), 201-214. 
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  Figure 5. Pre- and post-assembly approaches for functionalization of polymeric NPs 
2.4.2 Amphiphilic block copolymers 
     Amphiphilic block copolymers have unique properties and numerous potential applications 
due to the ability to form various types of self-assembling structures. Novel synthetic techniques 
allows to obtain block copolymers with well-defined compositions and molecular weights 
depending on the intended application. These copolymers are produced throughout the 
polymerization process. Basically two or more chemically different monomers, usually one 
hydrophobic and the other hydrophilic, are linked together by covalent bonds. The versatility 
of block copolymers is enhanced by the possibility to incorporate functional groups that allow 
further chemical modification after polymer formation. Basically, these process could be based 
on  covalent or non covalent bonds. The formation of covalent bonds between a polymer 
backbone and functionalized moieties has been the most commonly used method to modify 
polymer chains. This postmodification facilitates the production of multiple block architectures.  
The different architectures are shown in Figure 4. The simplest is AB-type, while other 
architecture can be formed from two B units connected to A or conversely and this is the ABA 
or BAB triblock. More configurations are the multiblock in which the two units are bounded n 
times and the star shape block copolymers. 
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Figure 6. Schematic representation of block copolymer structures: (a) A-B diblock, (b) A-B-A triblock, (c) B-A-
B triblock, (d)ABn multiblock and (e) AB star shape. 
The most common and extensively studied are linear amphiphilic block copolymers. The linear 
diblock are capable to self-assembly in aqueous media into spherical structures with an oil or 
aqueous core surrounded by a polymeric shell. The hydrophilic shell serves as an interface 
between the hydrophobic core and the environment. This unique architecture enables polymeric 
particles to serve as depots for poorly water-soluble compounds. There are many synthetic 
polymers used for the fabrication of polymeric nanoparticles like. Amid them, polyesters such 
as PLGA and PCL are the most widely used. PCL can be synthesized by ROP of monomeric 
unit of ε-caprolactone (Figure 5). 
 
Figure 7. Ring opening polymerization method (ROP). ROP is a chain-growth polymerization in 
which the terminal end group of a polymer chain acts as a reactive center where further cyclic 
monomers can be added by ring-opening and additon of the broken bond. 
 
This hydrophobic, semicrystalline polymer has been extensively explored because it is soluble 
in numerous organic solvents, has a low melting point (59-64°C) and can be bound with a wide 
range of polymers. In aqueous medium PCL is degraded by hydrolitic scission of ester bonds 
 22 
 
and the degradation product is the non-toxic 6- hydroxyhexanoic acid (HHA). Due to this slow 
degradation and safety PCL was used in the biomedical field and has already been approved by 
the U.S. FDA. 40 
As stated above, linear diblocks in aqueous media can self-assemble into sferical structures with 
a hydrophilic shell and a hydrophobic core that can be exploited to deliver poorly water soluble 
drugs (Figure 6).  
 
Figure 8. Schematic representation of core-shell self-assembled nanoparticle (b) from a hydrophilic/hydrophobic 
polymer diblock (a). The hydrophobic side of the diblock sets as the core of the particle appropriate for the loading 
of poorly water soluble molecules although the other half formed an hydrophilic shell serving as interface for the 
delivery into aqueous media 
Polymer based nanoparticles have a great potential in the field of nanomedicine, especially 
polymeric nanoparticles made of PEG-PCL diblock. PEG-PCL copolymers combine the 
features of the single unit yielding a new promising biomedical material with amphiphilicity, 
biodegradability and biocompatibility. Particles generated from this diblock are composed of a 
hydrophobic core formed by PCL and the external shell made by water soluble group of PEG. 
Poorly water-soluble drugs have been successfully loaded 
                                                          
40 Ulery, B. D., Nair, L. S., & Laurencin, C. T. (2011). Biomedical Applications of Biodegradable Polymers. J 
Polym Sci B Polym Phys, 49(12), 832-864. 
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inside these particles such as curcumin41,42, indomethacin43, rapamycin44, paclitaxel45,46 and 
docetaxel47,48.  
2.4.3 Active folate targeting 
     The efficiency of nanotherapeutics shall be measured by the amount of cancerous cells 
recognised and killed without damaging healty cells. In order to increse the ability of these 
vectors to bind solely the diseased cells one of the most promising strategies is the decoration 
of the surface of the particles with moieties that recognized receptors overexpresed at the tumor 
site, known as active targeting. An increased action specificity and improved internalization 
throug endocytosis mechanism can improve the effectiveness of treatment and decrease the 
possibility of serious side effects. Among the targeted receptors, folate drew considerable 
attention. Folate are part of the family of vitamins B and require specific transport systems to 
be delivered to systemic tissues include the reduced folate carrier (RFC) (SLC19A1), the proton 
coupled folate transporter (PCFT) (SLC46A1) and four isoforms of folate receptors (FRα, FRβ, 
FRγ and FRδ). RFC, the major transporter of reduced folate, is an organic anion antiporter that 
utilizes the transmembrane phosphate gradient to transport folate into cells. PCFT also belong 
to the solute carrier (SLC) group of transporters but differs from RFC in that works optimally 
at acid pH (~5.5) rather than neutral as the RFC and furthermore it shows differences in binding 
various anti folate substrates. The folate receptors (FRs) are expressed at the cell surface, 
anchored in the cell membrane by a glycosylphosphoinositol (GPI) domain. Distribution of the 
isoforms is different. FRα is expressed on ephitelial tissues and it is even more expressed in 
various tumors still of epithelial origin (ovarian, mammary, lungs, kidney, bladder, cervical, 
                                                          
41 Bisht, S., Feldmann, G., Soni, S., Ravi, R., Karikar, C., & Maitra, A. (2007). Polymeric nanoparticle-
encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology, 5, 3. 
42 Udompornmongkol, P., & Chiang, B. H. (2015). Curcumin-loaded polymeric nanoparticles for enhanced anti-
colorectal cancer applications. J Biomater Appl, 30(5), 537-546. 
43 Rezaei Mokarram, A., Kebriaee Zadeh, A., Keshavarz, M., Ahmadi, A., & Mohtat, B. (2010). Preparation and 
in-vitro evaluation of indomethacin nanoparticles. Daru, 18(3), 185-192. 
44 Bisht, S., Feldmann, G., Koorstra, J. B., Mullendore, M., Alvarez, H., Karikari, C., et al. (2008). In vivo 
characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities. Mol Cancer 
Ther, 7(12), 3878-3888. 
45 Zhang, L., He, Y., Yu, M., & Song, C. (2011). Paclitaxel-loaded polymeric nanoparticles based on PCL-PEG-
PCL: preparation, in vitro and in vivo evaluation. J Control Release, 152 Suppl 1, e114-116. 
46 Hu, J., Fu, S., Peng, Q., Han, Y., Xie, J., Zan, N., et al. (2017). Paclitaxel-loaded polymeric nanoparticles 
combined with chronomodulated chemotherapy on lung cancer: In vitro and in vivo evaluation. Int J Pharm, 
516(1-2), 313-322. 
47 Maiolino, S., Russo, A., Pagliara, V., Conte, C., Ungaro, F., Russo, G., et al. (2015). Biodegradable 
nanoparticles sequentially decorated with Polyethyleneimine and Hyaluronan for the targeted delivery of 
docetaxel to airway cancer cells. J Nanobiotechnology, 13, 29. 
48 Ungaro, F., Conte, C., Ostacolo, L., Maglio, G., Barbieri, A., Arra, C., et al. (2012). Core-shell biodegradable 
nanoassemblies for the passive targeting of docetaxel: features, antiproliferative activity and in vivo toxicity. 
Nanomedicine-Nanotechnology Biology and Medicine, 8(5), 637-646. 
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endometrial and brain).49 The function of the folate in tumor progression is unknown and 
therefore the reason of overexpression of the FRα is not clear. Folic acid is involved in DNA 
synthesis, cell division and growth possibly. FRα might confer a growth advantage to the tumor 
by modulating folate uptake from serum or by generating regulatory signals. The role of 
targeted drug delivery systems is improved efficacy by increasing drug concentration at a 
desired site and simultaneously reducing toxicity. This technology did not gave the expected 
results and several factors need to be considered in the development of future targeted 
nanocarriers generation. The current targeted nanoparticles are developed to treat cancer by 
intravenous administration route and this costitute an issue for the desired cellular selectivity in 
that it is almost impossible to reach only one cellular population even with a driving molecule. 
Moreover, the biodistribution profiles showed that this carriers accumulate in liver and spleen 
also when this accumulation is not sought. Probably, this is due to the the surface adsorption of 
serum proteins that lead to interaction with the MPS. Also the formed protein corona cause a 
reduction in the exposition of ligands. Evenmore, the cellular uptake is sensitive to the 
physochemical features of the particles such as size, surface charge and shape and the 
decoration with this molecules negative affect the the therapeutic impact of the NPs with a 
lower accumulation through passive meccanisms (Figure 7). There are also important temporal 
aspects affected by targeting including the relationship between pharmacokinetics, drug release 
kinetics and the therapeutic window for effective disease treatment. A correct approach will 
focus attention before on the biological features that define a disease and after on nanoparticles 
development to design a targeting system that is specifically tailored to these characteristics. 50 
                                                          
49 Parker, N., Turk, M. J., Westrick, E., Lewis, J. D., Low, P. S., & Leamon, C. P. (2005). Folate receptor 
expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal 
Biochem, 338(2), 284-293. 
50 Cheng, C. J., Tietjen, G. T., Saucier-Sawyer, J. K., & Saltzman, W. M. (2015). A holistic approach to targeting 
disease with polymeric nanoparticles. Nat Rev Drug Discov, 14(4), 239-247. 
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Figure 9. Selected challenges facing molecular targeting of polymeric NPs 
3 Microsized drug delivery systems  
3.1 Multistage vector (MSV) 
     Despite nanotechnology brought innovation and new strategies are still developing this field 
did not achieve the expected results, indeed Wilhelm et all showed that only a small portion of 
the injected dose reaches the site of action.51 This could be due to the presence of multiple 
biological barriers including enzymatic degradation, uptake by the immune system, renal 
clearance throughout their passage in the circulatory system, cell membranes and various efflux 
pumps once the particles reach the cells. This represents major obstacles for the delivery of 
therapeutic compounds.52 Newely research efforts has been made based on the micro scale by 
combining different disciplines together such as biology, chemistry, physics and engineering. 
The multistage vector (MSV) is an innovative platform that combine nano and micro 
technology to overcome the biological obstacles in a sequentially manner (Figure 8).53 This 
platform consists of three components. The first stage is a discoidal porous silicon 
microparticles designed to adhere to the tumor abnormal endothelial wall. To achieve this the 
                                                          
51 Wilhelm S. , T. A. J., Dai Q. , Ohta S. , Audet J. , Dvorak H.F. & Chan W. (2016). Analysis of nanoparticle 
delivery to tumors. Nature Reviews Material. 
52 Blanco, E., Shen, H., & Ferrari, M. (2015). Principles of nanoparticle design for overcoming biological 
barriers to drug delivery. Nat Biotechnol, 33(9), 941-951. 
53 Venuta, A., Wolfram, J., Shen, H., & Ferrari, M. (2017). Post-nano strategies for drug delivery: multistage 
porous silicon microvectors. [10.1039/C6TB01978A]. Journal of Materials Chemistry B, 5(2), 207-219. 
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discoidal shape plays a fundamental role because previous study showed that discoidal particles 
marginate against the vascular wall better than spherical particles54 also the red blood cells push 
the microparticles towards the vasculature due to shape interactions.55 Even more the nature of 
the tumor enviroment promotes the accumulation of the microparticles due to the low shear 
rates56 and increases the degradation through presence of reactive oxygen species (ROS).57 
With these features the microvectors arise as an excellent vehicle for the second nanostage. 
Depending on the application, different types of nanoparticles can be loaded into the pores of 
the microparticle, including liposomes58,59, polymeric nanoparticles60,61,62, micelles63, and gold 
nanoparticles.64 The second stage (nanoparticle) enters into the cells by exploiting the fenestred 
vascular endothelium and the third stage, the therapeutic agent, is relesed. 
 
 
 
                                                          
54 Gentile, F., Chiappini, C., Fine, D., Bhavane, R. C., Peluccio, M. S., Cheng, M. M., et al. (2008). The effect of 
shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows. J 
Biomech, 41(10), 2312-2318. 
55 Lee, T. R., Choi, M., Kopacz, A. M., Yun, S. H., Liu, W. K., & Decuzzi, P. (2013). On the near-wall 
accumulation of injectable particles in the microcirculation: smaller is not better. Sci Rep, 3, 2079. 
56 Jain, R. K., Martin, J. D., & Stylianopoulos, T. (2014). The role of mechanical forces in tumor growth and 
therapy. Annu Rev Biomed Eng, 16, 321-346. 
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Figure 10. The multistage vector (MSV) a) Schematic representation of the MSV, which is composed of three 
components. The first stage vector is a biodegradable porous silicon microparticle that can be loaded with second 
stage nanoparticles, which encapsulate third stage therapeutic agents. The microstage, nanostage, and drug 
component are sequentially utilized to overcome biological barriers in the body. b) Scanning electron microscopy 
(SEM) images of MSVs. Scale bar, 500 nm (left), 10 µm (right). 
3.2 Fabrication of MSV 
     Silicon has been widely used for implantable biomedical applications65 and for injectable 
drug delivery systems66,67,68 possesing several advantages including biodegradability69,70 , the 
                                                          
65 Coffer, J. L., Whitehead, M. A., Nagesha, D. K., Mukherjee, P., Akkaraju, G., Totolici, M., et al. (2005). 
Porous silicon-based scaffolds for tissue engineering and other biomedical applications. physica status solidi (a), 
202(8), 1451-1455. 
66 Anglin, E. J., Cheng, L., Freeman, W. R., & Sailor, M. J. (2008). Porous silicon in drug delivery devices and 
materials. Adv Drug Deliv Rev, 60(11), 1266-1277. 
67 Santos, H. A., Mäkilä, E., Airaksinen, A. J., Bimbo, L. M., & Hirvonen, J. (2014). Porous silicon nanoparticles 
for nanomedicine: preparation and biomedical applications. Nanomedicine (Lond), 9(4), 535-554. 
68 Wang, C. F., Sarparanta, M. P., Mäkilä, E. M., Hyvönen, M. L., Laakkonen, P. M., Salonen, J. J., et al. (2015). 
Multifunctional porous silicon nanoparticles for cancer theranostics. Biomaterials, 48, 108-118. 
69 Park, J. H., Gu, L., von Maltzahn, G., Ruoslahti, E., Bhatia, S. N., & Sailor, M. J. (2009). Biodegradable 
luminescent porous silicon nanoparticles for in vivo applications. Nat Mater, 8(4), 331-336. 
70 Godin, B., Gu, J., Serda, R. E., Bhavane, R., Tasciotti, E., Chiappini, C., et al. (2010). Tailoring the 
degradation kinetics of mesoporous silicon structures through PEGylation. J Biomed Mater Res A, 94(4), 1236-
1243. 
 28 
 
opportunity to control shape, size and porosity through different fabrication protocols71 and 
biocompatibility. Numerous studies based on the administration of silicon microparticles 
revealed the absence of toxicity.72,73,74,75 Additionally humans have several grams of silicon 
distributed throughout the body, primarily in the bones, nails, and kidneys. The fabrication of 
MSV consists of two major steps: a silicon wafer is shaped by photolitography and 
subsequentialy an eletrochemical etch formed porous silicon particles of desire porosity pore 
size and thickness. The silicon particles are suspended in isopropyl alcohol (IPA) and stored at 
20°C. Mostly microparticles are made in two sizes a small one (1 µm x 400 nm) and a bigger 
one (2 µm x 700 nm). These differ in pores size and more important for the biodistribution 
profiles in that both accumulate in liver and spleen but only the bigger one accumulate into the 
lungs aiming to specific application.  
3.3 Second generation of MSV 
     In addition to the general application a new generation of MSV that displays additional 
properties was developed in seeking to improve the therapeutic performance of this platform. 
As an example MSV-based strategies that exploit biomimetic coating to overcome biological 
barriers or novel approaches to load inside the micro discoidal particles different 
nanotherapeutics were developed. 
3.3.1 MSV for combination therapy 
     Often the combination therapy can be more effective than the conventional single 
treatment.76,77 Difficulty arises from physicochemical properties of the drugs, because if they 
are too different it is really hard to deliver them simultaneously with the same nanovector. 
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Thereby MSV result very useful since nanotherapeutics with distinct physical features can be 
loaded into them. For example MSV was used to deliver siRNA loaded liposomes and docetaxel 
polymeric nanoparticles to treat metastatic melanoma lesions in the lungs.78 The most common 
mutation in metastatic melanoma is the B-Raf proto-onocogene serine/threonine kinase 
(BRAF) V600E, which is strongly correlated with reduced survival rates.79 The use of a BRAF 
inhibitors such as vemurafenib and dabrafenib had a positive impact in the treatment of 
metastatic melanoma.80 Drug resistence develops over time against the BRAF inhibitors so the 
use of combination therapy that can suppress tumor growth through multiple mechanisms is 
used to improve the anticancer efﬁcacy.81 Against that background the MSV aims at delivering 
all the therapeutics into an ideal platform for combination therapy. Also spontaneous 
accumulation of the larger particles at the tumor metastasis site as the lungs makes them even 
more suitable. In fact Mi et al.54 showed that the survival rate of melanoma tumor mice increase 
of ~60% in the group treated with MSV loaded with NPs and liposomes despite the group 
treated with NPs or monotherapy.  
3.3.2 Stimuli responsive MSV 
     The microdevice can exploit the tumor enviroment to release the cargo like the stimuli 
responsive NPs that release the therapeutics under specific condition. Mettalloproteinase-2 
(MMP2) play a major role in tissue penetration by cancer cells and the secretion is elevated in 
numerous human cancer and thus may be used as target to improve the accumulation into 
diseased tissues. Polymeric NPs bound to the MSV surface through a peptide substrate linker 
responsive to MMP2 get a chance to exploit this cancer feature and the biodistribution profile 
of the silicon vectors.82 The work show a major difference in the NPs release profiles from the 
silicon surface in presence or in absence of MMP2 proving that MSV could be used as a stimuli 
responsive platform.  
3.3.3 Biomimetic MSV 
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     Other interesting application of the MSV is in the field of biomimetic strategies for drug 
delivery. Synthetic systems that mimic the function or the structure of biologically substances 
such as surface coating with a phospholipid bilayer or monolayer, surface decoration with 
proteins, carbohydrates, peptides or antibodies are an attractive way for addressing the issue of 
biological barriers inside the body.83 This approach has been widely applied to nanosystems but 
less for microdevices. A model for the application of this technology is the one proposed by 
Parodi et all in which the discoidal silicon micro particles are covered with proteo-lipid patches 
obtained from fresh leukocytes cellular membranes.84 These anionic patches are bound to the 
cationic surface by electrostatic and hydrophobic interactions. Interestingly, the protein 
contenent was analyzed and more than 300 leukocytes membrane proteins were found on the 
patches, notably proteins involved in endothelial adhesion and transendothelial migration, 
which could enhance the interaction with the inflamed endothelium like the leukocytes do.85 To 
assess the overcoming of the cellular membrane a transwell chamber assay was carried out in 
presence of tumor necrosis factor (TNF-α) to simulate an inflammatory enviroment the results 
showed that the proteo-lipid coated microparticles cross the endothelium considerably more 
than non-coated particles. For the in vivo studies two different coating were prepared one 
derived from syngenic murine leukocyte membrane and the other from xenogenic human. The 
biodistribution profile differs in that the syngenic showed a delay in liver accumulation and 
consequentially a longer circulation time.86 
3.3.4 Immunotherapy 
     Cancer and immune system are closely interrelated to one side release of antigens from 
tumor and subsequent presentation of these antigens by antigen-presenting cells (APCs) to 
native T cells which after activation migrate into the tumor and kill cancerous cells as effector 
T cells and on the other side tumours suppress immune responses by activating negative 
regulatory pathways (checkpoints). Therefore dendritic cell-based vaccines and immune 
checkpoint inhibitors have harvested interest in the field of cancer research in recent past. Most 
important achievement in cancer immunology led to Sipuleucel-T (Provenge®) the first FDA 
                                                          
83 Gong, Y. K., & Winnik, F. M. (2012). Strategies in biomimetic surface engineering of nanoparticles for 
biomedical applications. Nanoscale, 4(2), 360-368. 
84 Parodi, A., Quattrocchi, N., van de Ven, A. L., Chiappini, C., Evangelopoulos, M., Martinez, J. O., et al. 
(2013). Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. 
Nat Nanotechnol, 8(1), 61-68. 
85 Corbo, C., Parodi, A., Evangelopoulos, M., Engler, D. A., Matsunami, R. K., Engler, A. C., et al. (2015). 
Proteomic Profiling of a Biomimetic Drug Delivery Platform. Curr Drug Targets, 16(13), 1540-1547. 
86 Evangelopoulos, M., Parodi, A., Martinez, J. O., Yazdi, I. K., Cevenini, A., van de Ven, A. L., et al. (2016). 
Cell source determines the immunological impact of biomimetic nanoparticles. Biomaterials, 82, 168-177. 
 31 
 
approved immune cell based vaccine that showed an increased overall survival in prostate 
cancer patients.87 This treatment is based on the incubation ex vivo of antigen protein and 
patient’s APCs that only later are injected again. New strategies needs to be developed to 
stimulate the APCs cells in vivo and in that nano- and micro-carrier could be helpful.88,89 Porous 
silicon particles were recently expolited as adjuvants for cancer vaccine.90 Human epidermal 
growth factor (HER2) peptide antigen containing liposomes were loaded into the pores of the 
microparticles. The peptide was used to stimulate an antigen specific immune response against 
cancer cells that overexpress this receptor. APCs such as dendritic cells (DC) or B cells display 
antigen complexed with major histocompatibility complexes (MHCs) on their surfaces; this 
process is known as antigen presentation. T cells recognize these complexes using T cell 
receptors (TCRs) and this leds to the activation of effector T cells that at this point are able to 
recognize and kill the cancer cells. The porous particles generated a strong anti-tumor immunity 
in mice tumor model by inducing efficient antigen cross-presentation and also by actived 
simultaneously a type I interferons (IFN-I) response. These findings highlight the advantage of 
particulate vaccine and the IFN-I signaling for successful immunotherapy. 
3.3.5 Injectable nanoparticle generator (INPG)  
     An innovative approach consists in the injectable nanoparticle generator. The microdevice 
is used to deliver a chemotherapeutic agent covalently linked to poly(L-glutamic acid), the 
exposure to acqueous media triggered the formation of polymeric nanoparticles sizied by the 
pore of the silicon vector and released as the silicon degraded. Triple negative breast cancer 
(TNBC) mouse model was used to evaluate the platform. Unlike other thypes of breast cancer 
TNBC does not express receptors such as estrogen receptor (ER), progesterone receptor (PR), 
or HER-2. This makes chemotherapy, hormone therapies, and targeted therapies inefficient. 
Also TNBC is often associated to the development of liver and lungs metastases. The MSV is 
able to accumulate preferentially into the metastasized organs and release therapeutic agent 
only in acidic environment. This result as very promising approach in the treatment of TNBC. 
In the work of Xu et all the median survival is evaluated into TNBC mouse model by comparing 
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the traeatment between free doxorubicin, Doxil® and the nanoparticles generator. It was 
observed that the survival rate increases in the group treated with the microparticles despite the 
groups treated with free doxorubicin and Doxil.91  
4 Brain therapy 
     Despite this wide range of application, this versatile platform has not yet been used to treat 
brain disease. This is because brain represents a major challange in drug delivery. The 
development of innovative therapeutic strategies for the treatment of the brain diseases 
constitutes a great challenge and the major hindrance is the overcoming of the Blood Brain 
Barrier (BBB). Although the knowledge of the BBB continues to evolve in the years, a structure 
has been delineated characterized by the presence of closely associated areas named tight 
junctions (TJ) and from the lack of fenestrature.92 Such anatomical features determine the 
formation of a continuous barrier among the blood stream and the interstitial fluid that restricts 
permeability of most substances from blood to brain. However the BBB, in the cerebral 
microvessels, constitutes the principal site of exchange between the whole organism and the 
central nervous system (CNS) because it serves to exclude the xenobiotic substances and at the 
same time to regulate brain homeostasis. Therefore some transport mechanisms are located at 
BBB level including i) simple diffusion for transport of water, gases and lipophilic substances, 
ii) carrier-mediated transport involved in the carriage of nutrients as the glucose transporter 1 
(GLUT-1), ions transport, monocarboxylic acid and neutral amino acids transports, iii) two 
transcytosis systems, one receptor-mediated (insulin and transferrin) and the other based on 
electrostatic interactions.93 Further, biological barriers at BBB including cytochrome P450 
(CYPs) systems and more the presence of efflux transporter that can actively transport a huge 
variety of drugs out of the cell. These transporters are belonging to the family of the gene ABC 
(ATP-binding cassettes)/MDR1 as the Glycoprotein P (P-gp) that has a key role in the transport 
of drugs through the BBB. Brain metastases commonly arise from lung, breast and skin 
(melanoma) cancers and the approaches to the treatment of the patients with this metastases 
include whole brain radiotherapy (WBRT), surgery and stereotactic radiosurgery (SRS). 
Chemotherapy is used only in association to the radiotherapy or to the surgery to maintain under 
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control the systemic disease because the presence of the BBB prevents the 98% of the 
chemotherapeutic to access the SNC.  
5 Aim of the work  
     In this context, our overall aim was to develop different strategies for the delivery of 
conventional chemotherapeutics in the field of cancer therapies. 
The first mark was to develop a rationally-designed Dox-dextran conjugate with appropriate 
MW based on estimated EPR effect in established liver metastases mice model to overcome the 
limited clinical efficacy of pegylated liposomes and Dox. 
In the field of physically entrapped drug into polymeric NPs we develop novel folate-targeted 
polymeric NPs made of PEG-PCL diblock by the solvent displacement method. Notably the 
fabrication method can affect the amount of PEG on the particles surface therefore the 
interaction with plasma protein and the exposition of the folate moieties. The aim was to test 
different length of PEG chains (short 1.0 kDa, long 2.0 kDa) to maximize the surface 
exposition of folate and how this could change the interaction with human cells and biological 
fluids.  
A third aim of the project is the development of novel approaches based on the combination of 
micro- and nano-delivery systems to treat brain metastases arise from primary tumors as 
melanoma and breast cancer. The basic concept is to functionalize the micro-vector surface 
with a Polysorbate 80 (Tween 80) coating to have a preferential accumulation at the brain 
microvasculature. Overcoating with these materials seems to lead to the adsorption of 
apolipoprotein E from blood plasma onto the nanoparticle surface. The particles then seem to 
mimic low density lipoprotein (LDL) particles and could interact with the LDL receptor leading 
to their uptake by the endothelial cell. Alternatively molecules able to bind receptors highly 
expressed at the BBB such as transferrin (Tf) will be covalently linked to the silicon surface to 
obtain the same preferential accumulation. Thereafter, the capacity of transporting 
simultaneously more than one active component in the porous micro particle will be exploited. 
Especially will be developed targeted NPs capable to overcome the BBB by taking advantage 
of receptors such as GLUT-1. These nanoparticles will be loaded in the pore of the microparticle 
togheter with an efflux pump inhibitor to increase the efficiency of drug delivery. Aproof-of-
concept will be provided by in vitro and in vivo models.  
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The research activity has been summarized in three chapters and two annexes: 
- Synthesis and characterization of rationally-designed Dextran-Doxorubicin conjugate: a novel 
strategy to improve the antitumor efficacy of doxorubicin in multiple breast cancer liver 
metastases (Chapter 2) 
- Shedding light on surface exposition of poly(ethylene glycol) and folate targeting units on 
nanoparticles of poly(ε-caprolactone) diblock copolymers: beyond a paradigm (Chapter 3) 
- Strategies to overcome the Blood Brain Barrier (BBB) (Chapter 4) 
In Annex I the development of a novel antibacterial polymeric film of poly(lactic-co-glycolic 
acid) (PLGA) for the release of nitric oxide (NO) under visible light is reported. In Annex II a 
study of the growth of the drug delivery literature published during 1974-2015 was discussed. 
The work has ben carried in colaboration with the Institute of Polymers, Composites and 
Biomaterials (Italian National Research Council, Pozzuoli, Napoli, Italy) Department of 
Biology (University of Padua, Italy), Department of Drug Science (University of Catania, Italy) 
and Department of Nanomedicine (Houston Methodist Research Institute, Houston, Texas). 
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Chapter 2 
 
Synthesis and characterization of rationally-designed 
Dextran-Doxorubicin conjugate: a novel strategy to 
improve the antitumor efficacy of doxorubicin in multiple 
breast cancer liver metastases. 
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1 Introduction 
     Metastatic breast cancer (MBC) is the common cause of cancer death in women and 
generally is considered incurable (Redig & McAllister, 2013). The choice of the treatment 
depend on several consideration such as the characteristics of the cancer cells, where the cancer 
has spread and previous therapy. In the case that cancer is hormone receptor-positive or HER2-
positive, the first line treatment is hormone therapy or targeted therapy respectively 
(Abdulkareem & Zurmi, 2012; Fabi, Malaguti, Vari, & Cognetti, 2016). Chemotherapy has a 
fundamental role in the treatment of this disease, in that it can be used to reduce the growth of 
tumors or to ease symptoms of the cancer itself. Amongst the chemoterapeutics anthracyclines 
have a central role in the treatment of MBC (Rivera, 2003). However, these therapeutics are 
often associated to severe systemic side effects such as the case of Doxorubicin (Dox) that 
causes myelosuppression, alopecia, gastrointestinal toxicity, and cardiotoxicity and 
furthermore does not achieve expected drug concentration inside tumors (Kaminskas et al., 
2012; McGowan et al., 2017). This is due to the spreading of the drug from blood stream to 
various organs through blood vessels caused by its small molecular size. Moreover, size affects 
the exposition of tumor cells to drugs, because of small molecules are rapidly cleared up from 
the body. Taken together, the non-specific accumulation and limited pharmacokinetic (PK) 
profile of this compound both in systemic circulation and tumors has been considered a major 
reason for insufficient therapeutic index (Speth, van Hoesel, & Haanen, 1988). The 
development of a carrier able to avoid the rapid clearance and the non-specific accumulation is 
a crucial needing for MBC treatment. For this purpose nanoparticles (NPs) have been developed 
as novel drug carriers that due to the largest size, as compared to conventional drugs, are able 
to overcome these limits. The preferential accumulation of NPs into the tumor site is based on 
the enhanced permeability and retention (EPR) effect (Bazak, Houri, Achy, Hussein, & Refaat, 
2014; Ngoune, Peters, von Elverfeldt, Winkler, & Pütz, 2016). Indeed, solid tumor show 
vascular abnormalities that increase the accumulation of macromolecules in tumor tissues and 
moreover prolong their retention for long periods (Carmeliet & Jain, 2000). This delivery 
strategy has the potential to lead to superior therapeutic indices. Despite this, only a limited 
number of NPs expoliting EPR effect have been approved for clinical use (Ragelle, Danhier, 
Préat, Langer, & Anderson, 2017). The first-appoved formulation for the delivery of 
chemotherapeutics was a pegylated liposome able to reduced systemic side effects compared to 
the free drugs but not to significally improve the anti tumor effects into the metastatic diseases 
(O'Brien et al., 2004). This clinical evidence suggests that further delivery approaches needs to 
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be developed and there is a need for an in depth study of the anatomical knowledge of the EPR. 
Another strategy to improve the systemic PK profile of Dox in circulation is the use of 
polysaccharides such as Dextrane that have been widely used in polymer-drug conjugates 
(Varshosaz, 2012). Advantages of polysaccharides as a drug carrier include a repetitive and 
well-defined chemical structure, reactive groups useful for drug conjugation, high stability, 
biodegradability and water solubility. Preclinical studies using primary tumor models have 
shown less systemic side effects and superior anti-tumor effects in primary tumors compared 
to conventional drug formulations. Dox-dextran 70 kDa was tested in a phase I clinical trial, 
but clinical efficacy was comparable with Dox (Danhauser-Riedl et al., 1993). One of the key 
factors in the development and successful utilization of therapeutic agents is the understanding 
of the mechanisms regulating their delivery to the tissue. Using real-time live imaging in tumor-
bearing animals such as Intravital Microscopy (IVM) an enhanced understanding of several 
pathological and physiological dynamic processes at a subcellular resolution have been 
elucidated such as: (i) local PK in tumors/organs (using fluorescently labeled antibody, 
chemotherapy or liposomes); (ii) vascular pathology (vascular density/architecture); (iii) 
vascular physiology (flow rate and vascular permeability using fluorescence tracers/labeled 
blood cells); and (iv) local pharmacodynamics (PD) (tumor size, proliferation, apoptosis using 
labeled cancer cells) (Beerling, Ritsma, Vrisekoop, Derksen, & van Rheenen, 2011). The 
application of IVM, however, is limited by the accessibility of the tumors and by the survival 
of the animals following surgical procedures. Recently, imaging window chambers have been 
developed for animals to allow optical access to large target areas without repeated surgical 
exposure of organs or tumors, allowing both local PK and PD analysis in the targeted area. 
The final aim of this work was to select the ideal molecular weight dextran as a Dox carrier for 
liver metastases using IVM imaging.To evaluate the EPR effect in MBC, a mouse model with 
multiple liver metastases by injecting 4T1 or MDA-MB-231 murine breast cancer cells into the 
spleen was developed. Once multiple liver metastases were well established, a window chamber 
was implanted above the liver.To estimate the relative EPR effect in metastatic liver tumors the 
diffusion of systemically injected fluorescently labeled dextran tracer with different molecular 
weight 10 kda 70 kda inside/outside tumors in liver using IVM through window chamber was 
evaluated.  
2 Experimental section 
2.1 Materials 
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Aldehyde functionalized dextrans (Dex-CHO) with average molecular weight of 10 kDa and 
70 kDa were obtained from Nanocs Inc, Doxorubicin hydrochloride (DOX-HCl) and Dimethyl 
Sulfoxide (DMSO) were bought from Fisher Scientific Co L.L.C. Triethylamine (TEA) 
(≥99%), Acetone and Dimethyl sulfoxide-d6 were bought from Sigma-Aldrich, Phosphate 
Buffered Saline (PBS), ethylenediaminetetraacetic acid (EDTA). Roswell Park Memorial 
Institute (RPMI) 1640 Medium (Life Technologies, Inc., Grand Island, NY), and a penicillin–
streptomycin mixture (Flow Laboratories, Rockville, MD) 
2.2 Synthesis of Dextran10k-Doxorubicin (Dex-Dox) 
Dex10k-CHO and DOX-HCl were coupled to give Dex10k-DOX through Schiff base reaction 
between aldehyde groups of Dex10k-CHO and amino groups of DOX-HCl. The molar ratio 
between Dex10k-CHO, DOX-HCl and TEA was 1:1:1.2. Briefly, Dex10k-CHO was dissolved in 
0.5 mL of DMSO and after TEA was added to the solution. Then DOX-HCl was dissolved in 
0.5 mL of DMSO, slowly dropped into the Dex10k-CHO/TEA solution and stirred for 1.5 h at 
RT in the dark. The final product was precipitated in acetone and the unbound Dox was 
removed by centrifugation at 4700 rpm x 10 mins. Finally, the purified Dex10k-DOX was dried 
under vacuum. Ultraviolet-visible (UV-vis) spectrophotometry was conducted to determine the 
Dox contenent in Dex10k-DOX by a standard curve method (λabs = 480nm, DU 730 Beckman 
Coulter). Proton Nuclear Magnetic Resonance (1H NMR) spectroscopy was employed for 
determining the percentage of the bond in the purified product (Bruker 400 MHz NMR) in 1 
mL of DMSO-d6.  
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      Figure 1. Syntethic strategy for synthesis of Dex-DOX conjugate. 
2.3 Cancer cell preparation 
4T1 mouse breast cancer cells were kindly provided by Dr. Isaiah J. Fidler (UT MD Anderson 
Cancer Center). The cells were cultured in RPMI 1640 medium, completed by adding 10% fetal 
bovine serum and 1% penicillin streptomycin solution (Cellgro, MA), at 37 °C in a humidified 
incubator in 5% CO2. Cells were grown to 80% confluency, trypsinized with 3 ml of 0.25% 
trypsin 0.53 mM EDTA solution for 5 min at 37 °C until cells started to detach. Trypsin was 
quenched with 9 ml of medium, and cells were then washed with 9 mL of PBS containing 1 
mM EDTA. Final 4T1 cell concentration was ~5 × 105 cells/mL. Human cancer cell line MDA-
MB-231 from ATCC (Manassas, VA) was cultured in Dulbecco’s modified Eagle medium 
(DMEM)/F-12 base medium (Lonza, Walkersville, MD) supplemented with 10% FBS and 1% 
penicillin streptomycin solution. Cell culture was maintained in humidified environment with 
5% CO2 at 37 °C. At 80% confluence, cells were harvested by incubation with trypsin solution 
(PromoCell, Heidelberg, Germany). 
2.4 Cell cytotoxicity 
MTT (3-[4,5- dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) (Sigma, USA) assay 
was performed according to the manufacturer’s protocols to assess viability of 4T1 cells. Cancer 
cells were seeded into 96-well plates at concentrations 1×103 cells/well and feded with new 
medium (negative control) or medium containing increasing concentrations of Dex-Dox and 
free Dox. After 72h of incubation cell viability was assessed at 570 nm. Localization of Dox-
dextran conjugates inside cells wase determined using confocal microscope. 
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2.5 In Vivo Model of Breast Cancer Liver Metastasis  
Animal studies were performed in accordance with approved protocols by Houston Methodist 
Research Institute Institutional Animal Care and Use Committee (AUP-1214-0066). Balb/c 
mice and immunodeficient SCID mice were purchased from Charles Rivers Laboratories 
(Wilmington, MA) and mouse breast cancer liver metastases xenograft were generated by 
splenic injection of 1 × 105 4T1 tumor cells/200 μL PBS or MDA-MB-231 1×106 tumor 
cells/200 μL respectively. 
2.6 Models of breast and lung cancer liver metastasis and primary breast tumor 
Female Balb/c mice, 10 to 12 weeks old were maintained in animal facilities at Houston 
Methodist Research Institute approved by the American Association for Accreditation of 
Laboratory Animal Care and in accordance with current regulations and standards of the United 
States Department of Agriculture, Department of Health and Human Services, and NIH 
(Bethesda, MD). 
To establish experimental liver metastasis, breast cancer 4T1 cells (1 × 105/200 μL) or MDA-
MB-231 cells (1×106 cells/200 µl) were injected into the spleen of female Balb/c or 
immunodeficient SCID mice respectively. The cells injected in the spleen disseminate to the 
liver through portal vein, producing experimental liver metastasis. The spleen was removed 10 
min after the injection to prevent tumor growth in this organ. Six days after the injection, mice 
have been anesthetized and window chamber was implanted into the abdominal wall above the 
liver.  
All the surgical procedures were approved by the Institutional Animal Care and Use Committee 
(IACUC) of Houston Methodist Research Institute. 
 
2.7 Intravital microscopy analysis 
Seven days after tumor inoculation, tumor-bearing mice were injected with fluorescently-
labeled dextran tracer or Dex-Dox conjugates of different MW (10 [red], 70 [green] kDa of 
Dextran) intravenously into the retro-orbital space of the mice immediately before intravital 
microscopy (IVM). IVM imaging through window chamber was performed, 3 min, 3 h, 24 h 
after injection, to determine local PK of these drugs in tumors. Mice were anesthetized with 
isoflurane and mounted on heated microscope stage during IVM imaging under Nikon A1R 
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multiphoton microscope (Nikon Inc.). The images were processed for evaluation of fluorescent 
intensities of the tracers inside and outside the lesions at different times using NIS-Elements 
Image Processing Software (Nikon). The recorded fluorescent intensities in the site of interest 
were then normalized to the fluorescent intensity in the unaffected liver. 
3 Results and discussion 
3.1 Molecular weight dependent tumors accumulation of dextrans 
To estimate the relative EPR effect in metastatic liver tumors we evaluated the diffusion of 
systemically injected fluorescently labeled dextran tracer with different molecular weights (10 
kDa [red] and 70 kDa [green]) inside and outside tumors in liver using IVM through abdominal 
window chamber (Fig 2). Live imaging of multiple tumors at different time points after 
injection of both tracers revealed a MW-dependent difference in accumulation in tumors. While 
fluorescence intensity of both tracers outside of tumors decreased over time, 10k but not 70k 
tracers accumulated in tumors as a function of time. 
 
Figure 2. Perfusion and accumulation of fluorescently-labeled dextran tracers with molecular weight of 10 kDa 
and 70 kDa into mice liver metastases at different time points (T1- 3 min, T2- 3h and T3- 24 h). Scale bar 500 µm. 
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3.2 Synthetic strategy 
Based on the evidence of IVM images a Dex10kDa-Dox conjugate was succesfully synthesized 
through a Schiff base formation between the aldehyde group of the Dextran and the ammino 
group of Dox. The purification of the final product was carried out by several washes exploiting 
the different solubility of the conjugate and the free drug, since the conjugated polysaccharide 
precipitates in acetone. Finally, the purified Dex10kDa-Dox was dried overnight under vacuum. 
The amount of Dox linked to the polysaccharide was quantified by UV–vis spectroscopy (78 
µg/mg), using Dox standard solutions in water to construct calibration curves. Reaction was 
confirmed by 1H NMR; the absence of azide band in the spectrum of Dex10kDa-Dox accounts 
for a 100% conversion (Fig. 3). 1H NMR analysis, spectra were recorded with Bruker 400 MHz 
NMR spectrometer. The NMR spectrum of the Dex10kDa-Dox conjugate exhibits an evident 
decrease (dark blue inset) in aldehyde group associated with the Dex10kDa-CHO (light blue 
inset) and as well the presence of aromatic protons associated with Dox (orange inset). The 
absence of unbound Dox was also confirmed by filtration through Sephadex G-10 columns that 
allow separation on the basis of different molecular weights. 
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Figure 3. Comparision of 1H-NMR spectra of Dex10kDa -Dox conjugate and Dox in DMSO-d6. Dark blue inset 
showed the decrease of the aldehyde group associated with the Dex10kDa-CHO, orange inset represents Dox 
aromatic protons. 
 
3.3 Cell proliferation assay 
The conjugate and the free drug showed similar effects on 4T1 cell viability in vitro (Fig.4A ). 
Upon application of Dox-dextran conjugate or free Dox to culture media of 4T1 cells, the 
conjugate was found localized in the nucleus at 3 h in a manner similar to free Dox (Fig. 4B). 
 
Figure 4 A) Effect of Dox-dextran conjugate and free Dox on 4T1 cell viability B) nuclear localization of drugs 
imaged in vitro. 
 44 
 
 
Upon IV administration in mice bearing 4T1 liver metastases, the Dox10kDa-dextran conjugate 
accumulated in tumors at 24 h after the injection (Fig. 5). This result was in contrast to the 
imaging data previously acquired (data not showed) in which almost no accumulation was 
found of Dox or pegylated liposomes inside tumors.  
 
Figure 5. Accumulation of Dox-dextran in 4T1 metastatic tumors in liver. Scale bar 100 µm (left) and 200 µm. 
 
4 Conclusions 
These preliminary data suggest that rationally-designed Dox-dextran conjugates may result in 
improved accumulation as compared with pegylated liposomes and free Dox. Live imaging of 
multiple tumors at different time points after injection of both tracers reveled a molecular 
weight-dependent difference in accumulation in tumors. These data suggest that the drug 
delivery and the EPR effect in metastatic liver tumors is different from that in primary tumors: 
i) EPR effect inside 4T1 liver metastatic tumor is limited to allow only 10 kDa Dextran to 
accumulate; and ii) 10 kDa Dextran can be used as drug carrier of Dox for 4T1 liver metastases. 
Finally, we have successfully developed a rationally-designed Dox-dextran conjugate with 
appropriate MW based on estimated EPR effect in established liver metastases to overcome the 
limited clinical efficacy of pegylated liposomes and Dox.   
Antitumor efficacy and safety of Dox-dextran conjugates as compared with those of free Dox 
and pegylated liposomes is ongoing on already established multiple liver metastases using 4T1 
murine and MDA-MB-231 human breast cancer cells xenographts. Kinetic profiles of 
systemically injected Dox-dextran in circulation (blood), major organs (heart, lungs and 
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kidneys) and liver tumors will be determined using high performance liquid chromatography 
(HPLC), confocal microscopy imaging, or tissue MSI.  Statistical analysis will be performed to 
correlate kinetic profiling data of fluorescently-labeled dextan and Dox-Dex conjugates. There 
is the possibility for heterogeneity in accumulation of tracers among multiple metastases due to 
difference in tumor size. We will evaluate this heterogeneity and correlate tumor size and 
accumulation of tracers among multiple tumors. Possible personalization of metastasis therapy 
using Dox-dextran conjugates with appropriate MW, selected by dextran-based clinically-
relevant imaging analysis (e.g., PET scan), could possibly translate in rapid clinical application. 
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Abstract 
Polymeric nanoparticles (NPs) of poly(ε-caprolactone) (PCL) covered with a hydrophilic 
poly(ethylene glycol) (PEG) shell are usually prepared from diblock PEG-PCL copolymers 
through different techniques. Furthermore PEG, NPs can be decorated with targeting ligands to 
accumulate in specific cell lines. However, the density and conformation of PEG on the surface 
and its impact on the exposition of small targeting ligands has been poorly considered so far 
although this has a huge impact on biological behavior. Here, we focus on PEG-PCL NPs and 
their folate-targeted version to encourage accumulation in cancer cells overexpressing folate 
receptor α. NPs were prepared from copolymer mixtures with different PEG length by the 
widely employed solvent displacement method. An in depth characterization of NPs surface by 
1H NMR, fluorescence and photon correlation spectroscopy was carried out in the attempt to 
evaluate PEG/Folate spatial organization in the shell and its impact on the interaction with 
proteins as well as uptake in human macrophages/cancer cells. Overall, the present results 
demonstrate that PEG length critically affects protein interaction and folate exposition with a 
logical impact on receptor-mediated cell uptake. Our study highlights that the too simplistic 
view suggesting that PEG-PCL gives NPs with a brush shell needs to be reconsidered in the 
light of actual surface properties, which should always be considered case-by-case. 
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1. Introduction 
     Polymeric nanoparticles (NPs) are in the limelight in cancer nanotechnology due to the 
advantages of prompt manipulation of the overall features (size, surface hydrophilicity/charge, 
release rate, biodegradability) through appropriate tailoring of the chemistry of building blocks 
(Grossen, Witzigmann, Sieber, & Huwyler, 2017). Amid the huge amount of biomaterials 
developed so far, poly(ε-caprolactone)-poly(ethylene glycol) PEG-PCL copolymers with 
different hydrophilic/lipophilic balance and architectures have been synthesized resulting in a 
wide arsenal for drug delivery application (Z. Li & Tan, 2014). In the context of cancer therapies, 
NPs of PEG-PCL block copolymers have gained attention in preclinical studies and in clinical 
settings with the promise to ameliorate chemotherapy outcome and decrease treatment toxicity. 
As far as PEG-PCL NPs for intravenous injection are concerned, a PEGylated surface can help 
to escape mononuclear phagocyte system (MPS), to attain long-circulation and to promote 
extravasation in inflamed tissues with a typical dysfunctional capillary bed such as in tumors 
(3). While demonstrating excellent stability in PBS, PEG-PCL NPs were even found to 
aggregate in the presence of serum (4).  
Surface modification of PEGylated NPs with covalently-linked small ligands is a further 
strategy followed to increase drug level in cancer cells. To this purpose, the design of folate-
decorated NPs carrying a chemotherapeutic and internalizing in cancer cells through FRα-
mediated endocytosis has become a hot topic (5). FRα expression level is a marker of tumor 
aggressiveness, plays a role in the low response rate to chemotherapeutics resistance and is 
insensitive to chemotherapy regimen (5), thus strengthening the potential utility of FR-mediated 
delivery.  Folate decoration of PEG-PCL NPs has been attempted by us and other authors by 
synthesizing all-in-one amphiphilic block copolymers bearing folate at PEG hydroxyl-end 
group and able to form core-shell NPs (1). When the amphiphilic diblock polymers self-
assemble into NPs in an aqueous phase, the PEG segments are expected to form the outer corona 
allowing the conjugated folic acid to become fully accessible on the surface. In contrast to this 
paradigm, we observed that for highly PEGylated micelle-like NPs, folate exposition in the 
presence of serum is highly dependent by the formation of a protein corona (6). 
Another aspect to consider when fabricating PEG-PCL NPs refers to the mode of copolymer 
assembly. While dialysis has been largely employed to prepare PEG-PCL micelles/NPs, scale-
up of production as well as in-process sterilization is feasible with microfluidics which takes 
after solvent displacement (nanoprecipitation) techniques. Importantly, mode of assembly of 
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PEG-PCL copolymers can highly affect the amount of PEG on the surface (7) while its impact 
on protein adsorption and targeting features has been poorly considered.  
On this basis, it is evident that PEG coverage plays a crucial role in controlling the biological 
fate of PEGylated NPs with an huge impact on the processes driven by protein interactions 
(immune system recognition, biodistribution), transport through biological matrices (tumor 
extracellular matrix, mucus, bacteria biofilm), and target recognition and docking (cell uptake) 
(8). Despite  the extensive use of PEG, there is no consensus on the target product profile in 
term of PEG density, molecular weight and conformation when developing PEGylated NPs 
intended for a specific application, in cancer as well (9). Thus, surface of NPs should be 
characterized in depth through complimentary techniques in view of a full optimization of the 
nanocarrier and following clinical application (8). 
In this study, we try to focus on the surface exposition of PEG and folate targeting units on NPs 
of PEG-PCL diblock copolymers prepared by solvent displacement technique and to relate shell 
features to uptake in human cells. To this purpose, we synthesized PEG-PCL copolymers with 
either 1 kDa or 2 kDa PEG chains and a Fol-PEG-PCL copolymers with 1.5 kDa PEG segment. 
Shell properties of untargeted and folate-targeted NPs were fully characterized through 
complementary techniques, such as 1H NMR, fluorescence, photon correlation spectroscopy 
and ξ potential. The impact of shell features on NPs interaction with human serum albumin, 
stability in biologically-relevant media as well as internalization in human macrophages and 
cancer cells overexpressing folate receptor were investigated. 
2 Experimental section 
2.1 Materials 
 Poly(ethylene glycol) (PEG) with Mn 1.5 kDa (PEG1.5k, Sigma-Aldrich, Milan, Italy), 
monomethoxy-poly(ethylene glycol) with Mn 2.0 kDa (mPEGL, Sigma-Aldrich, Italy) and 
monomethoxy-poly(ethylene glycol) with Mn 1.0 kDa (mPEGS, Nanocs Inc., USA) were 
dehydrated by azeotropic distillation with dry toluene in a Dean-Stark trap. ε-Caprolactone (CL, 
Sigma-Aldrich, Italy) was distilled over CaH2 under vacuum. Stannous-(2-ethylhexanoate)2 
(Sn(oct)2), N-hydroxysuccinimide (NHS), N,N′-dicyclohexylcarbodiimide (DCC), 
triethylamine (TEA), dimethylaminopyridine (DMAP), tosyl chloride (TsCl), folic acid (Fol), 
propargylamine, triphenylphosphine (PPh3), silver(I) oxide, potassium iodide and sodium azide 
were used without further purification. Copper wires (Carlo Erba, Italy) were treated with H2S04 
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for 3 min, washed with water and methanol, and finally dried under vacuum in an oven for 30 
minutes at 60°C. 1,4-butandiol, 1-hexanol, N,N-dimethylformamide (DMF) and 
dichloromethane (DCM) were dried before use according to standard procedures. All the other 
solvents (analytical grade) were purchased from Sigma-Aldrich and used as received. (2-
Hydroxypropyl)-β-cyclodextrin (HPβCD, DS 0.9), Nile Red (NR) and Human Serum Albumin 
(HSA) were from Sigma (Italy). 
2.2 Copolymer characterization 
FTIR analysis was performed with a Perkin-Elmer spectrometer (Paragon 500) equipped with 
a ZnSe attenuated total reflectance (ATR) crystal accessory. Samples were placed in direct 
contact with the ATR crystal and pressed with a pressure clamp positioned over the 
crystal/sample area to allow intimate contact between the material and the crystal. Spectra were 
acquired in the 4000-400 cm-1 range, at a resolution of 2 cm-1 (average of 20 scans). 1H NMR 
analysis, spectra were recorded with a Bruker Avance DPX400 apparatus operating at 400 
MHz. For GPC analysis, samples were dissolved in THF and passed through a 0.22 μm PTFE 
membrane filter. Measurements were performed on an injected volume of 100 μL by using a 
Malvern-Viscotek GPC MAX/TDA 305 quadruple detector array equipped with a precolumn 
and two Phenogel columns (Phenomenex) with exclusion limits 106 and 103 respectively. The 
GPC instrument was used at a flow rate of 0.8 mL/min and at columns and system temperature 
of 35 °C. Triple detectors calibration was based on a standard of polystyrene with molecular 
weight 104,959 Da. Residual copper content was estimated by Microwave Plasma-Atomic 
Emission Spectrometry (MP-AES) with a Agilent 4100 spectrometer. A microwave digestion 
system Milestone Ethos Touch Control was used for digestion of sample. The finely ground 
sample (0.1 g) was transferred in a teflon microwave digestion vessel and treated with 6 mL of 
HNO3, 3 mL of HCl and 1 mL of H2O2 (Ultrapure Reagents, trace metal grade < 1 μg/L). The 
samples were processed by microwave digestion as follows: ramp to 200 °C over 10 min, then 
hold at 200 °C for 20 min. After digestion, the samples were cooled to room temperature, 
filtered, transferred in a 50 mL volumetric flask and adjusted to 50 mL with distilled water for 
spectrometric analysis. The amount of Fol linked to the copolymer was quantified by UV-vis 
spectroscopy on DMSO polymer solutions (0.2-2 mg/mL), using Fol standard solutions in 
DMSO to construct calibration curves. The absorbance of the sample was evaluated at 360 nm 
on a Shimadzu 1800 spectrophotometer. 
2.3 Synthesis of MPEGS-PCL and MPEGL-PCL  
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Linear diblock copolymers were prepared by ring-opening polymerization (ROP) of CL at 120 
°C for 24 h using mPEGL or mPEGS as initiator and Sn(Oct)2 as catalyst (20%). CL/initiator 
molar ratio = 36. 1H NMR (CDCl3, δ in ppm), PCL block: 1.29–1.78 (m), 2.19–2.43 (t) 3.20 
(m); 3.92–4.21 (t), 4.31(t); PEG block: 4.10 (t), 3.64 (s), 3.38, (t).  
2.4 Synthesis of Fol-PEG-PCL  
2.4.1 Synthesis of PCL-PEG-azido copolymer (N3-PEG-PCL) 
 Step 1. Synthesis of monotosyl-PEG (Ts-PEG-OH). PEG (5.00 g, 3.34 mmol) was dissolved 
in 50 mL of dry toluene. Ag2O (1.161 g, 5.01 mmol) and KI (110 mg, 0.668 mmol) were finely 
dispersed in the solution by stirring, then TsCl (2.76 g, 14.5 mmol) was added. The reaction 
mixture was kept at room temperature under stirring and nitrogen atmosphere for 12 h. The 
solution was filtered and solvent removed by rotary evaporation. The polymer was dissolved in 
10 mL of DCM and precipitated in cold diethyl ether (yield 95%). 1H NMR (d6-DMSO, δ in 
ppm): 7.79 (2H, d), 7.49 (2H, d), 4.56 (1H, t), 4.11 (2H, t), 3.49 (128H, s), 2.43 (3H, s). Step 2. 
Synthesis of monoazido-PEG (N3-PEG-OH). Ts-PEG-OH (1.00 g, 0.66 mmol) was dissolved 
in 15 mL of dry DMF, then NaN3 (214 mg, 3.3 mmol) was added and the mixture was stirred 
at 90 °C overnight under nitrogen atmosphere. The reaction mixture was cooled to room 
temperature, filtered, and DMF removed under vacuum. The product was dissolved in 10 mL 
of DCM and the solution was extracted twice with brine and twice with water in a separating 
funnel. The organic phase was dried over anhydrous Na2SO4, concentrated and poured in cold 
diethyl ether. Polymer was collected by filtration (yield 81%). 1H NMR (d6-DMSO, δ in ppm): 
4.56 (1H, t), 3.6 (2H, t), 3.5 (127H, s, PEG backbone), 3.4 (2H, t). FTIR diagnostic band: 
2107cm-1 (N3 stretching). Step 3. Synthesis of N3-PEG-PCL copolymer. N3-PEG-OH (600 mg, 
0.393 mmol), CL (1.572 g, 13.77 mmol) and Sn(Oct)2 (31 mg, 0.078 mmol) were charged in a 
flask under dry nitrogen. The polymerization was carried out at 120°C for 24 h under stirring. 
The copolymer was dissolved in 10 mL of  DCM, precipitated in cold hexane, recovered by 
filtration and finally dried (yield 91%). 1H NMR (CDCl3, δ in ppm): 3.6 (2H, t), 3.5 (127H, s, 
PEG backbone), 3.4 (2H, t), 1.29–1.78 (139H, m); 2.19–2.43 (82H, m), 3.92–4.21 (82H, t),  
4.31 (2H, t); Mn of PCL evaluated by 1H NMR = 4,6 kDa.  
2.4.2 Synthesis of propargylfolate 
Fol (500 mg, 1.13 mmol) was charged in a flask under dry nitrogen and dissolved by stirring in 
20 mL of DMSO over mild heating, then DCC (446 mg, 2.16 mmol) and NHS (260 mg, 2.26 
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mmol) were added. Reaction was carried out in the dark at room temperature for 17 h,  the 
solution was filtered to remove the side product (dicyclohexylurea, DCU), then propargylamine 
(124 mg, 2.25 mmol) and TEA (228 mg, 2.25 mmol) were added. The reaction was left 
overnight. The product was precipitated with a diethylether/acetone 80/20 mixture, repeatedly 
washed first with acetone and then with diethylether, and finally dried under vacuum overnight. 
A yellow powder was obtained and analyzed by LC-MS (Agilent Technologies, 6230 ESI-TOF) 
on a Phenomenex Jupiter column (C18, 3μm, 150x2.0 mm) with a gradient of acetonitrile (0.1% 
TFA) in water (0.1% TFA), from 5 to 50% in 15 minutes at a flow rate of 0.2 mL/min.    
2.4.3 Click conjugation of propargylfolate with N3-PEG-PCL (Fol-PEG-PCL ) 
 N3-PEG-PCL (800 mg, 0.12 mmol) dissolved in 15 mL of DMSO was charged in a flask under 
dry nitrogen, then propargylfolate (86 mg, corresponding to a propargyl/N3 molar ratio of 1.1) 
and copper wires (120 mg) were added; the reaction was carried out under stirring at room 
temperature overnight. The solution was filtered to remove copper and then dialyzed against 
DMSO with a 2000 cut-off dialysis tube for 4 days, in order to eliminate free propargylfolate 
and other side products.  Finally, DMSO was evaporated under nitrogen stream.  The 
occurrence of reaction was confirmed by FTIR through the complete disappearance of 2097 
cm-1 N3 stretching band (yield 95%). Fol content =6.5% by wt, functionalization degree=90%. 
2.5 Preparation and characterization of nanoparticles 
Non-targeted NPs were prepared from mPEGS-PCL and mPEGL-PCL while folate-decorated 
NPs were prepared from a mixture of mPEGS -PCL or mPEGL -PCL with Fol-PEG-PCL. NPs 
were formed by solvent diffusion of an organic phase (10 mg of copolymer in 1 mL of acetone) 
added dropwise in water (2 mL) under magnetic stirring (500 rpm). After solvent evaporation, 
NPs were filtered through 0,45 μm Phenex® filters (Phenomenex, USA). NPs could be freeze-
dried after the addition of HPβCD as cryoprotectant (polymer: HPβCD 1:10 wt. ratio) and 
stored at 4 °C. Recovery yield of the production process was evaluated on an aliquot of NPs 
without cryoprotectant by weighing the solid residue after freeze-drying. To evaluate cell 
uptake, the lipophilic dye NR was physically entrapped (0.2% of copolymer weight). The 
hydrodynamic diameter (DH), polydispersity index (PI) and zeta potential (ξ) of NPs were 
determined on a Zetasizer Nano Z (Malvern Instruments Ltd).  
Fixed aqueous layer thickness (FALT) of NPs was measured by monitoring the influence of 
ionic strength on ξ. Different amounts of NaCl stock solutions were added to NPs dispersed in 
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water (5 mg/mL, 100 μl) and zeta potential of the samples measured. A plot of ln ξ against 
3.33[NaCl]0.5 gives a straight line where the slope represents the thickness of the shell in nm. 
(10) 1H NMR was carried out on NPs dispersions to evaluate the amount of PEG on the surface. 
Spectra were recorded for either NPs prepared in D2O or NPs freeze–dried without 
cryoprotectant (5 mg) dissolved in d6-DMSO. Steady state fluorescence spectra were carried 
out with a RF6000 spectrofluorimeter (Shimadzu, Japan). Fluorescence lifetimes were recorded 
with Fluorolog-2 spectrofluorimeter (Model F111, Horiba) equipped with a TCSPC Triple 
Illuminator. The samples were irradiated by pulsed diode excitation source Nanoled at 370 nm. 
The kinetics were monitored at 450 nm nm and each solution was used to register the prompt 
at the excitation wavelength. The system allowed measurement of fluorescence lifetimes from 
200 ps. The multiexponential fit of the fluorescence decay was obtained using the following 
equations:  
I(t) = 1exp(-t/1) + 2exp(-t/2). 
All measurements were performed in a thermostated quartz cell (1 cm path length, 3 mL 
capacity).  
Stability of NPs in the presence of HSA (1-500 µM) was evaluated by placing a NPs sample 
(0.05 mg/mL) in the HSA water solution and monitoring immediately the size distribution by 
PCS.   
2.6 Intracellular uptake of NPs in cancer cells 
KB carcinoma cells (American Type Culture Collection, ATCC, Rockville, USA) over-
expressing FR (FRα) were selected to study the specific internalization of Fol-decorated NPs 
vs. non-targeted NPs. The cells were grown in Eagle’s medium (MEM) (Life Technologies) 
supplemented with 10% fetal bovine serum (FBS) (Gibco), 100 U/mL Penicillin G and 100 
µg/mL Streptomycin and maintained at 37 ◦C in a humidified atmosphere containing 5% CO2. 
Flow cytometry measurements of the uptake of DBLS, DBLs/DBL-Fol, DBLL, DBLL/DBL-Fol 
were performed using fluorescent NR-loaded NPs. For all the experiments mentioned above, 
cells were seeded in 24 wells/plate (40000 cells/well) in folate-deficient RPMI medium (Life 
Technologies) supplemented with 10% FBS. After 24 h of growth at 37 ◦C, the cells were 
incubated for 1 h with 20 µg/mL of NR-loaded NPs, freshly re-suspended in milliQ water and 
diluted in RPMI medium with or without 10% of FBS. After incubation with NPs, the cells 
were washed, detached from the plates with trypsin (Life Technologies), centrifuged and re-
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suspended in Versene before measuring NR fluorescence using a BD FACSCantoTM II 
instrument (Becton Dickinson). The blue laser at 488 nm was used as excitation source and the 
PerCP channel (670–735 nm) and the PE channel (564-606 nm) were selected for the detection 
of NR fluorescence, respectively. 104 events/sample were acquired and analyzed with the 
FACSDiva Software. Competition experiments with 1 mM free Fol (Sigma Aldrich) were 
carried out incubating the cells for 1 h prior to the addition of NPs in order to saturate FRs 
present on cell surface. The internalization of NPs in cells pre-incubated or not with 1 mM free 
Fol was assessed also by confocal microscopy using a SP5 laser scanning microscope (Leica 
Microsystems). 6 x 104 cells were seeded in special tissue culture dishes for fluorescence 
microscopy (μ-Dish 35 mm, high, Ibidi GmbH), were allowed to growth for 24 h and then 
incubated for 1 h with 20 μg/mL NPs in medium added with 10% FBS. After incubation, the 
cells were washed twice with PBS with Ca2+ and Mg2+ and immediately visualized under the 
microscope.  
2.7 Capture of NPs by human macrophages 
The capture by human macrophage of NPs decorated or not with Fol and pre-incubated in 
human serum (HS) was measured in order to assess their stealth properties. A positive control 
of non-PEGylated NPs (PCL) was tested too. Macrophages were derived from monocytes 
isolated from buffy coats of healthy donors by centrifugation over a Ficoll-Hypaque step 
gradient and subsequent Percoll gradient (Sigma-Aldrich). 2 x 106 isolated monocytes/well 
were seeded in 24 wells/plate and cultured for 7 days in RPMI 1640 medium (Life 
Technologies) supplemented with 20% FBS and 100 ng/mL of human macrophage colony-
stimulating factor (Peprotech) to promote macrophage differentiation. On day 4 from the seed, 
the macrophage colony-stimulating factor was added again. For the uptake experiment, 
macrophages were incubated for 3 h in RPMI added with 10% FBS and 20 µg/mL fluorescent 
NPs previously incubated at 37 °C in human serum type AB (Sigma-Aldrich) for 0, 10 or 30 
min. Macrophages were then washed and detached from the plates using PBS with 5 mM 
EDTA, centrifuged, re-suspended in PBS + 1% BSA and analyzed by flow cytometry for 
fluorescence as described previously. Propidium Iodide (1 µg/mL) staining of the samples 
during flow cytometry acquisition was used to measure the macrophage viability, which was 
higher than 95%.  
 
 
 57 
 
2.8 Statistical analysis:  
The Primer software for biostatistics (McGraw-Hill, Columbus, USA) was used for statistical 
analysis of the data. The data are expressed as means ± SD of at least 3 independent 
experiments. The difference between groups was evaluated using the Student’s t-test considered 
significant for p < 0.05. 
3 Results and discussion 
3.1 Synthetic strategy 
The following PEG-PCL diblock copolymers with different PEG lengths were synthesized: i) 
Fol-PEG-PCL  copolymer (PEG MW= 1.5 kDa); ii) MPEG-PCL  with a PEG MW= 1.0 kDa 
(PCL-mPEGS); iii) MPEG-PCL  with a PEG MW= 2.0 kDa (PCL-mPEGL). Copolymers were 
synthesized by typical ROP polymerization of ε-caprolactone using a mono-hydroxyl PEG as 
initiator. The molecular weight of PCL block was controlled by the CL/initiator molar ratio in 
the feed. A value of around 4.0 kDa was fixed for PCL on the basis of previous works (6,11-
12). 
 To prepare Fol-PEG-PCL copolymer, Cu(I)-catalyzed 1,3-Huisgen cy-cloaddition (“click” 
reaction) was chosen to conjugate folate to PEG-PCL (13). 1,3-Huisgen cycloaddition is the 
addition of alkynes to azides, with formation of highly stable 1,2,3-triazoles. The reaction is 
high yielding, stereospecific, does not create any byproduct, and can be conducted in mild 
conditions. PEG was first modified by in-troduction of an azide on one terminal group (Scheme 
1). Synthetic strategies aimed to asymmetrically modify PEG are largely explored in the 
literature. In general, the reported methods suffers from a complex chemistry and/or low purity 
of the final product (14,15). The most common way to synthesize heterot-elechelic PEG 
remains polymerization of ethylene oxide from different initiators (16,17,18,19,20). To achieve 
mono-functionalization, the use of a large excess of PEG has been reported too (21) although 
separation of non-modified from modified polymer requires tedious chromatography and yields 
are gen-erally low. In the present paper, we used a method recently reported (22) to achieve 
asymmetric activation of low molecular weight alcohols to low molecular weight PEG, so that 
it be comes possible to selectively link a biomolecule of interest to one end of PEG, and use the 
residual OH for copolymerization. 
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Scheme 1. Synthetic pathway for synthesis of N3 -PEG-PCL diblock copolymer. Monofunctionalization of PEG 
was checked by 1 H NMR analysis through the ratios between the intensities of OH (4.56 δ) and CH2 O
Ts (4.11 δ) protons of PEG, and aromatic (7.79, 7.49 δ) and CH3  (2.43 δ) protons of tosyl group (step 1). 
 
N3-PEG-OH is used as initiator for ring-opening polymerization of CL, leading to a PEG-azido 
functionalized copolymer. Azide is stable at the temperature required by ROP (120°C), as 
confirmed through FTIR analysis, where no change of diagnostic band of azide at 2097 cm-1 is 
detected in the copolymer spectrum.  Mn of PCL block in the copolymers was calculated by the 
ratio between intensities of the resonance associated to–CH2–OH methylene protons at 3.64 δ 
and –CH2–CO– units in the PCL chain at 2.31 δ of  1H NMR spectrum. A good agreement 
between theoretical and experimental values is found (Table 1). In order to introduce an alkyne 
group, folic acid was first conjugated with propargylamine through carbodiimide chemistry. It 
is known from the literature that only γ-folate conjugates retain affinity towards the receptor 
(Chen et al., 2013) Remarkably, γ-conjugates are intrinsically obtained as the major product in 
reactions with carbodimide ((Viola-Villegas, Rabideau, Cesnavicious, Zubieta, & Doyle, 
2008); nevertheless, a clean product is hard to obtain, as separation of γ-conjugate from  α- and 
bis-conjugates and unreacted folic acid is troublesome. For this reason, it is critical to find 
reaction conditions under which formation of “clickable” α- and bis-conjugates is negligible. 
In this case, the crude product can be used as such for coupling with N3-PEG-PCL, then final 
Fol-PEG-PCL  copolymer will be easily separated from non-conjugated folic acid and other 
byproducts (i.e., activated folic acid, Fol-NHS) by dialysis ((Liu, Zheng, Renette, & Kissel, 
2012). For purposes of optimization, a screening at different reaction conditions (type and 
amount of catalyst and propargylamine/catalyst molar ratio) was preliminary carried out, and 
products were characterized by LC-MS (Table S1 and Fig. S1, supplementary material). 
Identification of α- and  γ-conjugate peaks was made according to literature ((Trindade et al., 
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2014). Conditions in which no - and bis-conjugate are forming, were adopted for -
propargylfolate synthesis.                                                      
 
 
 
                                                    Table 1.Theoretical and experimental molecular weights of copolymers. 
Sample 
Mn Mn Mn Mw PDId 
(Da)a (Da)b (Da)c (Da)c (Mw/Mn) 
      
N3-PEG- 5547 6203 5943 8049 1.36 
PCL      
PCLmPEGS- 5047 5446 5059 6737 1.33 
PCLmPEGL- 6047 6579 6594 8720 1.35 
a Theoretical number-average molecular weight.   
b Number-average molecular weight evaluated by 1H NMR.   
c Molecular weight obtained by GPC.    
d Molecular weight polydispersity index obtained by GPC.   
 
In the click reaction, copper in form of wires was preferred as catalyst, since concentration of 
Cu(I) ions in solution is very low with respect to other catalysts type (Nahrwold et al., 2013), 
avoiding long purification steps. The total amount of crude propargylfolate used was such as to 
have a propargyl/N3 molar ratio = 1.1. The copolymer is easily purified by extensive dialysis to 
remove non-conjugated molecules. Reaction was followed by FTIR; the absence of azide band 
in the spectrum of Fol-PEG-PCL accounts for a 100% conversion (Fig. S2, supplementary 
material). For sake of accuracy, Fol-PEG-PCL was analyzed by GPC-UV. The chromatogram 
shows a single peak at a retention time corresponding to that of pristine N3-PEG-PCL 
copolymer, confirming the absence of free folic acid and/or derivatives (Fig. S3, supplementary 
material). Finally, MP-AES analysis of Fol-PEG-PCL  gives an amount of copper as low as 12 
ppm, which allows to exclude any possible cytotoxic effect (Cao et al., 2012). 
 
 
Figure 1. Design of untargeted and targeted NPs prepared from PEG-PCL diblock copolymers with different PEG 
length. 
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3.2 Influence of PEG length on nanoparticle shell 
We aimed at studying the effect of PEG length on the shell properties of folate-decorated NPs. 
To this purpose, NPs based on mixtures of Fol-PEG-PCL  with either mPEGL-PCL 
(DBLL/DBL-Fol), where PEG is 2.0 kDa, or mPEGS-PCL (DBLS/DBL-Fol), where PEG is 1.0 
kDa (Fig. 1) were prepared. We fixed Fol-PEG-PCL  amount in the composition at 20% by wt 
based on the results obtained in a previous paper (Conte et al., 2016). Corresponding non-
targeted NPs were prepared from mPEGL-PCL (DBLL) and mPEGS-PCL (DBLS). Solvent 
diffusion method, currently indicated as nanoprecipitation, was selected since it is very popular 
for preparing biodegradable NPs. Furthermore, solvent diffusion is a working principle in 
microfluidics, a process useful to increase the scale of NP production. 
As can be seen in Table 2, monodispersed NPs spontaneously form in high yield without the 
help of any surfactant. DBLL are smaller than DBLS likely due to higher hydrophilicity of PCL-
mPEGL. A size lower than 100 nm as determined by dynamic light scattering and comprised in 
a narrow size range (PI<0.22) makes this formulation suitable for intravenous injection. ξ is 
slightly negative as commonly found for PEGylated NPs and unaffected by the incorporation 
of folate-modified copolymer. NPs exhibit spherical morphology and preserve their shape once 
freeze-dried in the presence of HPβCD (Fig. S4, supplementary material). 
The amount of PEG on NPs surface was evaluated by 1H NMR and the packing extent of PEG 
on the surface calculated (Auguste et al., 2006; Q. Xu et al., 2015). Results are reported in Table 
2. For all the samples, the experimental amount of PEG on the surface is much lower than the 
theoretical value, suggesting that, in the conditions adopted to produce non-targeted and folate-
targeted NPs, PEG is located inside NP core and partly confined to the surface. The amount of 
PEG on the surface decreases for DBLL (despite their low size) and more in general upon 
addition of folate copolymer. Furthermore, [Γ]/[Γ*] values well below the cut-off value of 1 
indicate that PEG chains are in the mushroom-like conformation. These data demonstrate that, 
although NPs are prepared from PEGylated copolymers, the amount of PEG on the surface is 
below 7%  in line with our previous results on triblock and star-shaped PEG-PCL copolymers  
(Ungaro et al., 2012). Similar degree of PEG coverage has been found preparing NPs by 
emulsion-solvent evaporation from mixtures of non-PEGylated and PEGylated copolymers  (Q. 
Xu et al., 2015). 
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Table 2.Properties of NPs prepared from short (DBLS) and long (DBLL) MPEG-PCL copolymers without and 
with Fol-PEG-PCL (DBL-Fol). 
  
Formulation DH
a (nm) PI ξ (mV) Surface PEGb (wt%) [Γ]c (chains/100 nm2) [Γ]/[Γ*]
d 
DBLS 78 ± 1 0.12 − 13 ± 2 7.1 2.3 0.10 
DBLS/DBL-Fol 20 82 ± 4 0.11 − 18 ± 2 4.2 1.4 0.07 
DBLL 34 ± 2 0.16 − 15 ± 1 3.5 0.6 0.06 
DBLL/DBL-Fol 20 59 ± 5 0.22 − 17 ± 3 2.0 0.6 0.05 
 
The thickness of the external shell of NPs was evaluated by FALT, measuring the values of 
NPs ξ in NaCl solutions at different concentrations and fitting the data to a regression line 
(r>0.980) (Fig. 2A). The slope of these lines in absolute value represents FALT in nm. FALT 
is lower for NPs prepared from DBLS with short PEG (2.51 ± 0.20 nm) and higher for NPs 
prepared from DBLL with long PEG (3.84 ± 0.15 nm). In folate-decorated NPs, however, FALT 
increases for DBLS/DBL-Fol (2.72 ± 0.11 nm) and dectreases for DBLL/DBL-Fol (3.58 ± 0.29 
nm) suggesting a different arrangement of folate in the shell. Folate folding in PEG chains on 
the surface is likely occurring for DBLL/DBL-Fol, which could hide targeting ligand on the 
surface and prevent receptor recognition. 
To gain insights into the environment experienced by folate moieties in the NPs, the emission 
behaviour of DBLS/DBL-Fol and DBLL/DBL-Fol was investigated by steady-state and time-
resolved fluorescence spectroscopy. In fact, folate is a fluorescent molecule emitting in the 
visible range with an emission maximum at 450 nm. Fig. 2B shows the typical fluorescence 
emission of the folic acid, which is slightly more intense for DBLL/DBL-Fol. Inasmuch the two 
samples contain the same number of fluorogenic units, these slight but reproducible differences 
account for a larger fluorescence quantum yield for DBLL/DBL-Fol. In principle, this can be 
the result of i) self-quenching effects occurring in DBLS/DBL-Fol, ii) the different polarity 
experienced by the folate groups, or both. The dynamic behavior of the fluorescence is in line 
with the former hypothesis. As shown in Table 3, the fluorescence decay was bi-exponential in 
both cases.  
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Table 3. Lifetimes (in ns) and amplitudes (Σα = 1) obtained by the biexponential fitting of the flu-orescence 
decay for the different samples (λex = 370 nm λem = 450 nm). 
Sample 
τ
1 
α
1 
τ
2 
α
2 
DBLS/DBL-Fol 20 0.50 0.30 7.71 0.70 
DBLL/DBL-Fol 20 0.63 0.22 8.00 0.78 
 
However, we observed a more pronounced contribution of the longer component in the case of 
DBLL/DBL-Fol. These finding are in fairly good agreement with a picture involving the folate 
group of DBLS/DBL-Fol more exposed to water pool instead of being extended in the PEG 
shell.  
 
Figure 2. Properties of the NPs shell. A) Thickness of the outer shell of non-targeted NPs (DBLS and DBLL) and 
targeted NPs (DBLS/DBL-Fol and DBLL/DBL-Fol). Shell thickness (in nm) can be derived from the absolute 
value of the slope in the regression lines. For clarity purpose, results of a single experiment are reported. B) 
Emission spectra of folate-deco-rated NPs (5 mg/mL) in water (λex = 370). 
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3.3 Interaction of nanoparticles with HSA  
Conformation of PEG on NPs surface can drive interactions with proteins. Here we focused on 
HSA, the most abundant protein in the blood pool. Interaction of NPs with HSA was clearly 
demonstrated by fluorescence spectroscopy. Fig. 3A shows the fluorescence spectra of HSA in 
the absence and in the presence of NPs upon excitation at 278 nm. This wavelength allows the 
selective excitation of HSA over folate. The black spectrum shows the typical dual band 
fluorescence spectrum of HSA, which reflects the contribution of the tyrosine (em ca 310 nm) 
and tryptophan (em ca 340 nm) fluorogenic centres. This strong emission is quenched by more 
than one order of magnitude upon addition of NPs. In contrast, the fluorescence of folate is 
basically unaffected in the presence of HSA (data not shown).  
Since the emission of HSA fluorescent aminoacids well overlaps with the absorption spectrum 
of the folate, one could explain the quenching observed as a result of a photoinduced energy 
transfer via FRET mechanism. However, this is not the case since no emission of the folate was 
in fact observed concurrently to the quenching. Rather, the fluorescence behaviour might be 
simply due to static quenching effects arising by the massive aggregation of HSA on the NPs.  
Formation of a HSA corona was evidenced also by evaluating size distribution curves of NPs 
at increasing HSA concentration (Fig. 3B). As compared to water, addition of HSA up to 5 μM 
does not change greatly the shape of the size curves, while at physiologically relevant HSA 
concentrations (500 µM) NPs mean size is increased  for NPs of DBLL series and is unaltered 
for DBLS. The appearance of the peaks  at 3 and 11 nm corresponding to free HSA 
monomers/tetramers/hexamers, indicate that in this adopted conditions, the surface of NPs is 
fully occupied by HSA. Remarkably, these results highlight that despite the low PEGylation 
extent, NPs developed here adsorb HSA forming a soft corona without inducing their 
aggregation. 
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Figure 3. Behaviour of NPs in the presence of HSA. A) Emission spectra of folate-deco-rated NPs (5 mg/mL) in 
the presence of HSA (3 μM). A reference curve of a HSA solution(0.3 μM) is reported for comparison. Excitation 
wavelength was 278 nm. B) Size distribu-tion curves of NPs (0.05 mg/mL) in the presence of HSA (1–500 μM). 
3.4 Interaction of nanoparticles with human macrophages  
To predict NPs in vivo capture by mononuclear phagocyte system (MPS) once NPs are 
intravenously injected, we studied in vitro their uptake in human macrophages differentiated 
from monocytes and isolated from human buffy coats. Untargeted and folate-targeted NPs were 
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pre-incubated with human serum for 10 or 30 min at 37 °C before a 3 h incubation with 
macrophages. A positive control of PCL NPs (non-PEGylated) was employed. Pre-incubation 
of NPs with human serum significantly increases the time-dependent uptake by macrophages 
for non-PEGylated NPs only (Fig. 4), while the uptake of all the PEGylated NPs is unaffected 
or shows the opposite trend. Confirming a general paradigm, non-PEGylated NPs demonstrate 
the highest capture level by macrophages. The uptake of untargeted NPs increases when 
shortening the PEG length from 2.0 kDa to 1.0 kDa. In any case, the presence of folate on the 
surface does not affect significantly NPs phagocytosis. This results are in line with the general 
observation that the presence of a PEG shell on NPs surface limits the adsorption of serum 
proteins largely preventing NPs capture by phagocytes as macrophages ((Walkey, Olsen, Guo, 
Emili, & Chan, 2012).  
3.5 Cellular uptake of nanoparticles in KB cancer cells 
To asses if the exposition of folate over the PEGylated surface increased the specific uptake of 
NPs in cells over-expressing FRs, we measured the uptake of targeted and non-targeted NPs in 
KB cells by flow cytometry. The uptake was measured in the absence and in the presence of 
10% serum in the cell incubation medium to highlight the impact of NPs interaction with serum 
proteins. As reported in Fig. 5A, the uptake of DBLS/DBL-Fol occurs at least in part through 
FR-mediated endocytosis. In fact, pre-incubation of cells with 1 mM free Fol for 1 h to saturate 
FRs prior to NPs addition significantly decreases internalization. The extent of FR-mediated 
endocytosis of DBLS/DBL-Fol is higher without serum in the medium, probably due to partial 
‘masking effect’ exerted by protein association to NPs shell (Conte et al., 2016). On the 
contrary, although PEGylation degree is low and PEG is in a mushroom conformation for both 
DBLS/DBL-Fol and DBLL/DBL-Fol, only DBLS/DBL-Fol allows the recognition of folate 
moieties by FR in the presence of serum. For DBLL/DBL-Fol, folate amount is lower than 
expected on the basis of fluorescence lifetimes, and is probably unable to extend over the NPs 
surface because of the presence of a serum proteins corona. Flow cytometry (Fig. 5A) and 
confocal microscopy analysis (Fig. 5B,C) confirm the capability of DBLS/DBL-Fol to be taken 
up by KB cells with some selectivity. Microscopy images highlight a cytoplasmic and more in 
particular a perinuclear localization of DBLS/DBL-Fol with a clear decrease of fluorescence 
signal in the case of cells pre-incubated with free folate. 
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Figure 4. NPs capture by macrophages. NPs were pre-incubated in human serum (HS) for 10 or 30 min before a 
3 h incubation with macrophages at 37 °C. Phagocytosis Index represents the median total fluorescence intensity 
measured per macrophage by FACS. *p < 0.005, **p < 0.001, with respect to NPs not pre-incubated with human 
serum (Stu-dent's t-test). 
 
Figure 5. Intracellular uptake of NPs in KB cells over-expressing FRs. Flow cytometry mea-surements of the 
uptake of 20 μg/mL of Nile Red-loaded NPs (A). Cells were incubatedwith NPs for 1 h with or without 10% serum 
in the medium and in the absence or the pres-ence of 1 mM free folate (competition experiment). Significant 
different for *p < 0.05, ***p < 0.001, Student's t-test. Confocal images of cells incubated with DBLS /DBL-Fol 
in the absence (B) or in the presence (C) of 1 mM free folate. (For interpretation of the refer-ences to color in this 
figure legend, the reader is referred to the web version of this article. 
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3.6 Modulating degree of valency in folate-decorated nanoparticles based on PCL-mPEGS 
As a final experiment, we prepared DBLS/DBL-Fol at different folate copolymer percentage 
(0-50% by wt of total copolymer) to understand if the amount of folate copolymer affected 
uptake in KB cells. Size distribution curves indicate that all the formulations are monodispersed 
(Fig. 6A) with a size below 100 nm up to 30% of folate copolymer. A trend toward an increase 
of mean size and PI is observed for NPs at 50% Fol-PEG-PCL . All the NPs show a negative 
surface (ξ potential from -13 to -18 mV) as generally found for PEGylated NPs. As it can be 
seen in Fig. 6B, emission intensity of NPs is increased when increasing folate content whereas 
NPs of PEGS-PCL (without folic acid) do not exhibit any fluorescence signal. Furthermore, 
increase of Fol-PEG-PCL to 50% does not increase significantly NPs fluorescence, confirming 
that a fluorescence quenching is observed when the surface is more populated by folate 
moieties. Uptake studies in KB cells incubated with DBLS/DBL-Fol containing 10%, 20% or 
30% DBL-Fol polymers (Fig. 6C) demonstrated that, even in the presence of serum all the 
folate targeted formulations are taken up by cells via FRα-mediated endocytosis. Nevertheless, 
the extent of NPs accumulation through FRα-mediated endocytosis was comparable for all the 
formulations suggesting that an increase of folate amount in the NPs does not improve the 
extent of NPs intracellular accumulation. 
 68 
 
 
Figure 6. Properties of DBLS /DBL-Fol NPs with different percentages of Fol-PEG-PCL. A) Size distribution 
curves. B) Emission spectra at λex  278 nm (NPs concentration was 5 mg/mL). C) Uptake of NR-loaded NPs (20 
μg/mL) in KB cells after 1 h incubation in the presence and absence of FCS. 
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4 Conclusions 
Our study highlights that the too simplistic view of PEGylated NPs, both untargeted and 
targeted, is out to be close to the actual situation and needs to be elucidated if one wishes to 
correlate appropriately NPs properties to biological behaviour. We demonstrate that NPs 
prepared from diblock PEG-PCL copolymers by the widely employed solvent displacement 
method show a degree of PEGylation much lower than expected which depends on the length 
of PEG block. PEG acquires a mushroom conformation on NPs surface and its length affects 
the thickness of the hydrophilic shell as well as folate amount and exposition. HSA interacts 
with all NPs forming a protein corona which is not detrimental for stability. While all NPs show 
limited uptake in human macrophages, only the presence of short PEG (1.0 kDa) in the 
copolymer ensures that folate-bearing NPs are accumulated in KB cancer cells via FRα-
mediated endocytosis.  
This study offers a proof on how complimentary and simple techniques such as light scattering, 
fluorescence and NMR, can be employed to finely characterize the shell of targeted NPs with 
a PEGylated surface in the attempt to drive downstream effect such as NPs internalization in 
sub-set cell populations.  
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1 Introduction 
     The development of therapeutic strategy to treat brain diseases drew major attention in the 
last decades. This is because, especially for diseases such as cancer, when the disease affects 
the brain region, life expectancy drastically reduces. Cancers that usually lead to brain 
metastases are lung cancer, that commonly is divided in non small cell lung cancer (NSCLC) 
causing the majority of brain metastases in lung cancer patient, as well breast cancer, particulary 
HER2/neu type and triple negative (TNBC). Melanoma skin cancer, colon cancer and kidney 
cancer are also related to the development of brain metastases (1). Presently, the most effective 
therapy is surgery (2) coupled with several approaches based on radiation such as intensity 
modulated radiation therapy (IMRT) (3), image guided radiation therapy (IGRT) (4), whole 
brain radiation therapy (WBRT) (which is associated to the highest success rate) (5), 
stereotactic radiosurgery (SRS) (6). No systemic drug therapy (chemotherapy, targeted or 
immune-based therapy) has received FDA approval for the treatment of brain metastases from 
solid tumor. This occurs because most chemotherapeutic agents are not able to cross the blood 
brain barrier (BBB).  
The idea of a brain barrier was first highlighted by Ehrlich and Goldman who observed that 
water soluble dyes injected through systemic injection did not stain the brain or the 
cerebrospinal fluid (CSF). Additional experiments showed that these same dyes injected 
directly into the brain colored the brain and CSF, but not other organs. The observations drawn 
from these dye studies brought about the concept of a barrier between blood and brain, known 
as BBB. The anatomical structural knowledge of the BBB is still growing although a basic 
architecture of the cerebral vascular endothelium has been outlined. It consists of highly 
specialized vascular endothelial cells (EC) associated with astrocytic and pericytes that 
maintain BBB properties such as tight junction (TJ) and regulation of vescicular trafficking (7). 
Also at endothelial level there is a system of P450 cytochrome and enzymes. Further, the 
presence of efflux transporter transporters belonging to the family of the gene ABC (ATP-
binding cassettes) /MDR1 as the Glycoprotein P (P-gp) that can actively transport a huge variety 
of drugs out of the cell plays a key role in the transport of drugs through the BBB (8). These 
anatomical features establish a continuous barrier between blood and brain interstitial fluid 
(ISF) with reduces permeability. Nonetheless, BBB represents the principal site of exchange 
between the whole organism and the central nervous system (CNS) because it serves to exclude 
the xenobiotic substances and at the same time to regulate brain homeostasis. Several 
mechanisms of membrane transport such as simple diffusion for transport of water, gases and 
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lipophilic substances, carrier-mediated transport is involved in the carriage of nutrient as 
glucose (GLUT-1), ions, monocarboxylic acid and neutral amino acids, while other two 
transcytosis systems, one receptor-mediated (insulin and transferrin) and the other based on 
electrostatic interactions, drive exchanges with blood. (9). Against this background, it is clear 
why systemic drug therapy fails since BBB prevents the passage of 98% of chemotherapeutics 
(10).  
In the development of novel approaches for brain tumors, nanotechnology seems very hopeful. 
Indeed, the possibility to design a carrier that protects the payload from the degradation in the 
blood stream, avoids the opsonization improving circulation time and biodistribution profile, 
circumvents the efflux pumps and even more drives therapeutic agents directly to the target site 
is a fascinating option. In brain cancer research, different types of nanoparticles (NPs) have 
been employed as imaging and delivery agents, including inorganic metal based NPs (magnetic 
Fe3O4 NPs (11), gadolinium NPs (12), gold NPs [AuNPs] (13) and quantum dots [QDs] (14)) 
and organic polymer based NPs (dendrimer (15), hydrogel (16) and polymer (17)). Metalilc 
NPs have gained major attention, owing to the fact that they can be used also in magnetic 
resonance imaging (MRI) as contrast agents for monitoring of brain tumors. Organic NPs on 
the other side give the opportunity to simply modify their surface properties, which is important 
in that one of the most popular method used to cross the BBB involves the conjugation of 
peptides, antibodies or small molecules directly to the drug of interest or to its delivery vehicle, 
to overcome the BBB through specific interaction with receptors that are expressed on 
endothelial cells. An example is the low-density lipoprotein receptor proteins (LRPs). LRPs are 
expressed on neurons and astrocytes, but are also overexpressed in malignant astrocytomas such 
as glioblastomas, which are the most common and aggressive forms of brain cancer. However, 
BBB still constitutes a hindrance and this technology has not achieved the expected results due 
to low accumulation to the cancerous areas.  
An innovative approach in this field could be the development of a platform able to protect 
these nanosized carrier into the circulatory system facilitating the transport directly into the 
cells. One possibility is combine micro- and nano-technology designing a carrier that can effort 
in a sequentially manner the various biological barriers such as Multi Stage Vectors (MSV) 
(18,19).  
In order to obtain preferential accumulation of a drug at the brain microvasculature, a 
functionalized MSV-based system was developed. The micro-vector surface was coated with 
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the surfactant Polysorbate 80 (Tween® 80) that seems to lead to the adsorption of 
apolipoprotein E from blood plasma onto the nanoparticle surface and to mimic low density 
lipoprotein (LDL) particles by interacting with the LDL receptor or with molecules such as 
transferrin (Tf) to exploit overexpressed receptors at the BBB for transport. After obtaining 
accumulation, near the endothelial wall, the capacity of transporting simultaneously more than 
one active component in the porous micro particle has been exploited in vitro and in vivo.  
2 Experimental section 
2.1 Materials 
3 -aminopropyltriethoxysilane (APTES), 3-(Triethoxysilyl)propyl isocyanate 95%, holo-
Transferrin human ≥98%, sulfuric acid (99.999% w/v), triethanolamine, 98+% (TEA) N,N-
dicyclohexylcarbodiimide (DCC) and N-hydroxysuccimide (NHS) were bought from Sigma-
Aldrich, Invitrogen Alexa Fluor 647 dye from ThermoFisher scientific , Phosphate Buffered 
Saline (PBS), Dimethyl Sulfoxide (DMSO), 30% hydrogen peroxide (30% w/v), polysorbate 
80 (Tween® 80) and 2-Propanol (Certified ACS) were bought from Fisher Scientific Co L.L.C.  
2.2 Oxidation and APTES modification of MSV 
The porous silicon particles were oxidized and chemically modified with 3 -
aminopropyltriethoxysilane (APTES). Piranha solution (9 mL) was prepared with 70% sulfuric 
acid (99.999% w/v) and 30% hydrogen peroxide (30% w/v) by first pouring the peroxide 
solution into a glass flask containing the MSV, which was positioned in an oil bath (∼95°C) to 
control the temperature. Then, the acid was slowly poured into the flask under stirring for 2 h. 
The reaction mixture was let overnight at room temperature and the oxidized-particles (OX-
MSV) were washed three times with 2-propanol (IPA). The OX-MSV were put in a 2% APTES 
IPA solution for 48 h at 65° C under stirring. The particles were washed twice with water by 
centrifugation (10000 rpm x 30 min) and stored in IPA at 4° C.  
2.3 Polysorbate 80 (Tween 80) coating 
For the overcoating with polysorbate 80, in two different glass vials respectively one and two 
percent (m/v) of polysorbate 80 was added to the microparticles suspensions under gentle 
stirring for 30 min (Tween80-MSV). The coating was evaluated by Scanning Electron 
Microscopy (SEM) and Energy Dispersive X-ray Analysis (EDAX).  
2.4 Conjugation of holo-Transferrin human (hTf) to MSV 
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The conjugation procedure was carried out by the surface activation method. Briefly, 5 billion 
of oxidized MSV were put overnight in 2% IPA solution of 3-isocyanatopropyltriethoxysilane 
under stirring at RT to conjugate isocyanate groups to the surface of MSV (MSV-NCO). MSV-
NCO were collected by centrifugation at 10000 rpm x 30 min and the solvent was removed 
under vacuum. The silicon surface was actived with an organic solution of N,N-
dicyclohexylcarbodiimide (DCC) and N-hydroxysuccimide (NHS) using dimethylsulfoxide 
(DMSO) as a solvent. NHS concentration was 0.1 M and that of DCC was 0.2 M in DMSO. 
The final product was washed 3 times with IPA. Human transferrin (hTf) was chemically 
grafted to the functionalized porous particles (hTf-MSV) using an aqueous solutions containing 
particles and hTF under magnetic stirring (100 rpm) at room temperature overnight . The 
protein concentration was determined using the BCA Protein Assay Kit (Pierce Biotechnology, 
Rockford, IL). Microplate assays was performed according to manufacturer’s recommendations 
and absorbance was measured on microplate reader (Synergy H4 hybrid reader, BioTek 
Instruments Inc., Winooski, VT).   The final product was washed with IPA and stored at 4° C 
after concentration (Vacufuge®). 
2.5 Fluorescent particles 
In order to track the accumulation of MSV inside brain microcirculation, fluorescent MSV 
covalently grafted with Alexa Fluor™ 647 were produced. For loading of Alexa Fluor™ 647 
(Invitrogen), approximately 1 bilion of MSV-OX were suspended in 400 μL of DMSO. 
Afterwards, 67 μL of a 1 mg/mL solution of Alexa Fluor™ 647 in DMSO and 40 μL of a 100 
mM triethanolamine, 98+% (TEA) in DMSO were added. The microparticles were then shaked 
for 2 h at room temperature and washed five times with sterile water. After sample 
concentration (Cacufuge®) overnight, the samples were stored at 4° C. 
3 In Vivo Studies 
The animal studies were performed in accordance with the guidelines of the Animal Welfare 
Act and the Guide for the Care and Use of Laboratory Animals and The Houston Methodist 
Institutional Animal Care and Use Committee based on approved protocols (AUP-1214-0066). 
Healthy 4- to 8-week-old female BALB/c were injected via retro orbital venous sinus with 
labeled MSV dispersed in 100 μL saline. 
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3.1 Inductively coupled plasma mass spectroscopy (ICP-MS) 
Si contents released from the particles during the degradation process were measured using a 
Inductively coupled plasma mass spectroscopy (ICP-MS). Si was detected at 250.69, 251.43, 
251.61, and 288.158 nm. Yttrium (1 ppm) was added to both standards and samples to correct 
for instrumental drift during the run. A calibration run including the internal control was made 
before each group of samples. The detection limit of Si was 15 ppb. The results are expressed 
as a percentage of the silicic acid released into the medium. At 2 h after the injection, the groups 
of animals (n = 4) were sacrificed and the major organs (liver, spleen, heart, lungs, and kidneys) 
were harvested, weighed, and processed for elemental analysis. Briefly, the organs were 
homogenized in 20% EtOH in 1 N NaOH and left for 72 h at room temperature for extraction 
of Si. Then the extracts were centrifuged at 5,000 rpm for 30 minutes and 0.5 mL of the 
supernatant was picked up, diluted with 2.5 mL of deionized water, and analyzed for Si 
contents. Si content was measured by ICP-MS as described earlier. Further, all results were 
recalculated considering the dilutions performed and were normalized to individual organ 
weight. 
3.2 Immunohistochemistry (IHC) 
To confirm that the MSV accumulated at the BBB, the animals (n = 4) were sacrified 2 h after 
the injection, and the brains were harvested, weighed, and frozen in optimal cutting temperature 
compound (OCT) at -80° C. The frozen block was cut into slices and fixed on glass to perform 
immunohistochemical analysis. Briefly, sections were incubated with a 4% paraformaldehyde 
solution in phosphate buffered saline (PBS) pH 7.4 and washed twice for 30 sec with PBS. 
Serial longitudinal sections (n=6, thickness 8 µm) were then incubated for 20 min at RT in a 
blocking solution containing 1% normal goat serum (NGS) and 5% normal horse serum (NHS) 
in PBS and overnight at 4°C with primary anti-mouse CD31 rat polyclonal antibody (Abcam) 
(Cambridge, MA, USA) appropriately diluted in blocking buffer (1:100). Control sections were 
incubated in the absence of primary antibody (data not shown). The following day, sections 
were rinsed in PBS (3 x 5 min) and incubated for 5 min at RT in blocking buffer, followed by 
1 h incubation at RT in the dark with diluted rhodamine (TRITC) AffiniPure F(ab')₂ Fragment 
Donkey Anti-Rat IgG (H+L) (Jackson immunoresearch). Sections were washed twice for 1 min 
with PBS and then incubated for 3 min with 4',6-Diamidino-2-Phenylindole, Dihydrochloride 
(DAPI) (Fisherscientific). Immunofluorescence was imaged by confocal microscopy (Nikon, 
Tokyo, Japan) and the fluorescent images were analyzed using NISElements software (Nikon). 
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3.3 Intravital Microscopy (IVM) 
Fluorescent MSV were functionlized as described above and the accumulation of the 
fluorescent hTf-MSV in the brain microcirculation was evaluated by intravital microscopy 
(IVM) in BALB/c mice. The animals was anesthetized by inhalation of isoflurane (4-5% + 0.8-
1 L/min) and then put on a polycarbonate plate with the head immobilized. Briefly, the animals 
were anesthetized and a longitudinal incision of the skin was made. The periosteum was scraped 
off and a 6-mm circle over the frontal and parietal regions of the skull was made by using a 
high-speed dental drill. The glass window was applied with the aid of glue. The plate was placed 
on the heated stage of an intravital fluorescence microscope. Under the microscope 
AlexaFluor647-labeled particles (1 bilion/ 23 g body weight) and the tracer fluorescein 
isothiocianate-conjugated dextran (FITClabeled 70 kDa dextran, see chapter 2 for details) (0.1 
ml/25 g body weight) were administered via retro-orbital injection. Tracer was used to delineate 
the vasculature. Video and images of blood flow were acquired using an upright Nikon A1R 
laser scanning confocal microscope equipped with a resonance scanner and heated stage at 
different time points (T1- 15 min, T2- 20 min, T3 – 90 min and T4 – 120 min). All settings 
including laser power, gain, offset, and pinhole diameter were maintained throughout each 
acquisition. All images were analyzed with NIS-Elements software to quantify the amount of 
particles in different tissues at different time points. Data were obtained by averaging results 
on at least three images from three mice 
3.4 In Vivo Imaging Systems (IVIS) 
Animals were sedated with isofluorane and imaged on an IVIS Lumina (Xenogen; Caliper Life 
Sciences, Hopkinton, MA) after intravenous administration of fluorescent-MSV decored with 
hTf (1 bilion/ 23 g body weight). Animals were imaged using Alexa Fluor 647™ excitation 
(650 nm) and emission (665 nm) filters. At 2 h groups of animals (n = 4) were sacrificed and 
their organs were excised and imaged under the same conditions as live animals to determine 
the organ distribution of fluorescent hTf-MSV. Images and data were analyzed using Living 
Image 4.0 software (Caliper Life Sciences). 
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4 Result and discussion 
4.1 Particles characterization 
4.1.1 MSV coated with polysorbate 80  
The formation of a polysorbate 80 coating was evaluated by Scanning Electron Microscopy 
(SEM) (Figure 1) and Energy Dispersive X-ray Analysis (EDAX) (Figure 2). The images 
revealed that the particles were successfully coated and element mapping performed with X-
ray spectrometer coupled to the microscope confirmed the parallel presence of elements such 
as Carbon and Oxygen together with Silicon presence. 
 
Fig 1. SEM images of uncoated and coated MSV. a) Uncoated discoidal porous silicon particles. Scale bar, 500 
nm; b) Particle coated with a 1 % solution of polysorbate 80. Scale bar, 400 nm; c) Particles coated with 2 w/v% 
solution of polysorbate 80. Scale bar, 400 nm. 
 
 
Fig 2. Elements mapping performed with EDAX. The resulting spectra reveal that in absence of Si, the main 
element in the composition of MSV, there is no evidence of C and O. a) Spectrum of an area without MSV, b) 
spectrum of a coated MSV. 
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4.1.2 MSV coated with hTf 
The quantification of the total amounts of hTf on the surface of MSV was performed with an 
indirect BCA assay. Briefly, for the BCA assay, protein reduces Cu2+ to Cu+ under alkaline 
conditions, and this ion binds 2 molecules of BCA dye, which absorbs at 562 nm and is sensitive 
in the range 20–2000 g/mL protein. Standard curves were prepared using BSA in H2O. The 
assay showed that hTf was succesfully conjugated to the microparticles surface, being the 
amount of protein on particles surface 2.83 mg/billion. Particles were also imaged by SEM 
(Fig.3). 
Figure 3. SEM images of hTf coated MSV. Scale bar, 5 m (left); Scale bar, 3 m (right). 
The reaction was followed also by monitoring the change of particle surface charge through the 
measurement of zeta potential (ζ). The conjugation of hTf resulted in a radical change of the 
surface charge frome negative to positive values due to its covalent anchoring (Table 1).  
 
Table 1. Surface charge of MSV before and after hTf decoration. 
 Zeta potential (ζ)  
(mV) 
MSV-OH -40 
MSV-NCO -45 
MSV-hTf +2.5 
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4.2 Brain accumulation 
To evaluate the accumulation of the functionalized vectors at BBB various techniques have 
been employed.  
4.2.1 Immunohistochemical analysis of frozen brain section  
Immunohistochemical analysis coupled with confocal microscopy allowed to observe the 
presence of fluorescence in brain sections in proximity of the nucleus (Figure 4). To clarify 
where the particles accumulated, CD31 was used to highlight if the hTF-MSV reached the 
endothelial cells in histological tissue. In contrast with the previous analysis no fluorescence 
was detected in the new sections (Figure5) thus led to further investigation on the ability of 
targeted particles to accumulate at the BBB. 
Figure 4 Immunohistochemical analysis of fluorescent hTF-MSV in brain sections from mice. 
Scale bar 5µm 
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Figure 5. Frozen section of  mouse brain mouse injected with hTF-MSV. Sections were stained with primary anti-
mouse CD31 rat polyclonal antibody followed by a secondary antibody and DAPI. Scale bar 
 
4.2.2 In vivo accumulation of functionalized particles 
Intravital imaging was performed at three time points (T1-15 min, T2-30 min and T3-2h) to 
monitor the behaviour of Tween 80 coated MSV and hTf-MSV in the brain environment. 
Particles were administrated via retro orbital injection and their circulation was monitored for 
2 h. In both cases, at T1 particles were detected in the bloodstream but after 30 min dissapeared 
from circulation showing no accumulation at the site of interest. 
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Figure 6 Brain microcirculation of BALB/c monitored in real time via intravital microscopy. Images were 
recorded at different time points (T1- 15 min, T2- 30 min and T3- 2 h) after injection of hTf-MSV (upper row) and 
Tween 80-MSV (lower row). Vessels were highlighted before MSV administration through injection of fluorescein 
isothiocyanate–dextran average MW 70k. No particle accumulation at BBB was detected after 2 h. Scale bar  
4.2.3 Evaluation of in vivo biodistribution 
To evaluate organ biodistribution after systemic injection, an in vitro optical imaging system 
based on NIR fluorescence detection was employed. After 2 h, corresponding to observation 
time T3 in the intravital microscopy of brain, the animals were sacrified and the major organ 
were harvested and weighted (Figure 7). At this time point, a prominent accumulation of the 
fluorescent signal was observed in the liver and in the lungs while in the case of hTf-MSV, 
particles accumulated also in the kidneys and in the spleen. No signal was detected from the 
brain. 
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Figure 7. In vivo NIR imaging following intravenous administration of hTf-MSV (a) and Tween 80-coated MSV 
(b) tagged with Alexa Fluor 647. Organs collected after sacrificing the animal (time point 2 hours) for ex vivo 
evaluation of the accumulation of the fluorescence signal in the different organs and tissues. 
4.2.4 Quantification of Si  
To further validate results obtained with IVIS, the amount of Si in different organs after MSV 
and hTf-MSV injection was quantified using ICP (Figure 8). The data were normalized to the 
weight of the corresponding organ. Among the tested tissues, significant amounts of MSV were 
found in the spleen, liver, and lungs. The presence of targeted particles in the heart, kidney and 
brain tissues was relatively low or undetectable. These data correlate well with the in vivo NIR 
imaging, supporting that no accumulation was detected at the BBB using functionalized 
particles. Nevertheless, it seems evident that targeting ability of MSV is changing upon hTf 
decoration increasing the accumulation in lung. This effect could be highly relevant to decrease 
accumulation of MSV in MPS organs and target lung metastasis. 
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  Figure 8.Biodistribution of Si (Si/organ) (µg/g) in mice organs after i.v injection of hTf-MSV. Significant 
amounts of MSV were found in the spleen, liver, and lungs. The presence of targeted particles in the heart, kidney 
and brain tissues was relatively low or undetectable. 
5 Conclusion 
This study showed that for the delivery of micro- particles to the brain site a surface 
functionalization is not enough. The MSV platform is well-suited to chemical modification that 
not affect the biodistribution of the disc shaped porous silicon particles. However further in-
depth studies should be made to achieve the intended result. Possibily, a shape and size 
modification might be a promising approach to exploit the anatomical features of the BBB in 
the disease. 
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Overcoming biological barriers including rapid clearence from the bloodstream, 
opsonization and subsequent sequestration by MPS, nonspecific distribution, blood vessel flow 
limitations, pressure gradients, cellular membrane, escape from endosomal and lysosomal 
compartments, drug efflux pumps and the blood brain barrier is a key issue in the field of cancer 
therapy.  The minimal therapeutic impact observed following the delivery of conventional 
chemotherapeutics is a direct consequence of their inability to overcome many of these barriers 
that basically prevents successful accumulation of therapeutic agent at the diseased sites. On 
this background the development of a single system able to drive the therapeutic agents through 
all the obstacles and applicable to all the different type of malignancies is a difficult aim. An 
efficient method consist in the use of different approaches to address all the challenges in drug 
delivery. The polymeric conjugate can serve to improve the pharmacokinetics profile, reduce 
the non-specific accumulation and therefore increase therapeutic effects of the conjugated drug. 
Chapter 2 “Synthesis and characterization of rationally-designed Dextran-Doxorubicin 
conjugate: a novel strategy to improve the antitumor efficacy of doxorubicin in multiple breast 
cancer liver metastases” showed how the conjugation of Doxorubicine with Dextran (10.000 
kDa MW) has the potential to increase the accumulation of the anticancer drug into tumor 
metastases in a time dependent manner. Further, this work has highlighted an heterogeneity 
among the tumor masses in terms of permeation to the macromolecules.  
Despite the proven benefits of the polymeric conjugate the most efficient way to drive 
molecules after the endhotelial wall consist in entrapping and protecting the therapeutic into a 
nano based carrier such as polymeric NPs. This approach offers several adavntages first of all 
the opportunity to obtain a controlled release of the cargo from the polymeric matrix.  A big 
deal in the field of nanoparticles is the interaction with the proteins in the blood pool that 
activate the capture by the macrophages and consequent reduce the circulation time of the 
carriers. PEG exposed on the surface act as hindrance for the proteins absorption resulting in 
prolonged life for the NPs. On the other hand this hydrophilic shell could affect the behaviour 
of the particles and for this reason in Chapter 3 “Shedding light on surface exposition of 
poly(ethylene glycol) and folate targeting units on nanoparticles of poly(ε-caprolactone) 
diblock copolymers: beyond a paradigm” the role of PEG in interactions with human 
macrophages and in the internalization in tumor cell line has been investigated. Definitely the 
PEGylation degree depends on the lenght of PEG chain used to formulate the NPs and 
specifically a short PEG chain can enhance the degree of PEGylation, reduce the capture by the 
phagocytic cells and improve cellular uptake resulting in a excellent drug delivery system.  
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Another approaches to protect the NPs and their cargo from degradation and opsonization 
in the bloodstream is to combining different scales of delivery systems. A model is a discoidal 
porous silicon microparticles designed to navigate into the blood flow and showing preferential 
accumulation within the inflamed endothelium as in the case of tumors that can be used as a 
depot for a second nanostage that overcomes intact the endothelial wall and brings its cargo to 
the diseased cells. This system has been utilised for several application but not to treat brain 
metastases. At this purpose in Chapter 4 “Strategies to overcome the Blod Brain Barrier (BBB)” 
the accumulation at the brain microvasculature of a functionalised multistage delivery system 
has been evaluated in vivo and ex vivo. No accumulation was detected in the brain tissue and 
this leads to the need of further modification to use this promising approach for the delivery of 
chemotherapeutics beyond the BBB . 
In conclusion the research work carried out during these three years of Ph.D. has 
demonstrated that only a multy-strategy approach razionalized on the basis of the application 
can result in an optimal drug delivery system. 
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Abstract 
A novel photoresponsive molecular hybrid has been embedded in poly(lactic-co-glycolic acid) 
(PLGA) to give an antibacterial polymeric film generating nitric oxide (NO) under visible light, 
with concomitant fluorescence reporting of NO release. The molecular hybrid integrates a 
nitroaniline NO photodonor and a coumarin latent fluorophore in the same molecular skeleton 
and results in quite homogeneous distribution in the polymer matrix where it preserves well the 
photobehavior exhibited in solution. The doped PLGA film shows an excellent optical 
transparency and can be excited by visible light leading to the production of NO and the parallel 
fluorescence revival of the coumarin fluorophore, which acts as an optical NO reporter. 
Photogenerated NO diffuses out of the polymer film, can be transferred to a biological milieu 
and induces remarkable antibacterial activity against Escherichia coli. 
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1.Introduction 
 
     The emergence of multi-drug resistance (MDR) bacteria (1,2-3) and the increase of 
opportunistic infections (4,5) associated with the alarmingly low turnover of new clinically 
approved antibiotic drugs (6) call for a shift of attention to other underappreciated or 
unexploited antibacterial treatment modalities. In this frame, one of the most promising 
approaches is based on the use of nitric oxide (NO) as a powerful antimicrobial agent (7,8). 
This small sized and uncharged radical does not suﬀer MDR problems (9) and represents a 
multitarget therapeutic species (10) with broad-spectrum antibacterial activity. Besides, as a 
result of its short half-life in blood (o1 s), NO diﬀuses into the cellular environ-ment over short 
distances (o200 mm) (11) confining the region of action and consequently avoiding systemic 
toxicity issues. Diﬃculties in the delivery of gaseous NO to selected targets have inspired the 
development of a range of molecular NO-donors (12,13) and their integration within a variety 
of materials where NO delivery is triggered by metabolic or light stimuli has been recently 
reported (14,15,16,17,18,19-20) Among these, photobactericidal film coatings are of particular 
relevance (21,22,23-24) not only due to the superb spatiotemporal control of NO that the light 
input oﬀers (18) but also because they can be designed for a large use both inside and outside 
the human body. The therapeutic eﬀects of NO are, however, strictly dictated by its 
concentration (25). This feature makes the quantification of the NO delivery a very important 
issue to be faced, especially when one is interested to reach a critical molecule concentration to 
induce a specific eﬀect. A suitable way to address this quantification task is based on the use 
of a fluorescent reporter. This elegant strategy relies on the simultaneous photorelease of the 
desired bioactive species, i.e. NO, and a fluorescent component (the reporter) from the same 
nonfluorescent precursor (26,27-28). In such a way, the release process can be easily quantified 
by monitoring the fluorescence emission of the reporter, which acts exactly as an optical 
counter of the bioactive species. NO photoreleasers with fluorescence reporting function have 
only recently attracted attention (29,30,31-32), mainly limited to the solution phase. In the 
frame of our ongoing interest in NO photoreleasing constructs for therapeutic 
applications,(17,18,33-34) we report herein the first example of an NO photoreleasing 
antibacterial film with fluorescence reporting function. 
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2.Experimental section 
2.1 Chemicals 
All chemicals were from commercial sources at the highest possible purity and used as received. 
All solvents used were of spectrophotometric grade. 
2.2 Synthesis 
Compound 1 was synthesized according to the synthetic steps illustrated in figure 1 and 
described in the following. Syntheses were carried out at a low intensity level of visible light. 
Compounds 1a and 1b were synthesized according to litera-ture procedures (35).  
 
Figure 1.Schematic synthesis of 7-[Hexyl(4-nitro-3-(trifluoromethyl)phenyl)amine-amino]-4-methylcoumarin. 
7-[6-Bromohexyl-(4-methanesulfonyl-phenyl)-amino]-4-methyl-coumarin (1c). Compound 1b 
(0.50 g, 1.52 mmol) was dissolved in CH3CN (100 mL). Then Cs2CO3 (0.54 g, 2.28 mmol) 
and excess of 1,6-dibromohexane (3.7 g, 0.015 mol) were added to the solution under confined 
conditions, and the reaction was refluxed for 3 h. After filtration, the solution was evaporated 
and purified by means of silica gel column chromatography (EtOAc/hexane 1 : 2) to give a 
colourless solid 1c (0.72 g, 95% yield), Rf = 0.75 (EtOAc/hexane 1 : 2). 1H NMR (CDCl3, 500 
MHz): d = 7.60 (d, J = 8 Hz, 1H), 7.47 (d, J = 8.5 Hz, 2H), 7.28 (d, J = 8 Hz, 2H), 7.26 (dd, J = 
8.5, 2 Hz, 1H), 6.87 (d, J = 2 Hz, 1H), 6.30 (s, 1H), 3.56 (t, J = 6.5 Hz, 2H), 3.37 (t, J = 6.5 Hz, 
2H), 2.45 (s, 3H), 2.44 (s, 3H), 1.80 (m, J = 7 Hz, 2H), 1.43 (m, J = 6.5 Hz, 2H), 1.37 (m, 4H). 
13C NMR (50 MHz, CDCl3): 160.2, 153.4, 151.8, 143.9, 142.2, 134.4, 129.6, 127.4, 125.2, 
124.9, 119.1, 115.2, 115.1, 49.8, 33.6, 32.4, 27.7, 27.4, 25.4, 21.5, 18.6 ppm. 
7-[Hexyl(4-nitro-3-(trifluoromethyl)phenyl)amine-(4-methane-sulfonyl-phenyl)-amino]-4-
methylcoumarin (1d). A mixture of 1c (400 mg, 0.83 mmol), 4-nitro-3-(trifluoromethyl)aniline 
(172 mg, 0.83 mmol) and Cs2CO3 (407 mg, 1.25 mmol) was heated at reflux in acetonitrile 
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overnight. The reaction mixture was allowed to cool to room temperature. After filtration, the 
solvent was removed under vacuum and the residue was purified by column chromatography 
(EtOAc/hexane 70 : 30) to aﬀord com-pound 1d as a yellowish powder (0.36 g, 70% yield), Rf 
= 0.6 (EtOAc/hexane 1 : 2). 1H NMR (CDCl3, 200 MHz): d = 8.03 (d, J = 9 Hz, 1H), 7.59 (d, 
J = 8.6 Hz, 1H), 7.46 (d, J = 8.4 Hz, 2H), 7.28 (d, J = 8.4 Hz, 2H), 7.24 (dd J = 8.6, 2.2 Hz, 1H), 
6.87 (d, J = 2.2 Hz, 2H), 6.66 (dd, J = 8.8, 2.8 Hz, 1H), 6.29 (d, J = 1.2 Hz, 1H), 4.86 (broad t, 
1H), 3.57 (m, 2H), 3.23 (m, 2H), 2.43 (s, 6H), 1.64 (m, 2H), 1.41 (m, 6H). 13C NMR (50 MHz, 
CDCl3): 160.3, 153.4, 152.0, 151.9, 144.1, 142.1, 135.8, 134.3, 129.7, 129.2, 127.3, 126.7, 
124.9, 124.9, 119.1, 115.4, 115.1, 112.1, 104.9, 49.5, 42.8, 28.4, 27.4, 25.7, 25.4, 21.5, 18.5 
ppm. 
7-[Hexyl(4-nitro-3-(trifluoromethyl)phenyl)amine-amino]-4-methylcoumarin (1). Compound 
1d (100 mg, 1.75 mmol) was added to conc. sulfuric acid (5 mL) and the solution was stirred 
for 12 h at room temperature. The reaction mixture was cooled and carefully poured into water. 
The mixture was neutralized with saturated aqueous sodium bicarbonate and extracted with 
EtOAc three times. The organic solution was dried and evaporated to give 1 as a yellow powder 
(0.76 g, 94%), Rf = 0.38 (EtOAc/hexane 1 : 2). 1H NMR (CDCl3, 200 MHz): d = 8.03 (d, J = 
9.2 Hz, 1H), 7.35 (d, J = 8.6 Hz, 1H), 6.87 (d, J = 3 Hz, 1H), 6.66 (dd, J = 9, 2.6 Hz, 1H), 6.50 
(dd, J =8.6, 2.2 Hz, 1H), 6.42 (d, J = 2.2 Hz, 1H), 5.97 (s, 1H), 4.66 (broad t, 1H), 4.21 (broad 
s, 1H), 2.33 (s, 6H), 169–144 (m, 8H). 13C NMR (50 MHz, CDCl3): 162.1, 155.9, 152.3, 151.9, 
151.5, 135.9, 129.3, 126.9, 126.2, 124.9, 119.5, 112.1, 111.2, 110.3,109.0, 97.64, 43.2, 28.9, 
28.7, 26.6, 18.5 ppm. 
2.3 Instrumentation 
UV-Vis spectra were recorded using a JascoV-560 spectrophoto-meter using either quartz cells 
with a path length of 1 cm or a specific holder for thin films. Fluorescence emission spectra 
were recorded using a Spex Fluorolog-2 (mod. F-111) in air-equilibrated solutions either in 
right angle or in front face mode for solution or film samples, respectively. 1H NMR and 
13CNMR spectra were recorded on a VARIAN INOVA 200 spectrometer at room temperature 
at 200 MHz and 50 MHz, respectively, and calibrated using SiMe4 as an internal reference. 
Chemical shifts (d) are given in parts per million (ppm) and the coupling constants (J) in Hertz 
(Hz). 
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Irradiation conditions. Irradiation of the samples in solution was performed in a thermostated 
quartz cell (1 cm pathlength, 3 mL capacity) under gentle stirring, by using a continuum laser 
with lexc = 405 nm (ca. 3 W cm 2) having a beam diameter of ca. 1.5 mm. Irradiation of the 
film samples was performed using a 150 W xenon lamp having a beam diameter of ca. 3.5 cm, 
mounting a cut-oﬀ filter at 400 nm. 
Amperometric NO detection. NO release for samples in solution was measured using a World 
Precision Instrument, ISO-NO meter, equipped with a data acquisition system, and based on 
direct amperometric detection of NO with a short response time (o5 s) and a sensitivity range 
of 1 nM–20 mM. The analog signal was digitalized using a four-channel record-ing system and 
transferred to a PC. The sensor was accurately calibrated by mixing standard solutions of 
NaNO2 with 0.1 M H2SO4 and 0.1 M KI according to the reaction: 
4H+ + 2I + 2NO2 - 2H2O + 2NO + I2 
Irradiation was performed in a thermostated quartz cell (1 cm pathlength, 3 mL capacity) using 
the above continuum laser with lexc = 405 nm. NO measurements were carried out under 
stirring with the electrode positioned outside the light path in order to avoid NO signal artefacts 
due to photoelectric interference on the ISO-NO electrode. 
 
2.4 Chemical detection of NO 
NO release was also measured by means of the well-known, highly sensitive (detection limit 
on the order of the picomoles) fluorimetric bioassay of Misko et al. (36), based on the ring 
closure of the nonfluorescent 2,3-diaminonaphthalene (DAN) with nitrite to form the highly 
fluorescent product 2,3-diamino-naphthotriazole (DANT). Pieces of PLGA films (2 cm2) were 
placed in a quartz cell (3 mL capacity) filled with water and were irradiated at diﬀerent times 
or kept in the dark. Once photo-generated under aerobic conditions, NO, in the absence of other 
scavengers, is rapidly converted into nitrite and nitrate, its stable metabolites. Since only nitrite 
reacts quantitatively with DAN to give rise to DANT, the samples (1 mL) were incubated with 
nitrate reductase from Aspergillus niger and b-nicotinamide adenine dinucleotide phosphate in 
reduced form for 20 min at 37 1C, in order to convert nitrate to nitrite before addition of DAN. 
Afterwards 100 mL of 0.31 mM DAN in 0.62 M HCl were added and the solutions were stirred 
for 20 min at room temperature. After adding 100 mL of NaOH 2.8 M to the above solutions, 
the fluorescence emission and excitation spectra were recorded (Fig. S3, ESI†). A standard 
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calibration curve was obtained by using freshly prepared solutions of sodium nitrite in 
phosphate buﬀer 10 mM at pH 7.4. 
2.5 Film preparation 
A polymer film integrating the compound 1 was prepared by the solvent casting method. 
Resomers RG 855 (85 : 15 D,L-lactide : glycolide molar ratio, inherent viscosity 1.3–1.7 dl g 1 
for 0.1% solution in chloroform at 25 1C) from Boehringer Ingelheim (Germany) was used. 
Resomers RG 855 (150 mg) and polyethylene glycol 400 Da (37 mg) as plasticizers were first 
dissolved in 5.9 mL of methylene chloride by overnight stirring. Thereafter, 100 mL of a 
solution of 1 in methylene chloride (7 mg mL 1) were added to the polymer solution. The 
mixture was then cast onto a Teflons Petri dish (diameter 75 mm), covered with punctured 
Parafilms and placed on a levelled surface under a hood for 24 h to allow solvent evaporation. 
The thickness and the weight of the films were measured using a digital micrometer and a digital 
balance (sensi-tivity = 0.01 mg), respectively. The film thickness was quite uniform across all 
the sample (0.050 0.002 mm). The content of 1 in the film was 16 mg cm 2. Distribution of 1 in 
the polymer film was evaluated by dividing the film into 8 slices, which were singularly 
weighed and dissolved in 5 mL of tetrahydrofuran. The amount of 1 was quantified by UV 
absorption at l = 390 nm. A calibration curve in the range of 3–60 mg mL 1 was constructed 
and the linearity of response was verified (r2 = 0.995). The amount of 1 in the film was 3.38 
0.018 mg mg 1 film. Distribution of 1 in the polymer film was evaluated by dividing the film 
into 8 slices, which were singularly weighed and dissolved in 5 mL of tetrahydrofuran. The 
amount of 1 was quantified by UV absorption at l = 400 nm. A calibration curve in the range 
of 3–60 mg mL 1 was constructed and the linearity of response was verified (r2 = 0.995). The 
amount of 1 in the film was 3.38 0.018 mg mg 1 film. 
 
 
2.6 Antibacterial assay 
One hundred mL of a bacterial suspension (50 000 CFU per mL) of Escherichia coli ATCC 
25922 were placed into a 96-well microplate containing at the bottom the PLGA film (circular 
disk, diameter = 6 mm, each containing 4.5 mg of 1) and were irradiated for 5 and 20 min by 
using a 470 W Xe lamp equipped with a cut-oﬀ filter l 4 400 nm or kept in the dark. Equal 
aliquots of the bacterial suspension were also placed into a 96-well microplate in the absence 
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of the PLGA film and were irradiated under the same conditions. Afterwards, an aliquot of the 
bacterial suspension (20 mL) was placed on the sterile agar plate of MacConkey (Biokar 
diagnostics), where Escherichia coli grows with a typical pink color. The plates were incubated 
for 20 h at 37 1C to allow bacterial growth. 
3 Results and discussion 
To achieve our goal, we have designed the molecular hybrid 1 as a multifunctional component 
(Scheme 1). It consists of a nitroaniline-based NO photodonor developed in our group (37,38), 
linked to the coumarin 120 through an alkyl spacer. The working principle of 1 is sketched in 
Scheme 1 and the rationale behind the design of this molecular hybrid is described in the 
following.  
 
Scheme 1. The working principle of the functional molecular hybrid 1 
The coumarin component has been chosen because its intense fluorescence emission spectrum 
overlaps extensively the absorption spectrum of the nitroaniline NO photodonor (Fig. S1, 
ESI†). This condition, the close proximity of the two chromophores and the flexibility of the 
alkyl spacer are key prerequisites to make the fluorescence of the coumarin signifi-cantly 
quenched in the conjugate 1 by a Fo¨rster resonance energy transfer (FRET) mechanism. 
Excitation with visible light is expected to trigger NO photorelease from the nitroaniline moiety 
leading to a phenol derivative as a stable byproduct (37,38). In contrast to the nitroaniline 
chromophore this moiety is not able to accept the energy from the excited coumarin since its 
absorption spectrum, falling in the UV region, does not overlap any more the emission spectrum 
of the coumarin, making the FRET process thermodynamically not feasible. Consequently, the 
coumarin fluorescence is expected to be restored upon NO photorelease. The validity of our 
design was firstly proven by spectroscopic and photochemical experiments performed in 
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solution. The absorption spectrum of 1 reflects fairly well the sum absorption spectrum of the 
independent coumarin and nitroaniline compounds (Fig. S2, ESI†), ruling out any significant 
interaction between the coumarin and nitroaniline chromophores in the ground state. On the 
other hand, the fluorescence emission of the coumarin fluorophore is significantly quenched in 
the case of the conjugate 1 (Fig. S2, ESI†), suggesting a remarkable inter-action between the 
two chromophores in the excited state. Photoexcitation of 1 leads to a bleaching of the main 
absorption band (Fig. 1A). 
 
Figure 1. (A) Absorption spectral changes observed upon exposure of a water : methanol (20 : 80 v/v) solution of 
1 (15 mM) at lexc = 405 nm for regular intervals of 10 min. T = 25 1C; the inset shows a representative NO release 
profile from 1. (B) Evolution of the fluorescence emission spectra corresponding to the sample of (A) and recorded 
at lexc = 380 nm. 
This behaviour accords with the photorelease of NO and the formation of the phenol derivative 
2 as a stable photoproduct since it is in line with the photochemical pathway leading to NO 
release previously proposed in the case of the single NO photodonor unit.15 This was confirmed 
by the typical NO release profile obtained by the direct amperometric detection of this species 
in alternating cycles of light/dark shown in the inset of Fig. 1A. Besides, the ESI-MS analysis 
of the crude reaction mixture carried out immediately after the photolysis experiments (ca. 20% 
transformation) revealed a main peak with a [M + 1]+ value of 434.2, corresponding to the 
structure of the conjugate 2 (see Scheme 1) in addition to that of the remaining starting 
compound. Fig. 1B shows the evolution of the fluorescence emission spectra corresponding to 
the absorp-tion changes reported in Fig. 1A. These findings clearly indicate that 
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photodecomposition of 1 leads to a dramatic revival of the characteristic emission of the 
coumarin fluorophore which can be used as an optical reporter for the NO release. Polymeric 
films containing the functional conjugate 1 (16 mg cm 2) were prepared by solvent casting using 
poly(lactic-co-glycolic acid) (PLGA) as a suitable polymeric matrix. PLGA is a highly 
biocompatible polymer approved for biomedical use, which has been recently used as a scaﬀold 
for the fabrication of NO releasing films triggered by pH changes (39,40) or chemically 
modified to achieve NO release under UV light irradiation (21). The film exhibited a 
homogeneous distribution of 1 in the polymeric matrix (see Experimental) and an excellent 
optical transparency which allowed us to record its UV-Vis absorption spectra in transmission 
mode (vide infra). The incorporation of the functional molecular hybrid into the polymeric film 
does not change the nature of the photochemical process. Fig. 2A and B show the absorption 
and fluorescence spectral changes observed upon irradiation of the film with visible light. Apart 
from a slight spectral shift due to a solvent eﬀect, the behaviour observed is very similar to that 
exhibited by 1 in solution (see comparison with Fig. 1), since characterized by a bleaching of 
the main absorption band accompanied by a remarkable increase of the fluorescence intensity 
upon irradiation. NO photo-release from the film was detected by means of the sensitive and 
selective chemical method for NO detection based on the reaction between N2O3 (formed by 
reaction of NO with O2) and 2,3-diamino-naphthalene (see ESI† and Fig. S3). As illustrated in 
Fig. 2C, we found an excellent linear correlation between the concentration of NO 
photogenerated and the increase of the fluorescence intensity of the optical reporter. 
 
Figure 2. Absorption (A) and fluorescence (B) (lexc = 350 nm) spectral changes observed upon irradiation of the 
PLGA film doped with 1 for 0, 1, 5, 10 and 20 min with a Xe lamp (cut-oﬀ filter l 4 400 nm). (C) Correlation of 
the fluorescence increase observed in (B) and the concentration of NO released from the film (I and I0 represent 
the fluorescence intensities after and before irradiation, respectively). (D) Transfer of NO from the PLGA film to 
reduced Mb in phosphate buﬀer. Absorption spectra of oxidized Mb(FeIII) and reduced Mb(FeII) before (b) and 
after (c) 50 min of irradiation of the film. [Mb] = 2.5 mM; cell pathlength = 1 cm. 
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The doped PLGA film is a convenient NO dispenser for biological targets as demonstrated by 
its capability to transfer NO to a solution of equine skeletal myoglobin (Mb) (41) where the 
film was immersed. NO delivery to Mb can be easily monitored by absorption spectroscopy 
and the results obtained are illustrated in Fig. 2D. Mb exhibits its Soret absorption band at 410 
nm (spectrum a). The addition of dithionite resulted in a shift of the absorption maximum at 
432 nm, corresponding to the reduction of Mb (spectrum b). After irradiation of the film, the 
spectrum of the supernatant showed the appearance of a new Soret absorption band at 420 nm 
which, according to the literature (42), confirms the binding of NO to the Fe(II) of the heme 
group of Mb (spectrum c). Control experiments performed irradiating the solution containing 
the reduced Mb (i) in the absence of the film, (ii) in the presence of the film without 1 or (iii) 
keeping the film doped with 1 in the dark did not show any evidence for the formation of the 
420 nm band. It is important to note that NO is indeed released from the film and not from 
molecules of 1 diﬀusing from the film to the supernatant solution. In fact, the leaching test 
performed by leaving the film immersed in a phosphate buﬀer solution (pH 7.4, 10 mM) at 
room temperature in the dark did not show any detectable absorption spectrum of 1 in the 
solution over a period of one week, according to the insolubility of 1 in this medium. 
 
Interestingly, the release process with fluorescence reporting in the polymeric film is also 
triggered by sunlight and can be easily followed by the naked eye. The as-prepared PLGA film 
(Fig. 3A) was covered with a black plastic mask (Fig. 3B) and left for 30 min outdoor under 
sunlight. Fig. 3C shows the typical blue fluorescence of the reporter arising only from the 
illuminated sites, accounting for a remarkable spatial diﬀerentiation between the illuminated 
and non-illuminated areas. This finding clearly demonstrates that it is therefore possible to 
deliver NO to a specific location by either the covering of the surrounding areas or appropriately 
focusing the light source. 
 
Figure 3. PLGA film (A) and its selective exposition to sunlight for 30 min with a black plastic mask on top (B). 
Fluorescence image (lexc = 350 nm) of the irradiated film after removing the mask (C). 
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Antibacterial activity of the film was tested towards Gram-negative Escherichia coli ATCC 
25922 bacteria strain. The results in Fig. 4 show that no eﬀect on the bacterial growth is 
observed both in the presence of the film in the dark (A) and under illumination in the absence 
of the film (B). On the other hand, a remarkable reduction of the number of colonies was 
observed after irradiation with visible light in the presence of the PLGA film, in a manner 
clearly dependent on the irradiation time (C and D). 
 
 
Figure 4. MacConkey’s agar plates inoculated with 20 mL of bacterial sus-pensions of Escherichia coli ATCC 
25922 (ca. CFU 5 104 mL 1) after incubation with the PLGA film in the dark (A) and irradiated for 5 min (C) and 
20 min (D). Control of the bacterial suspension after 20 min of irradiation in the absence of the PLGA film (B). 
Irradiation was performed with a 470 W Xe lamp, cut-oﬀ filter l 4 400 nm. 
 
4 Conclusions 
We have achieved a biocompatible film of PLGA incorporating a novel tailored NO 
photoreleaser. The polymeric film is stable in the dark but it is able to release substantial 
amounts of NO with spatiotemporal control under excitation with visible light. The release 
process can be activated even by sunlight exposure and can be followed in real time by the 
intense blue fluorescence of a by-product, which acts as a convenient optical reporter of the NO 
concentration. To our knowledge, this is the first time that NO release with fluorescence 
reporting is demonstrated in film sam-ples. Once photogenerated, the NO radical promptly 
diﬀuses out of the polymeric matrix to reach biological targets. The film shows excellent and 
strictly light-dependent bactericidal activity against the Gram-negative E. Coli ATCC 25922 
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bacterial strain, opening intriguing possibilities for its further engineering in the perspective of 
coating and devices for biomedical applications. Finally, we would like to stress that the FRET 
mechanism occurring in compound 1 and the high two-photon cross-section of the cou-marin 
chromophore oﬀer, in principle, the possibility to trigger the NO photorelease and to detect the 
fluorescence of the reporter by two-photon excitation (TPE) of the coumarin component. In this 
regard, the study in progress in our laboratories is ongoing to demonstrate the possibility of the 
present system to eradicate biofilms with very high spatial resolution via TPE. 
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Abstract 
This study charts the growth of the drug delivery literature published during 1974-2015 from 
journals indexed in the Science Citation Index Expanded database. The growth of 
publications on drug delivery paralleled the total scientific publications for three decades 
(1974-2003); however, from 2004 to 2015 it exploded fourfold, while the total increased only 
1.75 fold. Industrialized countries (USA, UK, Germany, Japan, Italy, France and Canada) 
were the most prolific during the first decades, but in 2014-2015 China, India and South 
Korea ranked 1st, 3rd and 4th respectively among the productive countries. The number of 
participating countries increased fivefold (from 19 to 96). During the last 15years, the 
journals targeted by drug delivery research increased nearly 2.4 fold (416 to 1001) and three 
journals (Journal of Controlled Release, Advanced Drug Delivery Reviews, and International 
Journal of Pharmaceutics) published nearly one-fifth of the drug delivery research in 2014-
2015. 
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1. Introduction  
Drug delivery (D.D.) concerns a large spectrum of approaches, formulations, technologies, and 
systems used to achieve and optimize the transport of pharmaceutical compounds in the human 
body by increasing their quantity and half-life in biological fluids while minimizing their 
adverse effects. One of the main benefits of D.D. systems is the opportunity to select the 
anatomical route through which drugs can be administered to the human body on the basis of 
the desired effect, the disease, and the type of molecule. The first D.D. devices were developed 
in the nineties and solely consisted of transdermal and oral delivery systems based on improving 
the drug release kinetics in order to obtain a constant rate over a certain period of time to 
enhance drug bioavailability, patient compliance, and decrease therapy costs [1]. Interestingly, 
since diseases such as cancer have been addressed as transport issues [2], there has been an 
increase in the exploitation of nanoparticles for medical applications. As a result, 
nanotechnology, whose conceptual foundations were laid down by Richard Feynman [3], has 
become one of the fastest growing research areas [4]. In particular, nanotherapeutics (i) improve 
the properties of drugs without affecting the carried molecules, (ii) provide the drugs with the 
ability to overcome several biological barriers that normally reduce the accumulation of 
therapeutics in the target area (iii) can consist in nanovectors loaded with various compounds 
such as two different drugs or a drug with an imaging agent in order to track the particles, (iv) 
increase the therapeutic impact by interacting with specific tissues and cells through surface 
functionalization and, (v) permit potential clinical application. Several types of nanovectors 
such as liposomes [5–7], polymeric nanoparticles [8], micelles [9,10], and iron based 
nanoparticles [11] have been exploited. Unfortunately, nanotechnology did not achieve the 
expected results, in fact a recent work showed that only a small portion of the injected dose 
accumulated at the target site [12] due to the presence of multiple biological barriers in the body 
that represent the main obstacles of D.D [13]. New technologies arise from a multidisciplinary 
approach that involves biology, chemistry, physics, and engineering based on the micro scale. 
Multistage discoidal vectors are an example of the next generation D.D. systems, and can be 
loaded with nanotherapeutics thereby overcoming biological barriers in a sequential manner to 
promote the accumulation at the site of interest [14,15]. In addition to injectable D.D. systems, 
other devices must be mentioned. Examples include the transdermal drug D.D., which is an 
effective alternative to the oral administration of various compounds [16], osmotic D.D. 
systems, that are suitable for implantation as well as for oral delivery by exploiting the 
movement of water through a selectively permeable membrane driven by a difference in 
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osmotic pressure [17], and mucoadhesive D.D. systems which are tablets, polymer gels, and 
films that remain in close contact with the tissue such as the oral cavity, the eye, and the nasal 
cavity resulting in high drug accumulation at the site of release [18]. In addition, implantable 
D.D. systems are based on microfluidics and can exploit both micro- and nano-scale 
technologies. Such systems display some disadvantages such as higher cost and the necessity 
to be implanted with surgery, but at the same time they provide therapeutic drug concentrations 
over the whole treatment, even if it requires continuous or repeated administration [19–21]. 
External Medical devices play an important role in several therapies such as the therapies for 
pulmonary diseases. On the market there are several devices working with passive and active 
mechanisms such as dry powder inhalers (DPI) that make up a large part of the market [22]. It 
is important to stress that all this approaches, formulations, technologies, and systems arise 
from basic science or bench research and can potentially be translated into clinical applications. 
During the last decades, qualitative evaluations of the progress in D.D. are available through 
the publication of numerous reviews [23,24]. Although such literature reviews provide readers 
updated and synthesized subject information, to our knowledge there is an absence of 
quantitative data describing the scientific publishing pattern of D.D. over time thus preventing 
scientists, physicians, decision-makers, politicians, and others a global view of scholarly 
communication in this field. The aim of this study is to use bibliometric techniques to provide 
a 40+ year longitudinal view (1974 to 2015) of the evolution of the scientific literature on D.D. 
without focusing on a specific area. Two indicators were chosen to follow this evolution: the 
publishing outputs of D.D. research by countries, and the journals used to publish research on 
D.D. 
2. Method  
The data were collected between 20th October and 10th November 2016 from the Science 
Citation Index Expanded (SCI-E), a multidisciplinary index to the journal literature of science 
and technology, through the ISI Web of Knowledge™ (http://www.isiwebofknowledge. com/) 
– a part of the Web of Science (WoS) database. The search strategy consisted of: • all documents 
published in journals with at least one of the following keyphrases in the title: drug deliver*, 
drug release*, drug carr*, sustained release*, controlled release*, intranasal administra*, 
sustained deliver*, intelligent delivery system, pulsatile releas*, transdermal deliver*, drug 
nanocarr*, nasal deliver*, rectal deliver*, oral deliver*, buccal deliver*, drug nanopart*, 
nanopart* deliv*, nanopart* releas*, nanoparticule drug, with asterisks replacing characters 
following the word-stems; • all documents published in the following journals: Journal of 
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Controlled Release, Advanced Drug Delivery Reviews, Expert Opinion on Drug Delivery, 
Drug Delivery, Journal of Drug Delivery Science and Technology, Current Drug Delivery, 
Critical Reviews in Therapeutic Drug Carrier Systems, Drug Delivery and Translational 
Research, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Polymeric Drug 
Delivery I Particulate Drug, Cancer Drug Delivery, Polymeric Drug Delivery II Polymeric 
Matrix, Polysaccharides for Drug Delivery and Pharmaceutical Applications, Advances in 
Controlled Drug Delivery Science Technology and Products, Filled Elastomers Drug Delivery 
Systems. Only journal article and journal review-type publications (as de- fined in the SCI-E 
database) published during 1974–2015 were considered. The 2015 impact factors (IF) were 
collected using the Thomson Scientific Journal Citation Reports. Downloaded documents were 
then analyzed by countries, and for each two-year period from 1974 to 2015 the following 
parameters were considered: • the total number of publications authored or co-authored by 
researchers in each country – publications issued from more than one country were assigned 
equally to each contributing country – and, • the top-10 most prolific journals publishing drug 
delivery research. Publications originating from England, Wales, Scotland and Northern Ireland 
were assigned to the United Kingdom (UK), and the European Union (EU) was defined as the 
official member States registered on the 1st of January for each of the two year-periods 
considered. The set of BRICS countries includes Brazil, Russia, India, China and South Africa. 
3. Results and discussion 3.1. Evolution of the drug delivery research During the past 40+ years 
the scientific literature on D.D. emerged and has grown rapidly (Figure 1). The global evolution 
of D.D. literature can be split into 2 parts. From 1974 to the start of the 2000s, the D.D. scientific 
literature grew slowly (from 63 publications published in 1974–1975 to 1750 publications in 
2000–2001) paralleling the growth of the total WoS literature. However, from 2002 to 2015, 
the growth exploded: there was a fourfold increase of the D.D. literature (1848 D.D. 
publications published in 2002–2003 vs. 7823 in 2014–2015), while the total for the WoS 
literature only increased 1.75 fold. 3.2. Evolution of countries publishing drug delivery research 
As shown in Table 1, from 1974 to 2015 the number of countries involved in D.D. research 
increased fivefold: 19 countries in the 1974–1975 period, 36 in 1984–1985, 52 in 1994–1995, 
72 in 2004–2005, and 96 countries in 2014–2015. In the first four of the five two-year periods 
analyzed the USA was by far the most productive country with a lead of 43.6% of the total 
share in 1984–1985; however, it ranked second in 2014–2015 with only 21.4% of the total 
publications. Some industrialized countries (UK, Japan, Germany, France, Netherlands and 
Canada) that were present among the leading countries in 1984–1985 slowly lost their high 
ranking positions, but remained among the leading countries in 2014–2015. These observations 
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are in line with the domination (in terms of the number of publications) of these countries in 
various fields of Biology [25], Medicine [26,27], and in research fields more closely allied to 
D.D. research such as Nanotechnologies [28] and Liposomes 
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         D.D publications                                                                                    Total WoS publications 
 
Figure 1. Number of Drug Delivery and total WoS research articles and review publications: 1974-2015 
 
Table 1. The number of drug delivery research articles and review publications by countries, the EU countries, 
BRICS countries, and the World: 1974–1975, 1984–1985, 1994–1995, 2004–2005 and 2014–2015. 
 
 1974-1975   
Countries/Territories #publications % Rank 
World 63 100.0  
EU 18 28.5  
USA 22 34.9 1 
UK 12 19.0 2 
Canada 4 6.3 3 
Norway 3 4.7 4 
Fed Rep Germany 2 3.1 5 
Germany Dem Rep 2 3.1 5 
Sweden 2 3.1 5 
United Arab Rep 2 3.1 5 
Belgium 1 1.6 9 
Bulgaria 1 1.6 9 
Denmark 1 1.6 9 
Finland 1 1.6 9 
India 1 1.6 9 
Ireland 1 1.6 9 
Israel 1 1.6 9 
Netherlands 1 1.6 9 
New Zealand 1 1.6 9 
Switzerland 1 1.6 9 
Trinidad & Tobago 1 1.6 9 
 
 
1984-1985   
Countries/Territories # publications  % Rank 
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Table 1 continued 
World 527  100.0  
EU 169 32.0  
USA 230 43.6 1 
UK 80 15.1 2 
Japan 33 6.2 3 
Fed Rep Germany 26 4.9 4 
France 21 3.9 5 
Netherlands 18 3.4 6 
Canada 16 3.0 7 
Israel 13 2.4 8 
Denmark 11 2.0 9 
Austria 10 1.8 10 
India 10 1.8 10 
Italy 10 1.8 10 
Belgium 8 1.5 13 
Australia 6 1.1 14 
Switzerland 6 1.1 14 
Egypt 5 0.9 16 
Finland 4 0.7 17 
Sweden 4 0.7 17 
Turkey 4 0.7 17 
Czechoslovakia 3 0.5 20 
New Zealand 3 0.5 20 
P oland 3 0.5 20 
South Africa 3 0.5 20 
Taiwan 3 0.5 20 
Germany Dem Rep 2 0.3 25 
Ireland 2 0.3 25 
Jordan 2 0.3 25 
Norway 2 0.3 25 
Thailand 2 0.3 25 
Argentina 1 0.1 30 
Bahamas 1 0.1 30 
Hungary 1 0.1 30 
Kenya 1 0.1 30 
Nigeria 1 0.1 30 
P eoples R China 1 0.1 30 
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Table 1 continued    
P hilippines 1 0.1 30 
 
    
 1994-1995   
Countries/Territories # publications % Rank 
World 1329 100.0  
BRICS 67 5.0  
EU 411 30.9  
USA 533 40.1 1 
Japan 173 13.0 2 
UK 150 11.2 3 
France 62 4.6 4 
Germany 60 4.5 5 
Italy 57 4.2 6 
Canada 52 3.9 7 
Netherlands 42 3.1 8 
Israel 41 3.0 9 
India 36 2.7 10 
Belgium 31 2.3 11 
Sweden 23 1.7 12 
Switzerland 17 1.2 13 
Spain 17 1.2 13 
Denmark 17 1.2 13 
Finland 15 1.1 16 
P eoples R China 15 1.1 16 
Turkey 15 1.0 18 
Australia 14 <1 19 
Egypt 12 <1 20 
Taiwan 12 <1 20 
South Africa 10 <1 22 
New Zealand 9 <1 23 
Austria 8 <1 24 
Czech Rep 7 <1 25 
Norway 6 <1 26 
Russia 6 <1 26 
South Korea 6 <1 26 
Saudi Arabia 5 <1 29 
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Greece 4 <1 30 
Hungary 4 <1 30 
Iceland 4 <1 30 
Argentina 3 <1 33 
Bulgaria 3 <1 33 
Chile 3 <1 33 
Croatia 3 <1 33 
Hong Kong 2 <1 37 
Malaysia 2 <1 37 
Mexico 2 <1 37 
Nigeria 2 <1 37 
P ortugal 2 <1 37 
Singapore 2 <1 37 
Thailand 2 <1 37 
Bangladesh 1 <1 44 
Estonia 1 <1 44 
Ireland 1 <1 44 
Jordan 1 <1 44 
Philippines 1 <1 44 
P oland 1 <1 44 
Romania 1 <1 44 
Slovenia 1 <1 44 
Ukraine 1 <1 44 
 
    
 2004-2005   
Countries/Territories #publications % Rank 
World 2485 100.0  
BRICS 373 15.0  
EU 833 33.5  
USA 746 30.0 1 
Japan 262 10.5 2 
UK 222 8.9 3 
P eoples R China 169 6.8 4 
Germany 153 6.1 5 
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India 146 5.8 6 
South Korea 137 5.5 7 
Italy 126 5.0 8 
France 126 5.0 9 
Canada 98 3.9 10 
Spain 57 2.2 11 
Switzerland 56 2.2 12 
Netherlands 55 2.2 13 
Australia 47 1.8 14 
Belgium 46 1.8 15 
Singapore 45 1.8 16 
Taiwan 44 1.7 17 
Israel 38 1.5 18 
Turkey 36 1.4 19 
Austria 33 1.3 20 
Sweden 33 1.3 20 
Brazil 31 1.2 22 
Finland 23 <1 23 
Iran 23 <1 23 
Ireland 21 <1 25 
Denmark 17 <1 26 
Egypt 17 <1 26 
New Zealand 17 <1 26 
Russia 17 <1 26 
P ortugal 16 <1 30 
Thailand 15 <1 31 
Czech Rep 13 <1 32 
South Africa 12 <1 33 
Norway 11 <1 34 
Romania 11 <1 34 
Argentina 8 <1 36 
Greece 8 <1 36 
Mexico 8 <1 36 
Malaysia 7 <1 39 
Croatia 6 <1 40 
Kuwait 6 <1 40 
Slovenia 6 <1 40 
Iceland 4 <1 43 
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P hilippines 4 <1 43 
P oland 4 <1 43 
Cuba 4 <1 43 
Hungary 3 <1 47 
Jordan 3 <1 47 
Nigeria 3 <1 47 
P akistan 3 <1 47 
Saudi Arabia 3 <1 47 
Yugoslavia 3 <1 47 
Bulgaria 2 <1 53 
Estonia 2 <1 53 
Indonesia 2 <1 53 
U Arab Emirates 2 <1 53 
Bahrain 1 <1 57 
Chile 1 <1 57 
Kazakhstan 1 <1 57 
Latvia 1 <1 57 
Lebanon 1 <1 57 
Lithuania 1 <1 57 
Malta 1 <1 57 
Myanmar 1 <1 57 
Nepal 1 <1 57 
Rep Of Georgia 1 <1 57 
Serbia Montenegro 1 <1 57 
Slovakia 1 <1 57 
Tanzania 1 <1 57 
Tunisia 1 <1 57 
Ukraine 1 <1 57 
Uruguay 1 <1 57 
 
    
 2014-2015   
Countries/Territories # publications % Rank 
World 7824 100.0  
BRICS 3153 40.2  
EU 1924 20.5  
Peoples R China 2042 26.0 1 
USA 1675 21.4 2 
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India 872 11.1 3 
South Korea 408 5.2 4 
UK 383 4.8 5 
Germany 341 4.3 6 
Japan 290 3.7 7 
Italy 252 3.2 8 
France 236 3.0 9 
Iran 229 2.9 10 
Spain 219 2.7 11 
Australia 208 2.6 12 
Canada 190 2.4 13 
Brazil 146 1.8 14 
Taiwan 144 1.8 15 
Saudi Arabia 140 1.7 16 
Egy pt 139 1.7 17 
Netherlands 123 1.5 18 
Portugal 121 1.5 19 
Singapore 119 1.5 20 
Switzerland 113 1.4 21 
Belgium 95 1.2 22 
Malay sia 94 1.2 23 
Israel 83 1.0 24 
Denmark 71 <1 25 
Turkey 69 <1 26 
Thailand 65 <1 27 
Pakistan 62 <1 28 
Poland 61 <1 29 
Sweden 61 <1 29 
Russia 60 <1 31 
Romania 59 <1 32 
South Africa 54 <1 33 
Finland 52 <1 34 
Austria 48 <1 35 
Greece 48 <1 35 
Argentina 42 <1 37 
Ireland 42 <1 37 
Czech Rep 34 <1 39 
Hungary 34 <1 39 
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Norway 34 <1 41 
New Zealand 29 <1 42 
Serbia 23 <1 43 
Slovenia 23 <1 43 
Mexico 22 <1 45 
Nigeria 22 <1 45 
Jordan 18 <1 47 
Chile 17 <1 48 
Vietnam 16 <1 49 
U Arab Emirates 11 <1 50 
Estonia 10 <1 51 
Bulgaria 8 <1 52 
Croatia 8 <1 52 
Indonesia 8 <1 52 
Bangladesh 6 <1 55 
Colombia 6 <1 55 
Iceland 6 <1 55 
Slovakia 6 <1 55 
Algeria 5 <1 59 
Cuba 5 <1 59 
Sy ria 5 <1 59 
Iraq 4 <1 62 
Mauritius 4 <1 62 
Tunisia 4 <1 62 
Cy prus 3 <1 65 
Lebano 3 <1 65 
Luxembourg 3 <1 65 
Morocco 3 <1 65 
Philippines 3 <1 65 
Qatar 3 <1 65 
Rep of Georgia 3 <1 65 
By elarus 2 <1 72 
Ghana 2 <1 72 
Montenegro 2 <1 72 
Oman 2 <1 72 
Tanzania 2 <1 72 
Yemen 2 <1 72 
Azerbaijan 1 <1 78 
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Benin 1 <1 78 
Brunei 1 <1 78 
Burkina Faso 1 <1 78 
Cameroon 1 <1 78 
Costa Rica 1 <1 78 
Ecuador 1 <1 78 
Ethiopia 1 <1 78 
Keny a 1 <1 78 
Kuwait 1 <1 78 
Liby a 1 <1 78 
Macedonia 1 <1 78 
My anmar 1 <1 78 
Nepal 1 <1 78 
Sudan 1 <1 78 
Uganda 1 <1 78 
Ukraine 1 <1 78 
Venezuela 1 <1 78 
Zimbabwe 1 <1 78 
 
In the first four of the five two-year periods analyzed the USA was by far the most 
productive country with a lead of 43.6% of the total share in 1984-1985; however, it ranked 
second in 2014-2015 with only 21.4% of the total publications. Some industrialized countries 
(UK, Japan, Germany, France, Netherlands and Canada) that were present among the leading 
countries in 1984-1985 slowly lost their high ranking positions, but remained among the leading 
countries in 2014-2015. These observations are in line with the domination (in terms of the 
number of publications) of these countries in various fields of Biology [25], Medicine [26, 27], 
and in research fields more closely allied to D.D. research such as Nanotechnologies [28] and 
Liposomes [29]. Contrariwise, two Asian newcomers, China and South Korea, along with the 
continuous presence of India among the productive countries have progressively joined the 
industrialized countries in their D.D. research efforts: China from ranked 17t h in 1994-1995, 
4t h in 2004-2005, to 1st in 2014-2015; and South Korea from ranked 28t h in 1994-1995, 7t h 
in 2004-2005, to 4t h in 2014-2015. 
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The increasingly leading position of China is also supported by the fact that five of the 
ten most productive institutions in D.D. research are located in China (data not shown). The 
recent increase of Chinese D.D. publication (see Figure 2) can be correlated to the explosion of 
publications authored by Chinese scientists in Pharmacology and Pharmacy journals [30]. More 
globally, it can be seen as a consequence of the recent increase of China’s total expenditure on 
Research and Development – on average 23% per annum over the last decade [31]. 
Additionally, the recent ascendancy of China over the USA was predicted in a report of the 
Royal Society [32]. 
 
 
Figure 2.Number of Drug Delivery research articles and review publications for top-producing countries, the EU 
countries and BRICS countries: 1974-2015 
While the share of D.D. publications among the EU countries remained stable from 1994 
to 2005 (30.9% in 1994-1995, and 33.5% in 2004-2005) but decreased to 20.5% in 2014-2015; 
the share of the BRICS countries increased continuously (mainly due to the D.D. research 
output of China and India): 5.0% in 1994-1995, 15.0% in 2004-2005 and 40.2% in 2014-2015. 
As noted earlier, three members of BRICS (China, India and South Korea) were present in the 
top-ranking countries in 2004-2005 and in 2014-2015. 
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3.3. Evolution of journals publishing drug delivery research 
 
During the 40+ years studied, the number of journals targeted by D.D. researchers 
increased in two trajectories (Figure 3). From 1974 to the beginning of the 2000s, the increase 
of D.D. journals more or less paralleled that of the SCI-E database; however, from 2002 to 
2015, the number of D.D. journals increased 2.4 fold (416 journals in 2002-2003 and 1,001 for 
2014-2015) while the total number of journals indexed in the SCI-E increased only 1.2 fold 
(7,822 journals for 2002-2003 and 9,550 for 2014-2015). 
 
 
Figure 3. Number of journals publishing Drug Delivery research articles and review publications: 1974-2015 
 
The top-10 most productive journals on D.D. research in each of the last four time 
periods are presented in Table 2. During the last three periods analyzed (1994-1995, 2004-2005 
and 2014-2015) three journals (Journal of Controlled Release, Advanced Drug Delivery 
Reviews, and International Journal of Pharmaceutics) were ranked among the top-4 most 
productive journals; two other journals (Drug Delivery and Journal of Drug Delivery Science 
and Technology) were present among the top-10 most productive journals in the two most 
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recent rankings (2004-2005 and 2014-2015). For the last time period studied, eight of the top-
10 ranked journals had an IF >3.00 with a maximum IF of 15.60 for the journal Advanced Drug 
Delivery Reviews. 
Table 2.The top-10 journals publishing Drug Delivery research articles and review publications:1984-1985, 1994-
1995, 2004-2005 and 2014-2015 (including 2015 IFs) 
 
   % of  
 Source Titles # publications 527 WoS category 
 Cancer Drug Delivery 53 10.0 n.a. 
 International Journal of Pharmaceutics 29 5.5 Pharmacology & Pharmacy 
 Drug Development and Industrial Pharmacy 18 3.4 Chemistral, Medicinal;Pharmacology & Pharmacy 
 Journal of Pharmaceutical Sciences 17 3.2 Chemistry, Multidisciplinary; Chemistry, Medicinal; Pharmacology & Pharmacy 
 British Journal of Clinical Pharmacology 15 2.8 Pharmacology & Pharmacy 
 Journal of Pharmacy and Pharmacology 11 2.0 Pharmacology & Pharmacy 
 International Journal of Clinical Pharmacology and Therapeutics 11 2.0 Pharmacology & Pharmacy 
 Chemical Pharmaceutical Bulletin 11 2.0 Chemistry, Multidisciplinary; Chemistry, Medicinal; Pharmacology & Pharmacy 
 American Journal of Medicine 8 1.5 Medicine, General & Internal 
 Pharmacy International 7 1.3 n.a. 
 Biopharmaceutics Drug Disposition 7 1.3 Pharmacology & Pharmacy 
 Annals of the New York Academy of Sciences 7 1.3 n.a. 
 
 
Source Titles # publications % of 1329 WoS category 
Journal of Controlled Release 325 24.4 Chemistry, Multidisciplinary Pharmacology & Pharmacy 
Advanced Drug Delivery Reviews 107 8.0 Pharmacology & Pharmacy 
International Journal of Pharmaceutics 96 7.2 Pharmacology & Pharmacy 
Drug Development and Industrial Pharmacy 65 4.8 Chemistral, Medicinal;Pharmacology & Pharmacy 
Journal of Pharmaceutical Sciences 47 3.5 Chemistry, Multidisciplinary; Chemistry, Medicinal; Pharmacology & Pharmacy 
Pharmaceutical Research 45 3.3 Chemistry, Multidisciplinary Pharmacology & Pharmacy 
Chemical Pharmaceutical Bulletin 19 1.4 Chemistry, Multidisciplinary; Chemistry, Medicinal; Pharmacology & Pharmacy 
STP Pharma Sciences 17 1.2 Pharmacology & Pharmacy 
Journal of Pharmacy and Pharmacology 16 1.2 Pharmacology & Pharmacy 
Journal of Drug Targeting 15 1.0 Pharmacology & Pharmacy 
Journal of Clinical Pharmacology 15 1.0 Pharmacology & Pharmacy 
Critical Reviews in Therapeutics Drug Carrier System 15 1.0 n.a. 
 
 Source Titles # publications % of 2485 WoS category 
 Journal of Controlled Release 678 27.2 Chemistry, Multidisciplinary Pharmacology & Pharmacy 
 Advanced Drug Delivery Reviews 217 8.7 Pharmacology & Pharmacy 
 Journal of Drug Delivery Science and Technology 134 5.3 Pharmacology & Pharmacy 
 International Journal of Pharmaceutics 127 6.1 Pharmacology & Pharmacy 
 Drug Delivery 85 3.4 Pharmacology & Pharmacy 
 Biomaterials 46 1.8 Engineering, Biomedical; Materials Science, Biomaterials 
 Drug Development and Industrial Pharmacy 41 1.6 Chemistral, Medicinal;Pharmacology & Pharmacy 
 European Journal of Pharmaceutics and Biopharmaceutics 40 1.6 Pharmacology & Pharmacy 
 Pharmaceutical Research 31 1.2 Chemistry, Multidisciplinary Pharmacology & Pharmacy 
 Journal of Applied Polymer Science 31 1.2 Polymer Science 
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Source Titles 
# % of 
IF (2015) WoS Category 
publications 7823    
Journal of Controlled Release 962 12.2 7.44 Chemistry, Multidisciplinary Pharmacology & Pharmacy 
Advanced Drug Delivery Reviews 280 3.5 15.60 Pharmacology & Pharmacy 
Iinternational Journal of Pharmaceutics 277 3.5 3.99 Pharmacology & Pharmacy 
Expert Opinion on Drug Delivery 251 3.2 5.43 Pharmacology & Pharmacy 
RSC Advances 228 2.9 3.28 Chemistry, Multidisciplinary 
Journal of Drug Delivery Science and Technology 217 2.7 0.62 Pharmacology & Pharmacy 
Journal of Materials ChemistryB 186 2.3 4.87 Materials Science, Biomaterials 
Drug Delivery 179 2.2 4.84 Pharmacology & Pharmacy 
Colloids and Surfaces B Biointerfaces 141 1.8 3.90 Biophysics; Chemistry, Physical; Materials Science, Biomaterials 
 
Furthermore, during the same three time periods the distributions of publications in 
journals were markedly skewed: 
 
▪ in 1994-1995, 1% (3 journals) of D.D journals concentrated 39.7% of the 1,329 
 
publications, while 9l.3% (276 journals) of D.D. journals had ≤5 publications; 
 
▪ in 2004-2005, 1% (5 journals) of D.D. journals concentrated 50% of the 2,485 D.D. 
publications, while 9l.5% (457 journals) of D.D. journals had ≤5 publications; and 
finally 
 
▪ in 2014-2015, 1% (10 journals) of the journals concentrated 36.4% of the 7,823 D.D. 
publications, while 8l.9% (820 journals) of D.D. journals had ≤5 publications. 
 
 
With the rapid growth of the scientific literature, review publications are essential 
updating tools for researchers [33]. During the last fifteen years, the number of D.D. review 
publications increased 3.5 fold (347 reviews in 2000-2001 vs. 1,220 in 2014-2015) while the 
total number of reviews in the SCI-E database only increased 2.6 fold (60,394 in 2000-2001 vs. 
155,926 in 2014-2015). As in numerous scientific disciplines, a review journal, Advanced Drug 
Delivery Reviews, specifically dedicated to the field of D.D., was launched in 1987. This 
journal publishes approximately 150 publications per year, has a 2015 JCR impact factor of 
15.60, and ranked 3rd (of 255) among the leading journals in the Pharmacology & Pharmacy 
WoS category. Although this journal published most of the D.D. review publications, other 
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review publications were scattered among a broad range of journals: prestigious journals such 
as The Lancet [34], Nature [35], Nature Reviews Drug Discovery [36] 
 
and more specialized journals [37, 38]. Additionally, the increasing ratio of review 
publications / review+non-review publications from 1974 to 2000 and the stabilization since 
2001 to 2015 from between 15% to 20% are indications of the evolving and maturing of the 
D.D. field. 
 
Although two emblematic journals targeted by D.D. researchers began in the mid-1980s 
(The Journal of Controlled Release in 1984 and Advanced Drug Delivery Reviews in 1987), 
the recent explosion of the D.D. literature was accompanied by the launching of six more 
journals dedicated to D.D. in the 2000s: The Journal of Drug Delivery Science Technology 
(launched in 2004), Expert Opinion on Drug Delivery (2004), Current Drug Delivery (2004), 
Drug Delivery (2007), Journal of Aerosol Medicine and Pulmonary Drug Delivery (2008) and 
Drug Delivery and Translational Research (2011). 
 
From 1974 to 2015 the scientific literature on D.D. spread among a broad range of 
scientific fields (WoS subject categories): 24 in 1974-1975; 70 in 1984-1985, 100 in 1994-
1995; 124 in 2004-2005; and 144 in 2014-2015. During this period, the WoS subject category 
Pharmacology & Pharmacy was the most targeted field; some of the top-leading WoS fields 
(Ophthalmology and Dermatology) disappeared while other fields gained in importance: 
Biochemistry Molecular Biology in 1984-1985, Materials Science Biomaterials, Polymer 
Science, or Engineering Biomedical in 1994-1995, and Nanoscience Nanotechnology and 
Chemistry Physical in 2004-2005. 
 
 
 
4. Conclusion 
 
 
 135 
 
 
 
This brief bibliometric investigation on the evolution of the scientific literature on 
 
during 40+ years reveals three major trends: an explosion of D.D.-related publications (63 
publications for 1974-1975 vs. 7,824 for 2014-2015); the spread and distribution of publications 
among publishing countries (19 countries in 1974-1975 vs. 96 in 2014-2015); and an increase 
of the number of journals involved in D.D. publications (42 journals in 1974-1975 vs. 1,001 in 
2014-2015). Despite an overall increase in publications that seem to result in a rapid 
advancement of the field after an initial success achieved by the first D.D. systems, production 
of approved D.D. systems for clinical use slowed down in the following years. This happens 
because overcoming the physiochemical and biological barriers is still a challenge [39]. The 
development of new delivery systems that are able to address current challenges in medicine 
was often driven by discoveries in basic science. Specifically, biology gave a huge boost to the 
development of nanotechnologies with discoveries such as the enhanced permeability and 
retention (EPR) effect [40]. Likewise, chemistry and material sciences have had a tremendous 
impact on the development of all D.D. systems, while physics and mathematics have added to 
the understanding of transport through the organism. Therefore, it is easy to understand how 
the collaboration among different disciplines is fundamental and that it is critical to maintain a 
detached view from the major scientific trend to keep up with new scientific discoveries [41]. 
Overcoming such limits will have a great impact also on the healthcare economy by introducing 
new technologies. As an example, the commercialization of Doxil [42], the first approved 
nanoformulated drug, decreased the cost of treatment and hospitalization [43]. Furthermore, the 
economic investments play a critical role in the translation of basic research into the clinic. In 
particular, the funding management varies among countries. For example, there is a substantial 
difference in the funding approaches between the U.S. and China, which are the two leading 
countries in D.D. research. U.S. governmental agencies that provide research funding, such as 
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the National Institutes of Health (NIH), promote the development of projects in which the 
translational aspect is a major component, thereby making the U.S. the leader in translational 
research. On the other hand, in the last few decades China has been investing most of its funds 
in basic sciences, which has led to a massive production of scientific publications less focused 
on translational science. 
 
 
 
 
 
In the years to come there will be an increase in the development and the 
commercialization of D.D. systems thereby resulting in increased research activities worldwide 
and consequentially in an increased production of related scientific publications, probably with 
a similar trend observed in the last two decades among the countries considered. 
 
 
We hope that our study will arouse interest in scientists, physicians, decision-makers, 
and politicians in extending this bibliometric study of the D.D. field. 
D.D.  
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